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1 Summary 
 
Cancer treatments with classic cytotoxic drugs are constrained by the resistance of cancer cells 
and indiscriminate toxicity towards normal cells. They are gradually being replaced by the drugs 
and molecules targeting cancer-specific molecules and processes. However, only a few of such 
targeted drugs provide clinical benefits compared to cost-effective classical drugs. Herein, I 
investigated an unexplored approach of improving the efficacy of the classical anti-cancer drug 
etoposide. I hypothesized that the response to etoposide, a widely used topoisomerase II poison, 
can be safely enhanced by considering treatment-evoked gene expression changes. To this end, I 
analyzed the basal transcriptomes and etoposide-evoked transcriptional changes in fibrosarcoma 
and acute myeloid leukemia (AML) cell lines. Using two parallel approaches of co-regulation 
within gene expression networks and essentiality for cancer cell survival, I identified and validated 
druggable drivers of etoposide cytotoxicity. Drivers with pre-treatment expression modulating the 
etoposide cytotoxicity (e.g. BIRC5 and PARP9) synergized with etoposide. Drivers essential for 
cancer cell survival and repressed after etoposide treatment (e.g. PFKP and PLK1) contributed to 
its cytotoxicity by evoking cell death. Drivers with etoposide-like gene expression changes (e.g. 
ANLN and MYC) synergized with etoposide as well as exhibited standalone cytotoxicity. 
Altogether, both pre-treatment gene expression levels and treatment-evoked gene expression 
changes drive the etoposide cytotoxicity. These drivers could be targeted to potentially replace 
etoposide or to enhance its efficacy. This approach can further be used to identify replacements 
and rational combination partners of other classical anti-cancer drugs interfering with gene 
expression.
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2 Zusammenfassung 
 
Die Wirksamkeit von Krebsbehandlungen mit klassischen Zytostatika wird durch Resistenzen und 
Toxizitäten eingeschränkt. Die klassischen Zytostatika werden daher nach und nach durch 
Medikamente ersetzt, die auf krebsspezifische Moleküle und Prozesse abzielen. Im Vergleich zu 
kostengünstigen klassischen Medikamenten bieten jedoch nur wenige dieser zielgerichteten 
Arzneimittel klinische Vorteile. Im Verlauf dieser Arbeit versuchte ich, die Wirksamkeit des 
klassischen Antikrebsmedikaments Etoposid zu verbessern. Ich stellte die Hypothese auf, dass die 
Antwort auf Etoposid, ein weit verbreitetes Topoisomerase-II-Gift, gesteigert werden kann, wenn 
die durch die Behandlung hervorgerufenen Genexpressionsänderungen berücksichtigt werden. Zu 
diesem Zweck analysierte ich die basalen Transkriptome sowie die durch Etoposid 
hervorgerufenen transkriptionellen Veränderungen in Zelllinien des Fibrosarkoms und der akuten 
myeloischen Leukämie (AML). Mit zwei parallelen Ansätzen, d.h. der Ko-Regulation innerhalb 
von Genexpressionsnetzwerken und der essenziellen Bedeutung für das Überleben von 
Krebszellen, identifizierte und validierte ich therapeutische Zielmoleküle welche die Etoposid-
Zytotoxizität verstärken. „Drivers“, deren Expression vor der Behandlung die Etoposid-
Zytotoxizität beeinflussten (z. B. BIRC5 und PARP9), wirkten mit Etoposid synergistisch. 
„Drivers“, die für das Überleben von Krebszellen essentiell waren und nach einer Etoposid-
Behandlung reprimiert wurden (z. B. PFKP und PLK1), verstärkten dessen Zytotoxizität durch 
Zelltod. „Drivers“, die Etoposid-ähnliche Genexpressionsänderungen hervorriefen (z. B. ANLN 
und MYC) wirkten synergistisch mit Etoposid und zeigten eigenständige Zytotoxizität. 
Zusammengefasst steuern sowohl die Genexpressionsniveaus vor der Behandlung als auch die 
durch die Behandlung hervorgerufenen Genexpressionsänderungen die Zytotoxizität von 
Etoposid. Diese „Drivers“ könnten gezielt genutzt werden, um Etoposid zu ersetzen oder seine 
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Wirksamkeit zu steigern. Darüber hinaus könnten mit dieser Herangehensweise Alternativen 
sowie Kombinationen für andere klassischen Krebsmedikamente identifiziert werden, die die 
Genexpression beeinflussen.
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3 Introduction 
 
Most classic anticancer drugs are indiscriminately toxic towards both cancerous and normal 
dividing cells due to the interference with the fundamental cellular processes of DNA metabolism 
or mitosis. They are therefore gradually being replaced by drugs targeting molecules and processes 
more specific to cancer cells. For example, the identification of the bcr-abl fusion protein expressed 
exclusively in chronic monomyelocytic leukemia led to the development of the well-tolerated 
inhibitor imatinib (An, Tiwari et al. 2010). The development of this and of many other new 
anticancer drugs has been driven by advances in the understanding of tumor biology. In coming 
years, the cancer chemotherapy is most likely to be tailored to individual patients. However, 
development and approval of drugs targeting such individual targets will take several years. Even 
more, such targeted drugs often confer rather modest clinical benefits and they remain out-of-reach 
to most patients because of high cost (Schilsky and Schnipper 2018). 
An alternative approach of finding and targeting cancer-specific effectors of cytotoxic drugs has 
not been explored. Cytotoxic drugs display a remarkable sensitivity towards particular cancer 
entities (e.g. cis-platinum is effective against solid tumors like NSCLC, testicular cancer or ovarian 
cancer, but not against hematological cancers). This work explores the sensitivity-relevant 
transcriptional drivers of clinically used cytotoxic drugs to understand the basis of selective 
sensitivity and to further enhance it. 
3.1 Cancer chemotherapy 
Cancer remains one of the major health concerns worldwide. It is second-leading cause of death 
with 18.1 million new cases and 9.6 million deaths in 2018 globally (Bray, Jacques et al. 2018, 
Siegel, Miller et al. 2018). Several factors contribute to increased cancer prevalence, including 
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aging population, as well as environmental and lifestyle changes. This is especially evident in 
rapidly developing countries which display a shift from poverty-associated cancers to lifestyle-
associated cancers (Kanavos 2006). 
The complexity of cancer in terms of genetic constitution, combined with variability in response 
to chemotherapeutic drugs, make treating them particularly challenging (Hanahan and Weinberg 
2011). These variabilities are often observed within a single cancer entity. Cancer treatment 
strategies include surgery, radiotherapy, chemotherapy, and immunotherapy. Surgery is the ideal 
treatment for solid tumors detected at an early stage. For large tumors the radiotherapy provides 
an alternative for surgery (Urruticoechea, Alemany et al. 2010). However, both of these 
approaches are employed for local therapies. Chemotherapy is the preferred treatment for 
advanced solid tumors and for hematological malignancies. 
There are various classes of clinically used anticancer drugs including alkylating agents, antibiotics 
and antimetabolites, topoisomerase inhibitors, and mitosis inhibitors. Unlike local treatments, 
chemotherapy is not restricted to particular site, but rather targets proliferating cells. Hence, 
chemotherapeutic drugs are indiscriminately toxic towards cancer cells as well as normal dividing 
cells including hair follicles, gastrointestinal epithelial cells, and bone marrow cells. This results 
in numerous side effects, including, among others, hair loss, stomach ulcers, and anemia, in the 
patients receiving chemotherapy, restricting their applicability. 
There are numerous of drugs approved for each cancer type, which are either cytotoxic or targeted 
towards specific cancer entities (Table 3.1.1) (Sun, Wei et al. 2017). 
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Table 3.1.1: Overview of the number of drugs approved for each cancer type (Sun, Wei et al. 2017). 
Cancer 
Number of 
cytotoxic drugs 
Number of 
targeted drugs 
Total 
number of 
drugs 
Leukemia 24 16 40 
Lymphoma 14 14 28 
Breast cancer 13 14 27 
Lung cancer 10 7 17 
Prostate cancer 3 12 15 
Ovarian cancer 10 2 12 
Melanoma 1 10 11 
Colorectal cancer 5 5 10 
Kidney cancer 2 8 10 
Stomach cancer 5 5 10 
Brain cancer 6 2 8 
Multiple myeloma 3 5 8 
Pancreatic cancer 5 3 8 
Testicular cancer 6 0 6 
Head and neck cancer 3 2 5 
Sarcoma 3 2 5 
Bladder cancer 4 0 4 
Thyroid cancer 1 3 4 
Bone cancer 2 1 3 
Basal cell carcinoma 0 2 2 
Cervical cancer 2 0 2 
Gestational trophoblastic disease 2 0 2 
Adrenal cortical carcinoma 1 0 1 
Choriocarcinoma 1 0 1 
Esophageal cancer 0 1 1 
Gastroenteropancreatic 
neuroendocrine tumor 
0 1 1 
Kaposi’s sarcoma 0 1 1 
Liver cancer 0 1 1 
Mesothelioma 1 0 1 
Myelofibrosis 0 1 1 
Penile cancer 1 0 1 
Retinoblastoma 1 0 1 
Vulvar cancer 1 0 1 
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Even with current advancements and availability of number of drugs (Table 3.1.1), most patients 
with advanced cancers still exhibit poor prognosis, mostly because of residual cancer cells. And 
hence there is great need to improve the standard treatment regimen. Hence, there is ever-growing 
research to identify new potent drugs as well as to utilize alternative strategies such as 
immunotherapy (Zhang and Chen 2018). However, there are not many efforts addressing the 
efficacy and safety of existing chemotherapeutic drugs which are very potent despite lacking the 
cancer cell specificity. This is especially crucial considering increasing number of targeted drugs 
which are applicable to ever smaller cohort of patients (Arbiser 2007, Widakowich, de Castro et 
al. 2007). There are two ways of addressing this. First, replace these non-specific drugs with drugs 
targeting molecules and processes more specific to cancer cells. Second, combine existing 
chemotherapeutic drugs with synergistic partners to reduce their dosage and, hence, side-effects. 
3.2 Topoisomerase II as cancer targets 
Topoisomerase II (TOP2) poisons constitute one of the widely used and successful classes of anti-
cancer drugs (Nitiss 2009). Unfortunately, due to the involvement of TOP2 in such fundamental 
cellular processes as DNA replication and transcription, its poisoning affects both cancerous and 
normal cells, including non-dividing ones. Thus, in addition to the transient bone marrow toxicity, 
TOP2 poisons cause irreversible side-effects such as secondary leukemia due to chromosomal 
rearrangements (Pendleton, Lindsey et al. 2014), and cardiotoxicity (McGowan, Chung et al. 
2017).  
DNA topoisomerases are the essential enzymes involved in the processes such as replication and 
transcription. Human DNA topoisomerases consist of three types including type IA (TOP3A and 
TOP3B), type IB (TOP1 and TOP1MT), and type IIA (TOP2A and TOP2B). Monomeric type I 
enzymes catalyze DNA single-stand breaks, while dimeric type II enzymes catalyze DNA-double 
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strand breaks to relieve the topological strain (Pommier 2013). These enzymes resolve higher order 
DNA structure through two trans-esterification steps. The first trans-esterification step creates an 
DNA adduct, which generates TOP2-DNA cleavable complex causing the topological change. The 
second trans-esterification step re-seals the break. This process has extensively been exploited in 
cancer chemotherapy. TOP2 poisoning has been utilized in the clinic for more than 50 years as 
first-line therapy for blood as well as solid cancers (Marinello, Delcuratolo et al. 2018). 
Topoisomerase II (TOP2) poisons constitute one of the widely used and successful classes of anti-
cancer drugs (Nitiss 2009, Pommier, Sun et al. 2016). The main TOP2 poison classes include 
anthracyclines, camptothecins, and epipodophyllotoxins. TOP2 poisons, such as 
epipodophyllotoxin etoposide, target the short-lived TOP2-DNA cleavable complex and prevent 
the re-ligation of transient DSBs. This generates high number of TOP2-associated DSBs, which 
trigger apoptosis (Nitiss 2009, Pommier, Leo et al. 2010). The process of TOP2 poisoning by 
etoposide is depicted in Fig. 3.2.1. 
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Fig. 3.2.1: Pictorial representation of topoisomerase II (TOP2) poisoning by etoposide and its consequences. 
 
TOP2 poisons constitute one of the most important anti-cancer drugs. They are used in managing 
almost all types of chemotherapy-responsive cancers. Clinically used and approved TOP2 poisons 
are listed in the Table 3.1.1. 
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Table 3.2.1: Overview of the topoisomerase II (TOP2) poisons used in clinic (Cowell and Austin 2012, Chemocare 
2019). 
Class Drug Use 
Acridine Amsacrine Acute adult leukemia, Lymphoma 
Benzo[c]phenanthridine alkaloid NK314 Adult T-cell leukemia-lymphoma 
Anthracenedione Mitoxantrone Breast cancer, Leukemia, Non-Hodgkin lymphoma 
Anthracyclines 
Daunorubicin 
Acute myeloid leukemia, Acute lymphoblastic leukemia, 
Acute promyelocytic leukemia 
Doxorubicin 
Acute lymphoblastic leukemia, Acute myeloid leukemia, 
Bone sarcoma, Breast cancer, Endometrial cancer, Gastric 
cancer, Head and neck cancer, Hodgkin and non-Hodgkin 
lymphoma, Liver cancer, Kidney cancer, Multiple myeloma, 
Neuroblastoma, Ovarian cancer, Small cell lung cancer, Soft 
tissue sarcoma, Thyomas, Thyroid cancer, Transitional cell 
bladder cancer, Uterine sarcoma, Wilms' tumor, 
Waldenstrom macroglobulinemia 
Epirubicin Breast cancer 
Idarubicin 
Acute lymphoblastic leukemia, Acute myeloid leukemia, 
Chronic myelogenous leukemia 
Camptothecins 
Irinotecan Metastatic colon or rectal cancer 
Topotecan Lung cancer, Ovarian cancer 
Epipodophyllotoxins 
Etoposide 
Acute myeloid leukemia, Bladder cancer, Hodgkin's and 
non-Hodgkin's lymphoma, Kaposi's sarcoma, Lung cancer, 
Prostate cancer, Stomach cancer, Testicular cancer, Uterine 
cancer, Wilm's tumor 
Teniposide Acute lymphocytic leukemia (in children) 
Quinolones Voreloxin Acute myeloid leukemia 
 
Clearly, doxorubicin and etoposide are the TOP2 poisons most widely used against cancers, 
especially against hematological ones. The anti-cancer activity of doxorubicin is additionally 
contributed to by DNA intercalation and generation of reactive oxygen species, and hence not 
limited to TOP2 poisoning (Thorn, Oshiro et al. 2011). Because of wide applicability to a number 
of cancer types and specificity for TOP2, I have focused on etoposide. 
Etoposide is synthesized from podophyllotoxin isolated from Podophyllum peltatum rhizome. It 
targets the type IIA topoisomerases TOP2A and TOP2B. Its clinical use is limited by the 
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indiscriminate toxicity towards normal cells. Etoposide causes secondary leukemia due to 
chromosomal rearrangements (Pendleton, Lindsey et al. 2014), usually a translocation of the mixed 
lineage leukemia (MLL) gene on the chromosome 11q23. Clearly, there is a need to optimize 
etoposide-regimens to reduce such chromosomal rearrangements. 
3.3 Gene expression and drug response 
Ever-decreasing cost of genomic profiling has allowed for high-throughput profiling of cancer 
cells. This has elevated our understanding of tumor growth, progression, and response and driven 
the development of many targeted therapeutics. During the last decade, there have been several 
efforts to associate the base line transcriptomic levels and mutation profiles with the response to 
cytotoxic drugs (Whyte and Holbeck 2006, Zhang, Wang et al. 2015, Vural, Simon et al. 2018). 
The basal expression of some genes has been linked to the drug resistance (Robert, Vekris et al. 
2004). A well-characterized explanation of etoposide resistance is the overexpression of MRP1 
(encoded by ABCC1) (Legrand, Zittoun et al. 1999, Benyahia, Huguet et al. 2004). However, this 
and other identified targets have failed to make significant clinical impact. 
Considering the dynamic nature of the cells, there have been few efforts addressing the 
transcriptomic profiles generated by drug treatments. Recently, drug-evoked gene expression 
changes (GEC) have been investigated using network analysis of cellular perturbation profiles 
(Rees, Seashore-Ludlow et al. 2016). Further, drug-evoked GEC, have been utilized to investigate 
mechanism and downstream pathways of drug treatments (Iorio, Tagliaferri et al. 2009, Woo, 
Shimoni et al. 2015). Currently, there are a few ongoing big-data initiatives generating 
transcriptomic changes caused by drug treatments, including Connectivity Map (CMap) from the 
Broad Institute. Such resources could be implemented in drug discovery pipelines to facilitate 
target identification based on drug-evoked GEC. 
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Considering the role of TOP2A in transcription, I hypothesized that TOP2 poisoning with 
etoposide could evoke specific GEC across various cancer cell lines. I planned to investigate such 
TOP2A-dependent GEC using an engineered fibrosarcoma cell line (HTETOP) with inducible 
repression of TOP2A. I next planned to explore the etoposide-evoked GEC for treatment 
optimization in the cancer entity AML, described in following section. 
3.4 Acute Myeloid Leukemia 
Acute myeloid leukemia (AML) is a type of blood neoplasm characterized by numerous genomic 
alterations (such as FLT3, NPM1, RUNX1, and IDH1 & 2). AML accounts for 80% of leukemia 
cases in adult patients with 5-year survival rate of 24% (De Kouchkovsky and Abdul-Hay 2016, 
Pearsall, Lincz et al. 2018). Chemotherapy is the main form AML management (Dombret and 
Gardin 2016). Cytarabine and daunorubicin, or idarubicin or mitoxantrone, or sometimes 
cladribine are preferentially utilized for the induction therapy to destroy most of the bone marrow 
cells. However, such intensive therapy is not tolerable to older patients (Ossenkoppele and 
Lowenberg 2015). Furthermore, treatment strategies for relapsed AML are not yet clearly defined. 
MEC regimen (mitoxantrone in combination with etoposide and cytarabine) is one of the common 
regimens used for relapsed AML. However, it is associated with increased side-effects in AML 
patients (Ramos, Mo et al. 2015, Thol, Schlenk et al. 2015). Hence, there is a need to improve 
efficacy and reduce the toxicity of these treatment regimens. To this end, the classical 
chemotherapeutics in AML are gradually being supplemented by drugs targeting molecules and 
processes more specific to cancer cells. For example, midostaurin and enasidenib can be nowadays 
added to standard chemotherapeutic regimens (Stein, DiNardo et al. 2017, Stone, Mandrekar et al. 
2017). However, this option is reserved for patients carrying specific mutations in the protein 
targets of these drugs, FLT3 and IDH2, respectively. 
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I chose AML as a cancer model, since it is frequently treated with etoposide, especially for relapsed 
AML (Dombret and Gardin 2016). This work explores the alternative and largely untested 
approach of fine-tuning approved etoposide-based therapies by combining them with already 
approved or experimental drugs. I reasoned that, 
• etoposide-driven changes in the expression and activity of specific proteins mediate, at 
least in part, etoposide’s cell killing effects and 
• drugs targeting some of these mediators will be already available for testing as combination 
treatments. 
Apoptosis resulting from etoposide-driven DNA damage is accompanied by considerable gene 
expression changes of unexplored consequences (E. Jeong et al., 2018; Troester, Hoadley, Parker, 
& Perou, 2004). I assessed etoposide-driven gene expression changes by comparing pre-and post-
treatment cell transcriptomes. I also considered the impact of prior-to-treatment gene expression 
levels on the response to etoposide across AML cell lines. Here, I reasoned that, in addition to 
expression changes, the response to etoposide is likely to be affected by pre-existing levels of 
proteins modulating its effects. I intended to enrich for drivers as opposed by bystanders of 
etoposide cytotoxicity using two parallel approaches. Firstly, I focused on genes co-regulated 
within networks and additionally correlating with etoposide cytotoxicity. Genes involved in such 
networks are more likely to be involved in etoposide response compared to genes taken 
individually (Langfelder and Horvath 2008, Li, Zhou et al. 2018). Secondly, I focused on 
individual, but essential genes, i.e. on those reducing the survival of each of the AML cell lines 
investigated when knocked down using shRNA (Tsherniak, Vazquez et al. 2017). Here I 
considered that tumor growth and metastasis are driven only by a fraction of the accompanying 
molecular changes and assumed a similar relationship for etoposide response and gene expression 
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levels. Among drivers thus identified, I differentiated between modulators, mediators, and 
emulators of etoposide response. Etoposide modulators are genes, whose expression correlates 
with etoposide cytotoxicity, but remains unchanged upon treatment. Etoposide mediators are genes 
that convey cytotoxicity via etoposide-driven changes in their expression levels. Etoposide 
emulators are upstream gene modulations and other drugs that evoke gene expression profiles 
resembling those evoked by etoposide. 
To distinguish between cytotoxicity drives from bystanders, I developed two parallel approaches. 
Firstly, I considered the network of genes co-regulated across AML cell lines. The reason was 
such genes are more likely to be enriched for etoposide-relevant biological processes compared to 
individual genes (Langfelder and Horvath 2008, Li, Zhou et al. 2018). Secondly, to distinguish 
between mediators and bystanders of etoposide cytotoxicity among etoposide-evoked GEC, I 
considered each gene’s essentiality (Tsherniak et al., 2017) for cell survival in each individual 
AML cell line. Because of unavailability of HTETOP essentiality data, another approach, 
considering high pre-treatment expression, involvement in cancer-related processes, and 
comparative high expression in cancer tissues, was developed to define essentiality. I hypothesized 
that the modulators could be targeted to enhance the efficacy of etoposide, while effectors could 
be investigated for their involvement in the cytotoxicity. 
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4 Materials and methods 
 
4.1 Cell culture and drugs 
HTETOP cell line was kindly provided by Dr. Andy Porter (Imperial College London, UK). It was 
cultured in DMEM media (Sigma Aldrich, Germany) supplemented with 10% FCS, 20 mM 
HEPES buffer, 1 mM sodium pyruvate, and antibiotics as reported before (Carpenter and Porter 
2004). HTETOP cells were maintained at 37°C and 10% CO2. Tetracycline (TET) at 1 µg/ml was 
added to cells resulting in >95% TOP2A mRNA and protein repression (Yan, Deng et al. 2009). 
Acute Myeloid Leukemia (AML) cell lines HL-60, MOLM-13, MONO-MAC-6, MV-4-11, NB-
4, NOMO-1, OCI-AML3, and THP-1 were obtained from Dr. Thomas Kindler, University Medical 
Center, Mainz. Three additional AML cell lines (F-36P, KASUMI-1, and OCI-AML2) were 
purchased from Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ, Germany). 
Cell lines were maintained at 37° C and 5% CO2 in appropriate media (Table 5.7.1). 293T cells 
were cultured in DMEM (Gibco, Germany) along with 10% FBS (Biochrom, Germany). Cell lines 
were routinely verified for mycoplasma contamination using Venor®GeM Mycoplasma Detection 
Kit (Sigma-Aldrich, Germany). Cell lines were authenticated by Multiplexion, Germany. The 
inhibitors were purchased from Abcam (UK), Biozol (Germany), and Santa Cruz Biotechnology 
(US). 
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4.2 Cell viability assay 
1800 cells (in 100 µL media) were seeded in 96 well plates and incubated overnight at 37° C in 
10% CO2 incubator, followed by tetracycline treatment (2 µg/mL in 100 µL media) and incubated 
for 24 hours to knock down the TOP2A expression. Media was then replaced, and the cells were 
treated with different concentrations of etoposide and doxorubicin for 24 and 48 hours. After the 
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treatment, 20 µL MTT were added and cells were incubated for 4 hours at 37° C followed by 
addition of solubilization buffer and then incubated overnight in dark. Absorbance was measured 
at 570 nm. Cell viability in response to drug treatment was calculated considering the absorbance 
of DMSO treated cells as 100% cell viability. 
The viability of AML cell lines in response to etoposide treatment was monitored using WST-8 
cell viability kit (PromoKine, German). All AML cell lines were seeded (1 X 104 cells per well) 
in a 96-well plate and incubated overnight. Cells were then treated for 24 hours with various 
concentrations of etoposide (0.02, 0.05, 0.1, 0.2, 0.37, 0.78, 1.56, 3.13, 6.25, 12.5, 25, 50 µM)., 
after the treatment with etoposide, 10% WST-8 reagent was added to the cells. After 1-4 hours 
incubation in the dark at room temperature, absorbance was measured at 450 nm using Spectramax 
iD3 (Molecular Devices, US) spectrometer. Absorbance from the DMSO-treated cells (vehicle 
control) was considered as 100% cell viability and used to calculate percentage cell viability after 
etoposide treatment. 
4.3 Annexin V apoptosis assay 
The flow cytometry-based apoptosis detection was performed using FITC Annexin V apoptosis 
detection kit I (BD Biosciences). 2 X 105 cells/mL were seeded in a 6-well plate and incubated 
overnight. Cells were then treated with cell line-specific etoposide IC50 concentrations, derived 
from the cell viability assay, for 24 hours, washed twice with ice-cold PBS, and resuspended in 
binding buffer (1 X 106 cells/ml). Thereafter, 100 µL of cell suspension (1 X 105 cells) was 
transferred to a new tube, followed by addition of 5 µL each of Annexin V and PI staining solution 
(FITC Annexin V apoptosis detection kit I, BD Biosciences). Cells were then gently vortexed and 
incubated in dark for 15 minutes at room temperature. 400 µL of binding buffer was then added to 
the cells and analyzed using BD Accuri C6 flow cytometer (BD Biosciences, US). 
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4.4 RNA-Seq: RNA extraction and library preparation 
The gene expression profiles in untreated and etoposide-treated AML and HTETOP cell lines were 
determined by RNA sequencing. 1 X 106 cells per well were seeded in a 6 well plate containing 5 
mL of the media. Cells were incubated overnight and then treated for 24 hours with etoposide at 
cell line-specific IC50 concentrations (for AML cell lines) or at 20 µM concentration (for HTETOP 
cell line). HTETOP cell line was separately treated with doxorubicin at 1 µM concentration for 24 
hours in presence and absence of TOP2A. For HTETOP cell line, only one biological replicate 
was generated. AML cells from 3 wells were then pooled together and total RNA was isolated 
using TriFast, peqGOLD total RNA kit and DNase I Digest kit (VWR PEQLAB GmbH, Germany) 
according to manufacturer's instructions. The quality and integrity of the extracted RNA was 
examined using a 2100 Bioanalyzer (Agilent technologies). Samples were sequenced by Illumina 
HiSeq 2000 using TruSeq stranded mRNA HT sample prep kit. RNA quality analysis, library 
preparation and sequencing was performed by the Genomics Core Facility at the Institute of 
Molecular Biology (IMB, Mainz, Germany). The targeted sequencing depth was 30 million reads 
(for AML) or 50 million reads (for HTETOP). HTETOP samples were generated and sequenced 
at the Star Seq GmbH (Germany) by Dr. Shiwei Deng (University Medical Center, Mainz). 
4.5 RNA-Seq: Analysis 
The quality of raw sequencing reads was assessed using FastQC (Babraham Bioinformatics, 
Cambridge, UK). These reads were then mapped to the human reference genome (gencode release 
25 GRCh38.p7) using the STAR aligner (v2.5.3a) (Dobin, Davis et al. 2013), with the option "--
quantMode GeneCounts" to count the number of reads mapped per gene. Quality of the expression 
data was assessed using NOISeq (v2.20.0) (Tarazona, Furio-Tari et al. 2015) R package (R Core 
Team 2014). The differential gene expression analysis was then performed using edgeR (v3.20.1) 
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(Robinson, McCarthy et al. 2010). Genes with fold-change higher than 2 and false discovery rate 
(FDR) below 0.05 were considered as differentially expressed. The R script used in this analysis 
is appended. 
4.6 Weighted gene co-expression network analysis (WGCNA) 
To identify modulators and mediators of etoposide sensitivity, weighted gene co-expression 
network analysis (WGCNA) was performed using basal gene expression in AML cell lines prior 
and after etoposide treatment. The resulting co-regulated networks were compared to identify 
genes (a) co-regulated only before treatment, (b) co-regulated only after treatment, and (c) 
unaffected by treatment. Gene Ontology analysis was performed for identified networks using the 
Database for Annotation, Visualization and Integrated Discovery (DAVID, 
https://david.ncifcrf.gov/). Cell line specific expression levels of co-regulated genes unaffected by 
treatment were correlated with cell-specific etoposide IC50 concentrations by Pearson correlation 
statistics using the WGCNA package in R (Langfelder and Horvath 2008). The co-regulated genes 
with positive and negative correlation with etoposide IC50 were selected for Gene Ontology 
analysis using DAVID. 
4.7 Identification of mediators among etoposide-evoked gene expression changes 
The Project Achilles (PAch) (Cowley, Weir et al. 2014) dataset was utilized to retrieve genes most 
likely to be essential for AML cell survival. PAch investigated the effect of more than 11k shRNA-
mediated individual gene knockdowns on cell survival in 501 cancer cell lines, including all AML 
cell lines used in the present study. Genes with negative DEMETER scores (defined in a previous 
study (Tsherniak, Vazquez et al. 2017)) were considered essential for cancer cell survival. Genes 
essential for 6 or more AML cell lines as well as differentially expressed after etoposide treatment 
were considered potential essential mediators and validated experimentally. To identify mediators 
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of etoposide cytotoxicity in HTETOP cell line different approach was utilized because of 
unavailability of essentiality data from PAch. The genes highly expressed in HTETOP and 
repressed after etoposide treatment were selected. Gene Ontology analysis was performed using 
Ingenuity Pathway Analysis (IPA, Qiagen Inc., 
https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis) to restrict the 
repressing GEC to the pathways involved in cancer and cell proliferation.  For quantifying the 
gene expression in normal tissues, transcript per million (TPM) data was downloaded for 33 
normal tissues from GTEx. For cancer tissues, fragments per kilobase million (FPKM) data was 
retrieved for 29 cancer tissues from The Cancer Genome Atlas (TCGA). FPKM was then 
converted to TPM and the average expression was compared to normal tissues using R. The genes 
with high expression in cancer tissues were selected and were further screened for their etoposide-
evoked repression in other cancer cell lines obtained from Gene Expression Omnibus (GEO). 
Furthermore, the putative upstream regulators of etoposide-evoked GEC in HTETOP were 
identified using IPA and Connectivity Map (CMap). 
4.8 Prediction of etoposide emulators 
Emulators, i.e. gene modulations and compounds that evoke GEC similar to those following 
etoposides, were identified using the CMap (Subramanian, Narayan et al. 2017). CMap provides 
changes in the expression of 1000 genes following gene perturbations and treatments with 
numerous small-molecule compounds. These genes and drugs were identified by uploading the 
top 300 overlapping etoposide-evoked GEC (150 up- and 150 down-regulated) from AML and 
HTETOP cell lines to CMap via the CLUE platform (CMap and LINCS Unified Environment). 
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4.9 Driver validation using inhibitors 
The inhibitors against the selected drivers were identified using the GeneCards (Ben-Ari Fuchs, 
Lieder et al. 2016), IUPHAR/BPS guide to pharmacology (Alexander, Fabbro et al. 2017), and 
CMap (Subramanian, Narayan et al. 2017) resources. These drivers were then validated using 
WST-8 cell viability assay. AML cell lines were treated for 24 hours with 1 nM, 100 nM, and 10 
µM of each inhibitor alone, as well as in combinations with cell-specific IC25 concentrations of 
etoposide, followed by WST-8 cell viability assay. Percentage cell viability compared to vehicle-
treated cells, taken as 100%, was calculated for single and combination treatments. For 
combination treatment screening, the synergy was defined as per-response additivity approach 
(Foucquier and Guedj 2015). The combination index (CI) was calculated as CI =
EA+EB
EAB
, where EA 
is the effect of inhibitor A, EB is the effect of etoposide and EAB is the effect of combination of 
inhibitor A and etoposide. CI < 1 was considered as synergy with etoposide, while CI > 1 was 
considered as antagonism, and CI = 1 was considered as additive effect. 
4.10 Driver validation using sh/siRNA-mediated gene knockdown 
siRNA sequences targeting the gene of interest in HTETOP cells were selected using Project 
Achilles (PAch) database. The shRNA target sequences with highest consistency scores and lowest 
p-value were selected. The targets of these sequences were verified using online siRNA-Check 
tool developed by Genomics and Bioinformatics Group, LMP, CCR, National Cancer Institute. 
siRNAs were then synthesized using Sigma custom oligo service. HTETOP cells were then 
transfected with 10 nM siRNA for 24 hours using JetPrime transfection reagent. WST-8-based cell 
viability assay was performed 24 hours after transfection to evaluate the effect of gene knockdown 
on cell viability. The gene knockdown was monitored using SYBR green qPCR. Primers used in 
this work are listed in Appendix table 2. 
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To investigate the effect of individual gene knockdowns on AML cell survival, Viral Shah 
(University Medical Center Mainz) cloned shRNA targeting BCL2A1, IGFIR, and ROCK1 into 
Tet-pLKO.1-puro vector (kindly provided by Dimitri Wiederschain, Novartis Institutes for 
BioMedical Research, Cambridge, MA). shRNA sequences were obtained from the PAch resource 
and were synthesized by Sigma-Aldrich, along with RHS4743 expressing scrambled shRNA 
(supplementary data S1 Table 2). Lentiviral particles were generated by co-transfecting psPAX2, 
pMD2.G along with previously generated shRNA expressing vectors into 293T cells. Transfection 
was carried out using TransIT (Mirus) as per the manufacturer’s instructions. To achieve stable 
transduction, AML cell lines were seeded 1 X 106 in a 6-well plate, with each virus supernatant in 
presence of 5 µg/mL polybrene and spin-infected at 2500 rpm at 32°C for 1 and 45 hours. 
Following 16 hours incubation at 37°C, cells were supplemented with 1-2 µg/mL puromycin 
(Sigma-Aldrich, Germany). Furthermore, to induce knockdown of the indicated drivers, 5 X 105 
cells per well were seeded in 6-well cell culture plates. The knockdown was then induced by 
treating the cells with doxycycline (200 ng/mL) and cell viability was measured after 24, 48, and 
72 hours using the WST-8 assay. The effect of shRNA-mediated gene knockdown on cell viability 
was calculated by comparing doxycycline-untreated and -treated cells. 
4.11 DNA damage measurement using flow cytometry 
To compare the amount of DNA damage caused by etoposide alone and in combination with other 
drugs, the levels of phosphorylated H2A.X in HL-60 cells were measured using flow cytometry. 
The fixed HL-60 cells were stained using the H2A.X phosphorylation assay kit (Merck, Germany) 
according to manufacturer’s instructions. In short, 5 X 105 HL-60 cells were seeded per well in a 
6-well plate and incubated overnight. Cells were treated for 24 hours with IC25 concentration of 
etoposide alone and in combination with other drugs. Next, cells were harvested and washed with 
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PBS followed by fixation. Cells were then stained with either FITC-conjugated anti-phospho-
Histone H2A.X (Ser139) or with the negative control mouse IgG-FITC conjugate for 20 minutes 
on ice. The amount of H2A.X was then measured using BD Accuri flow cytometer. The data was 
then analyzed using FlowJo software (v10). 
4.12 TCGA survival analysis 
The raw gene expression counts for 151 AML patients were retrieved from TCGA through the 
Broad GDAC Firehose, along with the clinical data, using the R package RTCGAToolbox (v2.8.0) 
(Samur 2014). Univariate survival analysis compared the groups with high expression (above 
median) and low expression (below median) of selected drivers. p-values for Kaplan-Meier plots 
were calculated using Log-rank test. The comparison between gene expression in AML patients 
and normal blood samples was performed using Gene Expression Profiling Interactive Analysis 
(GEPIA) web server (Tang, Li et al. 2017). 
4.13 Statistical analysis 
Unless otherwise specified, the experiments reflect 3 biological replicates. Data was analyzed 
using R language packages and GraphPad Prism software (v7). Graphs were plotted as mean ± 
SD. The etoposide IC50 concentrations were calculated using GraphPad Prism software by fitting 
the dose response curve by non-linear regression. Shapiro-Wilk test was performed to determine 
normal distribution for parametric tests. Two-way ANOVA with Benjamini and Hochberg FDR 
correction was performed to identify inhibitors with significant cytotoxicity (Benjamini and 
Hochberg 1995). Mann-Whitney test was performed to identify significant expression change 
between resistant and sensitive AML cell lines. 
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5 Results 
5.1 Etoposide-mediated cytotoxicity in HTETOP is TOP2A-dependent 
To investigate the dependency of TOP2A for etoposide-evoked GEC, it was crucial to examine 
TOP2A-specific cytotoxicity of etoposide. To this end, HTETOP cells were treated with different 
concentrations of etoposide and doxorubicin for 24 and 48 hours, in the presence and absence of 
TOP2A. The cell viability was measured using MTT assay. As seen in Fig. 5.1.1, both etoposide 
and doxorubicin exhibited dose-dependent cytotoxicity in HTETOP cell line in the presence of 
TOP2A. However, TOP2A knockdown by tetracycline (TET) treatment inhibited etoposide-
mediated cytotoxicity (Fig. 5.1.1A and B). On the other hand, TOP2A knockdown had no effect 
on doxorubicin-mediated cytotoxicity (Fig. 5.1.1C and D). This is consistent with the known 
mechanism of action of these two drugs, where doxorubicin, in addition to TOP2 poisoning, exerts 
its cytotoxic potential through direct intercalation with the DNA, as well as through damage to the 
mitochondria by means of oxidative stress (ROS generation), and on the other side etoposide being 
solely dependent on TOP2 poisoning. The results demonstrate that, in absence of TOP2A, 
etoposide is very little cytotoxic. Its remaining cytotoxicity most likely results from TOP2B 
poisoning. 
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Fig. 5.1.1: HTETOP cell viability in response to TOP2 poisons. MTT-based cell viability assay in HTETOP cell 
line after treatment with topoisomerase-II (TOP2) poisons etoposide (A and B) and doxorubicin (C and D) after 24 
and 48 hours. Data are represented as mean values ± SD. 
5.2 Etoposide-evoked specific gene repressions in HTETOP cell line 
HTETOP cell line was sequenced by mRNA sequencing before and after 20 µM etoposide or 1 
µM doxorubicin treatment by Dr. Shiwei Deng (University Medical Center, Mainz). After 
processing for the quality control step using FastQC, the paired-end sequencing data was mapped 
to reference genome (hg38) using HISAT2 (version 2.0.4). The count for mapped reads were 
generated using htseq-count (version 0.6.1) and then DESeq2 was used to identify gene expression 
changes following the etoposide treatment. As shown in Fig. 5.2.1, etoposide-evoked gene 
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repressions accounted for 65% of all GEC. On the other hand, doxorubicin-evoked gene inductions 
accounted for 57% of all GEC (Fig. 5.2.2). Furthermore, doxorubicin evoked more GEC (4861) 
compared to etoposide (859) (Fig. 5.2.3A). 
 
Fig. 5.2.1: Effect of etoposide on gene expression in HTETOP cells. Volcano plot representing gene expression 
changes (GEC) in HTETOP cells following etoposide treatment (20 µM) for 24 hours. 
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Fig. 5.2.2: Effect of doxorubicin on gene expression in HTETOP cells. Volcano plot representing gene expression 
changes (GEC) in HTETOP cells following doxorubicin treatment (1µM) for 24 hours. 
I further compared the effect of TOP2A availability on GEC evoked by etoposide and doxorubicin. 
As observed with the cytotoxicity (Fig. 5.1.1), etoposide-evoked GEC were TOP2A dependent, 
while absence of TOP2A did not have high impact on doxorubicin-evoked GEC. In the absence 
of TOP2A, etoposide-evoked GEC reduced from 859 to 91 (Fig. 5.2.3C). There were 425 TOP2A-
dependent GEC evoked by etoposide and 112 evoked by doxorubicin (Fig. 5.2.3D). This reflects 
that, unlike with doxorubicin, a majority of etoposide-evoked GEC are mediated by TOP2A 
poisoning. 
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Fig. 5.2.3: TOP2A-dependent gene expression changes after etoposide and doxorubicin treatments of HTETOP 
cells. (A) Comparison of gene expression changes (GEC) after doxorubicin and etoposide treatment, (B) and (C) 
represent the numbers of GEC after doxorubicin and etoposide treatment respectively, in presence and absence of 
TOP2A, (D) comparison of TOP2A-dependent GEC after doxorubicin and etoposide treatments. 
5.3 Etoposide predominantly represses the high-expressing genes in HTETOP cell 
line 
To understand the mechanism of etoposide-evoked TOP2A-dependent gene repression, the basal 
gene expression level (GEL) in HTETOP cells was investigated. I quantified transcripts per million 
(TPM) from mapped RNA-Seq counts. To correlate TOP2 poisoning-related GEC as a function of 
GEL, I divided all expressed genes into 3 categories according to their TPM values. Next, a density 
graph of all TPM values was plotted to define expressed genes. Then quantile approach was 
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followed to define low, average and high expressing genes. Considering the role of TOP2A in 
transcriptional regulation, I compared etoposide-evoked GEC of high and low expressing genes as 
a function of TOP2A enrichment. High expressing genes were preferentially repressed after both 
doxorubicin and etoposide treatment. When considered at the entire transcriptome level, 22% 
(1067) of genes with high basal GEL were repressed after doxorubicin treatment (Fig. 5.3.1A) 
compared to 0.6% (28) of genes with low basal GEL (Fig. 5.3.1B) in the presence of TOP2A. The 
absence of TOP2A did not have significant impact on doxorubicin-mediated repression of genes 
with high basal GEL. Similarly, 6% (289) of genes with high basal GEL were repressed after 
etoposide treatment (Fig. 5.3.1C) compared to 0.15% (7) of genes with low basal GEL (Fig. 
5.3.1D) in presence of TOP2A. As expected, the absence of TOP2A reduced etoposide-mediated 
repression of the genes with high basal GEL from 6% (289) to 0.15% (7).
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Fig. 5.3.1: Predominance of gene repression after treatment with etoposide and doxorubicin in HTETOP cells. 
Percentage of high (A) and low (B) expressing genes from HTETOP cells differentially expressed after doxorubicin 
treatment in presence and absence of TOP2A. Percentage of high (C) and low (D) expressing genes differentially 
expressed after etoposide treatment in presence and absence of TOP2A. 
The predominance of gene repressions among high expressing genes is in agreement with the role 
of TOP2A in transcription. Some of the repressing GEC could contribute to cell killing effect of 
etoposide, especially repressions in genes essential for survival. 
5.4 Etoposide evokes specific GEC in other cancer entities 
To validate the findings from HTETOP cell line in other cancer entities, I obtained etoposide-
evoked GEC from GEO and CMap. There were 14 cell lines representing 8 cancer types (Table 
5.4.1). Out of these 14 cell lines, 6 cell lines exhibited predominance of etoposide-evoked 
repressing GEC, which could contribute in cell killing. However, all these cell lines had been 
treated with different etoposide concentrations for different timepoints. 
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Table 5.4.1: Effect of etoposide on gene expression in various cancer cell lines. Overview of etoposide-evoked 
gene expression changes (GEC) in the cell lines representing different cancer entities obtained from GEO and 
connectivity Map (CMap). 
Cancer 
type 
Cell line Source 
Accession 
number 
Etoposide 
concentra
tion (µM) 
Treatm
ent time 
(hours) 
Numbers 
of 
induced 
genes (%) 
Numbers 
of 
repressed 
genes (%) 
AML HL-60 
Connectivity 
Map 
- 7 6 185 (59%) 127 (41%) 
B cell 
lymphoma 
OCI-Ly3 GEO GSE60408 IC20 24 56 (1%) 
5478 
(99%) 
OCI-Ly7 GEO GSE60409 IC20 24 351 (64%) 198 (36%) 
U-2932 GEO GSE60410 IC20 24 280 (49%) 291 (51%) 
Breast 
cancer 
HME-CC GEO GSE1647 10 12 439 (54%) 380 (46%) 
MCF-7 GEO GSE1648 40 12 56 (43%) 74 (57%) 
ME-16-C GEO GSE1649 20 12 101 (49%) 107 (51%) 
ZR-75-1 GEO GSE1650 30 12 308 (31%) 681 (69%) 
Burkitt’s 
lymphoma 
Ramos GEO GSE23169 20 6 624 (34%) 
1218 
(66%) 
Colorectal 
cancer 
HCT-116 GEO GSE71980 20 - 
3016 
(51%) 
2844 
(49%) 
SW-620 GEO GSE33624 60 2 897 (58%) 661 (42%) 
Fibrosarco
ma 
HT-1080 GEO GSE59368 3 24 245 (47%) 281 (53%) 
Histiocytic 
lymphoma 
U-937 GEO GSE66660 0.4 48 359 (76%) 115 (24%) 
Melanoma MelJuSo GEO GSE33624 60 2 516 (78%) 144 (22%) 
Prostate 
cancer 
PC-3 
Connectivity 
Map 
- 7 6 14 (56%) 11 (44%) 
 
After comparing the etoposide-evoked GEC from all cancer cell lines obtained from GEO, CMap, 
and from my experiment in HTETOP, I identified overlapping GEC among these cell lines. BTG2 
(NGF-inducible anti-proliferative protein PC3) was induced in 8, while PLK1 (polo-like kinase 1) 
was repressed in 10 cancer cell lines after etoposide treatment ( 
 
 
32        Results 
 
Table 5.4.2A and B). 
 
 
 
Table 5.4.2: Overview of the etoposide-evoked gene expression changes (GEC) overlapping in 5 or more cancer 
cell lines. (A) Etoposide-evoked inducing GEC (B) Etoposide-evoked repressing GEC (top 22 shown). 
A   B  
Etoposide-
induced genes 
Number 
of cell 
lines 
 Etoposide-
repressed genes 
Number of 
cell lines 
BTG2 8  PLK1 10 
ATF3 7  CDC20 9 
CDKN1A 7  CENPE 9 
CD86 6  PSRC1 8 
GDXR 6  ASPM 7 
GDF15 6  BUB1 7 
IFI6 6  CCNB1 7 
RETSAT 6  CENPF 7 
SESN1 6  DLGAP5 7 
SLAMF7 6  HMMR 7 
TP53I3 6  MKI67 7 
ACTA2 5  STAG1 7 
ANKRA2 5  SYNCRIP 7 
CEACAM1 5  TOP2A 7 
CYFIP2 5  AURKA 6 
FAS 5  BIRC5 6 
FUCA1 5  BUB1B 6 
GAA 5  CCNB2 6 
GADD45A 5  CCNF 6 
JUN 5  DIAPH3 6 
SFN 5  DPYD 6 
TP53INP1 5  KIF4A 6 
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5.5 Prediction and validation of mediators of etoposide cytotoxicity in HTETOP cell 
line 
I restricted the prediction to the etoposide-evoked genes repressions because of their predominance 
in HTETOP cell line. To define essential gene repressions, I first selected the genes with high basal 
GEL and subsequent repression after etoposide treatment (289 genes). These genes were then 
restricted to 53 genes based on pathways involved in cancer and cell proliferation, using IPA. 
Then, the GEC from other cancer cell lines was used to select genes which are repressed in multiple 
cancer cell lines. Finally, gene expression for selected genes were compared in normal and cancer 
tissues to select essential gene repressions. Fig. 5.5.1 represents an example of DLGAP5 
expression across normal and cancer tissues. DLGAP5 and other selected genes had higher average 
expression in cancer tissues compared to normal tissues. 
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Fig. 5.5.1: Expression of etoposide-mediator in cancer tissues. Boxplot representing average DLGAP5 expression 
across 33 normal tissues obtained from GTEx and 29 cancer tissues obtained from TCGA. 
IPA and CLUE resources provided the putative upstream regulators modulating etoposide-evoked 
GEC in HTETOP cell line. Altogether, I selected 14 predicted essential repressing GEC and 6 
putative upstream regulators from IPA and CLUE (Table 5.5.1). All the identified targets were 
knocked down using siRNA-mediated transfection. The siRNA sequences are listed in Appendix 
table 1. The knockdown was confirmed by SYBR green qPCR using target specific primers. 
Table 5.5.1: Selected mediators among etoposide-evoked gene expression changes (GEC) and putative 
upstream regulators in HTETOP cell line. Log2FC represents fold change from RNA-Seq experiments after the 
etoposide treatment. Comparison with other cancer cell lines is based obtained from gene expression omnibus (GEO) 
and connectivity map (CMap). 
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Gene 
symbol 
Log2FC 
(HTETOP) 
Number of 
cancer cell lines 
gene repressed 
in 
Cancer cell lines gene repressed in 
Etoposide-repressed genes with high expression in HTETOP 
CDC20 -1.6 9 
HCT-116, HL-60, HT-1080, HTETOP, MCF-7, 
OCI-Ly3, Ramos, U-2932, ZR-75-1 
CDK6 -1.7 3 HME-CC, HTETOP, OCI-Ly3 
CENPF -1.6 7 
HCT-116, HL-60, HT-1080, HTETOP, MCF-7, 
OCI-Ly3, ZR-75-1 
DLGAP5 -1.2 7 
HCT116, HL-60, HT-1080, HTETOP, MCF-7, 
OCI-Ly-3, ZR-75-1 
FOSL1 -1.2 2 HTETOP, Ramos 
HMGA2 -1.6 1 HTETOP 
IGF2BP
1 
-1.1 2 HTETOP, OCI-Ly3 
KIF20A -1.2 5 HCT-116, HL-60, HTETOP, MCF-7, OCI-Ly3 
MCM6 -1.2 6 
HCT-116, HT-1080, HTETOP, MelJuSo, OCI-
Ly3, ZR-75-1 
NCAPD2 -1.4 4 HCT-116, HTETOP, OCI-Ly3, ZR-75-1 
PFKP -1.2 2 HTETOP, OCI-Ly3 
PLAU -1.4 2 HME-CC, HTETOP 
SLC7A5 -1.3 3 HME-CC, HTETOP, OCI-Ly3 
TPX2 -1.1 6 
HCT-116, HT-1080, HTETOP, MCF-7, OCI-
Ly3, ZR-75-1 
Upstream regulators (Ingenuity) 
ANLN -1.3 5 
HCT-116, HT-1080, HTETOP, OCI-Ly3, ZR-
75-1 
FOXM1 -1.4 3 HCT-116, HT-1080, HTETOP 
Gene knockdowns evoking etoposide-like GEC (emulators) 
MED1 - 1 ZR-75-1 
RPA2 - 1 HCT-116 
TOPBP1 - 1 HCT-116 
YWHAH - 2 ZR-75-1 
To achieve optimal gene knockdown, I optimized the cell seeding density and siRNA 
concentration. I selected the density of 5000 cells in as 96-well plate and 10nM siRNA 
concentration, as these parameters show minimum effect of scrambled sequence transfection on 
cell viability (Fig. 5.5.2). 
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Fig. 5.5.2: Optimization of cell numbers and siRNA concentration for knockdown in HTETOP cell line. 
Next, I measured the percentage of viable cells after knocking down all the selected targets using 
siRNA. In addition, I also investigated the effects of knockdown on etoposide sensitization by 
etoposide treatment at IC50 concentration for 24 hours after the siRNA transfection for 24 hours. 
As shown in Fig. 5.5.3, the knockdown of the predicted essential GEC PFKP and PLAU and of 
the putative upstream regulator ANLN exerted cytotoxic response in HTETOP cell line. However, 
no target sensitized cells to etoposide treatment. 
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Fig. 5.5.3: Effect of knockdown of the mediators of etoposide cytotoxicity on cell viability and etoposide 
sensitization using WST-8 cell viability assay. Predicted mediators of etoposide cytotoxicity were knocked down 
using siRNA for 24 hours. Percentage cell viability compared to untransfected cells, taken as 100%, was calculated 
and Mann-Whitney statistical test was performed using GraphPad Prism software (v7) to identify significant gene 
knockdowns compared to scrambled (SCR) sequence. (*q value < 0.05). 
 
5.6 Identifying transcriptional modulators and effectors of etoposide in AML: Pipeline 
overview 
To identify drugs that could supplement or replace etoposide, I determined, analyzed, and 
functionally verified gene expression profiles prior and after etoposide treatment (Fig. 5.6.1). 
Since multiple AML cell lines were available in contrast to HTETOP, an approach different from 
the one described for HTETOP cell line was developed to facilitate identification of etoposide 
cytotoxicity drivers. Two parallel approaches were followed. First, I identified networks of co-
expressing genes (step 1). Genes derived from co-expressing networks, whose co-regulation was 
unaffected by etoposide and whose expression correlated with etoposide IC50 were defined as 
potential modulators of etoposide cytotoxicity (step 2). Second, among the etoposide-evoked GEC 
(step 3), the essential genes were identified by applying PAch-derived survival essentiality filter 
(step 4). Putative etoposide emulators, i.e. gene modulations and drugs that cause GEC either 
similar or contrary to those evoked by etoposide, were identified using CMap (step 5). Putative 
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modulators, effectors and emulators thus identified were further scrutinized regarding biological 
function, relevance to a majority of AML cell lines, inhibitor availability, and subjected to 
functional validation. 
 
 
Fig. 5.6.1: Pipeline to identify transcriptional drivers of etoposide in AML. Step 1 and 2 represent quantification 
of genome-wide gene expression levels (GEL) prior and after etoposide treatment respectively, followed by co-
expression network construction in step 3 and 4. Step 5 corresponds to comparison of co-expressing gene clusters 
before and after treatment to identify differentially co-expressed genes (DCG). Gene expression changes (GEC) from 
step 6 were utilized to identify GEC essential for survival (step 7) and etoposide-like or -contrary transcriptional 
drivers (step 8). 
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5.7 AML cell lines are differentially sensitive to etoposide treatment 
I investigated the response of 11 AML cell lines to 6 or 24 hours of etoposide treatment (0.02 – 50 
µM) using WST-8 cell viability assay. Most of the cell lines did not respond sufficiently to 6-hour 
etoposide treatment (Fig. 5.7.1). Hence, the experiment was proceeded with 24 hours treatment, 
which revealed differential response by AML cell lines (Fig. 5.7.2). The IC50 concentrations varied 
from 0.3 µM, for the most sensitive cell line OCI-AML2, to 99 µM, for the most resistant cell line 
F-36P ( 
Table 5.7.1). 
Cell lines RRID 
AML 
classification 
Growth 
medium 
Fetal calf 
serum 
(heat 
inactivated) 
Supplements 
Growth 
condition 
Etoposide IC50 
(µM) 
Etoposide 
IC25 
(µM) 
F-36P CVCL_2037 AML M6 
RPMI 1640 
20% 
10 ng/ml 
granulocyte-
macrophhage 
colony 
stimulating 
factor 
37° C, 5% CO2 
98.81 25.96 
HL-60 CVCL_0002 AML M3 10% - 0.74 0.48 
KASUMI-1 CVCL_0589 AML M2 20% - 6.80 1.43 
MOLM-13 CVCL_2119 AML M5 10% - 0.39 0.12 
MONO-
MAC-6 
CVCL_1426 AML M5 10% 
MEM Non-
essential 
amino-acid 
solution, 
100mM Na-
pyruvate, 
10µg/mL 
human insulin 
4.39 2.34 
MV-4-11 CVCL_0064 AML M5 10% - 1.33 0.36 
NB-4 CVCL_0005 AML M3 10% - 0.50 0.25 
NOMO-1 CVCL_1609 AML M5 10% - 1.65 0.95 
OCI-AML2 CVCL_1619 AML M4 
alpha-MEM 
20% - 0.29 0.16 
OCI-AML3 CVCL_1844 AML M4 20% - 1.00 0.58 
THP-1 CVCL_0006 AML M5 RPMI 1640 10% - 1.01 0.63 
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Fig. 5.7.1: WST8-based concentration dependent effect of etoposide on survival of AML cell lines after 6 hours 
treatment. Percentage cell viability compared to vehicle-treated cells, taken as 100%, was calculated. Dose response 
curve was generated by fitting the data by non-linear regression using GraphPad Prism software (v7). Values represent 
mean ± SD from 3 biological replicates. 
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Fig. 5.7.2: WST8-based concentration dependent effect of etoposide on survival of AML cell lines after 24 hours 
treatment. Percentage cell viability compared to vehicle-treated cells, taken as 100%, was calculated. Dose response 
curve was generated by fitting the data by non-linear regression using GraphPad Prism software (v7). Values represent 
mean ± SD from 3 biological replicates. 
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Table 5.7.1: Culture conditions and etoposide response by all investigated AML cell lines. Etoposide IC50 and IC25 concentrations were derived using GraphPad 
Prism software (v7) by fitting the dose response curve by non-linear regression. RRID of the cell lines were obtained from the Resource Identification Portal.
Cell lines RRID 
AML 
classification 
Growth 
medium 
Fetal calf 
serum 
(heat 
inactivated) 
Supplements 
Growth 
condition 
Etoposide IC50 
(µM) 
Etoposide 
IC25 (µM) 
F-36P CVCL_2037 AML M6 
RPMI 1640 
20% 
10 ng/ml 
granulocyte-
macrophhage 
colony 
stimulating 
factor 
37° C, 5% CO2 
98.81 25.96 
HL-60 CVCL_0002 AML M3 10% - 0.74 0.48 
KASUMI-1 CVCL_0589 AML M2 20% - 6.80 1.43 
MOLM-13 CVCL_2119 AML M5 10% - 0.39 0.12 
MONO-
MAC-6 
CVCL_1426 AML M5 10% 
MEM Non-
essential 
amino-acid 
solution, 
100mM Na-
pyruvate, 
10µg/mL 
human insulin 
4.39 2.34 
MV-4-11 CVCL_0064 AML M5 10% - 1.33 0.36 
NB-4 CVCL_0005 AML M3 10% - 0.50 0.25 
NOMO-1 CVCL_1609 AML M5 10% - 1.65 0.95 
OCI-AML2 CVCL_1619 AML M4 
alpha-MEM 
20% - 0.29 0.16 
OCI-AML3 CVCL_1844 AML M4 20% - 1.00 0.58 
THP-1 CVCL_0006 AML M5 RPMI 1640 10% - 1.01 0.63 
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These IC50 concentrations were derived from WST8-based cell viability assay, which measures 
the metabolic activity of cells. Cellular dehydrogenases reduce WST-8 to water soluble formazan, 
whose level corresponds to viability of cells. This approach might leave out the metabolically 
inactive, but live cells. Hence, WST-derived IC50 concentrations were validated for apoptosis using 
flow cytometric measurements of Annexin V-FITC stained AML cell lines treated with cell-
specific IC50 concentrations of etoposide. I expected 50% apoptosis with etoposide treatment at 
cell-specific IC50 concentrations. I observed 19 – 51% apoptosis after etoposide treatment (Fig. 
5.7.3). 
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Fig. 5.7.3: Percentage of apoptotic AML cells in response to etoposide treatment. Different AML cell lines were 
treated with IC25 concentrations of etoposide for 24 hours, followed by Annexin-FITC and PI staining and detection 
by flow cytometry. Quadrant LL represents healthy cells, LR represents early apoptotic cells, and UR represents late 
apoptotic cells. 
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5.8 Modulators of etoposide synergize AML cell lines to drug 
To identify modulators of etoposide whose expression correlate with etoposide response, all AML 
cell lines were treated with cell-specific IC50 concentrations of etoposide for 24 hours to obtain 
similar cytotoxicity levels. The RNA-Seq data from etoposide-treated OCI-AML2 cells was 
discarded, because it failed in the quality control of raw RNA sequences. Using WGCNA, I 
identified genes co-regulated in all 11 untreated AML cell lines, as well as in the remaining 10 
etoposide-treated cell lines. I identified the genes co-regulated in untreated cell lines as well as in 
etoposide-treated AML cell lines. The co-regulated genes found only in untreated cells comprise 
cell proliferation, transcription, apoptosis, and others (Table 5.8.1). The genes co-regulated only 
in networks newly formed after etoposide treatment regulate, among others, transcription, response 
to DNA damage, and DNA repair (Table 5.8.2). 
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Table 5.8.1: Pathways corresponding to co-expressing gene clusters in untreated AML cell lines. WGCNA 
analysis was performed to identify gene clusters co-regulated in untreated AML cell lines. These clusters were 
annotated for biological processes using DAVID. Modules from last column (color names) represent identified 
clusters. Terms highlighted in bold type are etoposide-treatment related processes. 
Term Counts PValue Module names 
GO:0006351~transcription, DNA-templated 19 0.01 darkolivegreen 
GO:0000122~negative regulation of transcription from RNA 
polymerase II promoter 
12 0.01 orange 
GO:0000122~negative regulation of transcription from RNA 
polymerase II promoter 
11 0.00 darkolivegreen 
GO:0045892~negative regulation of transcription, DNA-
templated 
10 0.01 orange 
GO:0051301~cell division 9 0.03 salmon 
GO:0006915~apoptotic process 8 0.02 darkolivegreen 
GO:0008380~RNA splicing 8 0.00 orange 
GO:0000398~mRNA splicing, via spliceosome 8 0.00 orange 
GO:0007067~mitotic nuclear division 8 0.02 salmon 
GO:0016032~viral process 8 0.04 salmon 
GO:0000086~G2/M transition of mitotic cell cycle 7 0.00 orange 
GO:0043123~positive regulation of I-kappaB kinase/NF-
kappaB signaling 
7 0.01 salmon 
GO:0015031~protein transport 7 0.02 steelblue 
GO:0008285~negative regulation of cell proliferation 6 0.04 darkolivegreen 
GO:0006406~mRNA export from nucleus 6 0.00 orange 
GO:0051092~positive regulation of NF-kappaB transcription 
factor activity 
6 0.01 salmon 
GO:0007050~cell cycle arrest 6 0.02 salmon 
GO:0050852~T cell receptor signaling pathway 6 0.02 salmon 
GO:0098609~cell-cell adhesion 5 0.04 darkolivegreen 
GO:0010629~negative regulation of gene expression 5 0.02 orange 
GO:0006888~ER to Golgi vesicle-mediated transport 5 0.03 orange 
GO:0090090~negative regulation of canonical Wnt signaling 
pathway 
5 0.03 orange 
GO:0006397~mRNA processing 5 0.04 orange 
GO:0018105~peptidyl-serine phosphorylation 5 0.04 salmon 
GO:0010629~negative regulation of gene expression 5 0.00 skyblue3 
GO:0006890~retrograde vesicle-mediated transport, Golgi to 
ER 
5 0.00 steelblue 
GO:0031124~mRNA 3'-end processing 4 0.01 orange 
GO:0006405~RNA export from nucleus 4 0.01 orange 
GO:0032091~negative regulation of protein binding 4 0.01 orange 
GO:0006369~termination of RNA polymerase II transcription 4 0.01 orange 
GO:0016569~covalent chromatin modification 4 0.04 orange 
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GO:0070507~regulation of microtubule cytoskeleton 
organization 
4 0.00 salmon 
GO:0007249~I-kappaB kinase/NF-kappaB signaling 4 0.03 salmon 
GO:0071456~cellular response to hypoxia 4 0.01 skyblue3 
GO:0018105~peptidyl-serine phosphorylation 4 0.02 skyblue3 
GO:0042787~protein ubiquitination involved in ubiquitin-
dependent protein catabolic process 
4 0.05 steelblue 
GO:0048593~camera-type eye morphogenesis 3 0.00 darkolivegreen 
GO:0007052~mitotic spindle organization 3 0.02 orange 
GO:0000381~regulation of alternative mRNA splicing, via 
spliceosome 
3 0.03 orange 
GO:0010501~RNA secondary structure unwinding 3 0.04 orange 
GO:0014067~negative regulation of phosphatidylinositol 3-
kinase signaling 
3 0.00 salmon 
GO:0032006~regulation of TOR signaling 3 0.01 salmon 
GO:0030214~hyaluronan catabolic process 3 0.01 salmon 
GO:0021542~dentate gyrus development 3 0.01 salmon 
GO:0070423~nucleotide-binding oligomerization domain 
containing signaling pathway 
3 0.03 salmon 
GO:2001238~positive regulation of extrinsic apoptotic 
signaling pathway 
3 0.03 salmon 
GO:0046627~negative regulation of insulin receptor 
signaling pathway 
3 0.04 salmon 
GO:0010803~regulation of tumor necrosis factor-mediated 
signaling pathway 
3 0.04 salmon 
GO:0032480~negative regulation of type I interferon 
production 
3 0.04 salmon 
GO:0070555~response to interleukin-1 3 0.05 salmon 
GO:0051321~meiotic cell cycle 3 0.05 salmon 
GO:0007018~microtubule-based movement 3 0.04 skyblue3 
GO:0045931~positive regulation of mitotic cell cycle 3 0.01 steelblue 
GO:0007595~lactation 3 0.02 steelblue 
GO:0060337~type I interferon signaling pathway 3 0.05 steelblue 
GO:0061484~hematopoietic stem cell homeostasis 2 0.02 
Dark 
olivegreen 
GO:0071929~alpha-tubulin acetylation 2 0.02 salmon 
GO:0090140~regulation of mitochondrial fission 2 0.03 steelblue 
GO:0019885~antigen processing and presentation of 
endogenous peptide antigen via MHC class I 
2 0.04 steelblue 
GO:0051988~regulation of attachment of spindle 
microtubules to kinetochore 
2 0.04 steelblue 
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Table 5.8.2: Pathways corresponding to co-expressing gene clusters in etoposide-treated AML cell lines. 
WGCNA analysis was performed to identify gene clusters co-regulated in etoposide-treated AML cell lines. These 
clusters were annotated for biological processes using DAVID. Modules from last column (color names) represent 
identified clusters. Terms highlighted in bold type are etoposide-treatment related processes. 
Term Count PValue Modules 
GO:0006351~transcription, DNA-templated 61 0.00 tan 
GO:0006355~regulation of transcription, DNA-templated 52 0.00 tan 
GO:0006351~transcription, DNA-templated 40 0.05 magenta 
GO:0006355~regulation of transcription, DNA-templated 32 0.05 magenta 
GO:0006351~transcription, DNA-templated 23 0.02 royalblue 
GO:0000122~negative regulation of transcription from RNA 
polymerase II promoter 
22 0.00 magenta 
GO:0006364~rRNA processing 20 0.00 magenta 
GO:0051301~cell division 19 0.00 tan 
GO:0006260~DNA replication 17 0.00 tan 
GO:0007067~mitotic nuclear division 17 0.00 tan 
GO:0051301~cell division 14 0.00 magenta 
GO:0006281~DNA repair 13 0.00 tan 
GO:0006468~protein phosphorylation 12 0.00 Light yellow 
GO:0007062~sister chromatid cohesion 11 0.00 tan 
GO:0000398~mRNA splicing, via spliceosome 11 0.00 tan 
GO:0042384~cilium assembly 9 0.00 magenta 
GO:0060271~cilium morphogenesis 9 0.00 magenta 
GO:0000722~telomere maintenance via recombination 9 0.00 tan 
GO:0000082~G1/S transition of mitotic cell cycle 9 0.00 tan 
GO:0006974~cellular response to DNA damage stimulus 9 0.02 tan 
GO:0006281~DNA repair 8 0.00 Royal blue 
GO:0006888~ER to Golgi vesicle-mediated transport 8 0.01 tan 
GO:0098609~cell-cell adhesion 7 0.01 Dark red 
GO:0010501~RNA secondary structure unwinding 7 0.00 magenta 
GO:0070126~mitochondrial translational termination 7 0.00 magenta 
GO:0016569~covalent chromatin modification 7 0.00 royalblue 
GO:0008380~RNA splicing 7 0.00 royalblue 
GO:0051301~cell division 7 0.04 royalblue 
GO:0007059~chromosome segregation 7 0.00 tan 
GO:0000724~double-strand break repair via homologous 
recombination 
7 0.00 tan 
GO:1901796~regulation of signal transduction by p53 class 
mediator 
7 0.01 tan 
GO:0000086~G2/M transition of mitotic cell cycle 7 0.02 tan 
GO:0006888~ER to Golgi vesicle-mediated transport 6 0.00 darkred 
GO:0070125~mitochondrial translational elongation 6 0.00 ivory 
GO:0070126~mitochondrial translational termination 6 0.00 ivory 
GO:0070125~mitochondrial translational elongation 6 0.01 magenta 
GO:0090263~positive regulation of canonical Wnt signaling 
pathway 
6 0.04 magenta 
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GO:0042787~protein ubiquitination involved in ubiquitin-
dependent protein catabolic process 
6 0.00 royalblue 
GO:0007067~mitotic nuclear division 6 0.03 royalblue 
GO:0006271~DNA strand elongation involved in DNA 
replication 
6 0.00 tan 
GO:0000731~DNA synthesis involved in DNA repair 6 0.00 tan 
GO:0006302~double-strand break repair 6 0.00 tan 
GO:0019886~antigen processing and presentation of exogenous 
peptide antigen via MHC class II 
5 0.00 darkred 
GO:0000209~protein polyubiquitination 5 0.04 darkred 
GO:0001701~in utero embryonic development 5 0.04 darkred 
GO:0006364~rRNA processing 5 0.00 ivory 
GO:0006412~translation 5 0.01 ivory 
GO:0038061~NIK/NF-kappaB signaling 5 0.02 magenta 
GO:0051436~negative regulation of ubiquitin-protein ligase 
activity involved in mitotic cell cycle 
5 0.02 magenta 
GO:0051437~positive regulation of ubiquitin-protein ligase 
activity involved in regulation of mitotic cell cycle transition 
5 0.03 magenta 
GO:0031145~anaphase-promoting complex-dependent 
catabolic process 
5 0.03 magenta 
GO:0006368~transcription elongation from RNA polymerase II 
promoter 
5 0.04 magenta 
GO:0006364~rRNA processing 5 0.03 orange 
GO:0007062~sister chromatid cohesion 5 0.01 royalblue 
GO:0006511~ubiquitin-dependent protein catabolic process 5 0.04 royalblue 
GO:0006270~DNA replication initiation 5 0.00 tan 
GO:0042769~DNA damage response, detection of DNA 
damage 
5 0.00 tan 
GO:0019985~translesion synthesis 5 0.00 tan 
GO:0034080~CENP-A containing nucleosome assembly 5 0.00 tan 
GO:0043966~histone H3 acetylation 5 0.00 tan 
GO:0030307~positive regulation of cell growth 5 0.04 tan 
GO:0051436~negative regulation of ubiquitin-protein ligase 
activity involved in mitotic cell cycle 
4 0.01 darkred 
GO:0051437~positive regulation of ubiquitin-protein ligase 
activity involved in regulation of mitotic cell cycle transition 
4 0.01 darkred 
GO:0031145~anaphase-promoting complex-dependent 
catabolic process 
4 0.02 darkred 
GO:0030521~androgen receptor signaling pathway 4 0.00 lightyellow 
GO:0006446~regulation of translational initiation 4 0.02 magenta 
GO:0001541~ovarian follicle development 4 0.03 magenta 
GO:0075733~intracellular transport of virus 4 0.04 magenta 
GO:0006521~regulation of cellular amino acid metabolic 
process 
4 0.04 magenta 
GO:0030150~protein import into mitochondrial matrix 4 0.00 orange 
GO:0032508~DNA duplex unwinding 4 0.00 royalblue 
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GO:0006310~DNA recombination 4 0.02 royalblue 
GO:0006338~chromatin remodeling 4 0.02 royalblue 
GO:0000083~regulation of transcription involved in G1/S 
transition of mitotic cell cycle 
4 0.01 tan 
GO:0000732~strand displacement 4 0.01 tan 
GO:0006139~nucleobase-containing compound metabolic 
process 
4 0.04 tan 
GO:0009725~response to hormone 3 0.04 lightyellow 
GO:0007566~embryo implantation 3 0.04 lightyellow 
GO:0070936~protein K48-linked ubiquitination 3 0.05 lightyellow 
GO:0001522~pseudouridine synthesis 3 0.02 magenta 
GO:0030490~maturation of SSU-rRNA 3 0.02 magenta 
GO:0000470~maturation of LSU-rRNA 3 0.02 magenta 
GO:0042771~intrinsic apoptotic signaling pathway in 
response to DNA damage by p53 class mediator 
3 0.01 orange 
GO:0043124~negative regulation of I-kappaB kinase/NF-
kappaB signaling 
3 0.02 orange 
GO:0031124~mRNA 3'-end processing 3 0.05 royalblue 
GO:0046600~negative regulation of centriole replication 3 0.00 tan 
GO:0006269~DNA replication, synthesis of RNA primer 3 0.00 tan 
GO:0006884~cell volume homeostasis 3 0.01 tan 
GO:0031571~mitotic G1 DNA damage checkpoint 3 0.01 tan 
GO:0071732~cellular response to nitric oxide 3 0.02 tan 
GO:0007099~centriole replication 3 0.02 tan 
GO:0042276~error-prone translesion synthesis 3 0.03 tan 
GO:0007091~metaphase/anaphase transition of mitotic cell 
cycle 
2 0.03 darkred 
GO:0031325~positive regulation of cellular metabolic process 2 0.03 darkred 
GO:0032042~mitochondrial DNA metabolic process 2 0.03 lightyellow 
GO:0009299~mRNA transcription 2 0.04 lightyellow 
GO:0000472~endonucleolytic cleavage to generate mature 5'-
end of SSU-rRNA from (SSU-rRNA, 5.8S rRNA, LSU-rRNA) 
2 0.04 magenta 
GO:0042347~negative regulation of NF-kappaB import into 
nucleus 
2 0.06 orange 
GO:0032877~positive regulation of DNA endoreduplication 2 0.03 tan 
GO:0043009~chordate embryonic development 2 0.05 tan 
 
By comparing pre- and post-treatment networks, I identified and analyzed genes with co-regulation 
unaffected by the treatment (Fig. 5.8.1A and B). In the figure, color names highlighted in bold 
type on y-axis are the clusters uniquely present in either untreated or etoposide-treated AML cell 
lines. I further analyzed the gene clusters unaffected by the treatment. The 24 treatment-unaffected 
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clusters comprised 5711 genes. The genes with expression levels correlating with etoposide 
response were involved in processes such as apoptosis, proteasomal catabolism, response to DNA 
damage, and DNA repair. The 71 genes correlating positively (p < 0.05, Pearson’s r > |0.5|, S1 
Table 5) with etoposide IC50 concentrations were considered putative assisting modulators; the 
909 negatively correlating ones as putative impeding modulators. Among them, I identified the 
previously reported modulators SLFN11 (Zoppoli, Regairaz et al. 2012, Rees, Seashore-Ludlow 
et al. 2016) and SMARCA4 (Lee, Celik et al. 2018) whose expression correlated with etoposide 
sensitivity. 
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Fig. 5.8.1: WGCNA consensus network analysis. (A) Comparison of co-expression modules identified in untreated 
AML cell lines with consensus network (present in both untreated and etoposide-treated AML cell lines). (B) 
Comparison of co-expression modules identified in etoposide-treated AML cell lines with consensus network (present 
in both untreated and etoposide-treated AML cell lines). Color names on X- and Y-axis represent individual co-
expressing modules and the number next to module represent total number of co-expressing genes identified in that 
particular module. Numbers in the heatmap represent number of genes common to consensus network on the X-axis, 
while the number of genes to extreme right (common to Cons grey module) are the co-expressing genes unique to 
untreated AML cells. 
 
Fig. 5.8.2: Gene Ontology analysis for etoposide-modulators. Top 20 biological processes for the co-expressed 
genes from the consensus network negatively correlating with etoposide sensitivity. The scale represents number of 
genes enriched for individual biological processes. Processes previously linked to etoposide are shown in bold type. 
 
The putative impeding modulators BIRC5 and PARP9 (correlation is shown in Fig. 5.8.3) were 
selected for experimental validation using chemical inhibitors against their protein products 
because of their involvement in apoptosis regulation and in double strand break repair, 
respectively. NOTCH1 (Fig. 5.8.3) was selected for experimental validation to confirm its putative 
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etoposide-assisting activity. AML cell lines were treated for 24 hours with 3 concentrations (0.001 
µM, 0.1 µM, and 10 µM) of chemical inhibitors alone, as well as in combination with cell line-
specific IC25 concentrations of etoposide. The BIRC5 inhibitor GDC-0152 and the PARP inhibitor 
nicotinamide exhibited effects synergistic or additive to etoposide in 9 and 10 cell lines, 
respectively. The NOTCH1 inhibitor LY-3039478 antagonized with etoposide in 8 out of 11 AML 
cell lines (Fig. 5.8.4, Table 5.8.3, and Appendix table 5). Stand-alone cytotoxicity was observed 
in OCI-AML3 cells following BIRC5 inhibition and in two cell lines following NOTCH1 
inhibition (Table 5.8.3 and Appendix table 4). In summary, all putative modulators investigated 
were confirmed by chemical inhibitors. 
 
Fig. 5.8.3: Modulators gene expression correlation with etoposide sensitivity. Pearson correlations between the 
pre-treatment basal gene expression level of the impeding modulators BIRC5 and PARP9 and of the assisting 
modulator NOTCH1 with etoposide sensitivity across AML cell lines. 
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Fig. 5.8.4: Synergy of modulators with etoposide in AML cells. Combination index (CI; see Methods section 4.9 
for details) for the cytotoxicity following treatment with IC25 concentrations of etoposide with inhibitors targeting the 
impeding modulators BIRC5 and PARP9 and the assisting modulator NOTCH1. CI < 1: synergism, CI = 1: additivity, 
and CI > 1: antagonism. 
 
Driver type Targets (inhibitors) 
Stand-alone 
cytotoxicity (no. of cell 
lines) 
Synergy/additivity with 
etoposide (no. of cell 
lines) 
Modulators 
NOTCH1 (LY-3039478) 2 2 
BIRC5 (GDC-0152) 1 9 
PARP9 (Nicotinamide) 0 10 
Mediators 
BCL2A1 (Sabutoclax) 11 1 
PRKCH (Sotrastaurin) 7 3 
PLK1 (Volasertib) 11 1 
IGF1R (GSK-
1838705A) 
9 2 
Emulators 
MYC (TWS-119) 10 2 
mTORi (Rapamycin) 7 6 
HDACi (Vorinostat) 9 9 
ROCK1 (Rockout) 3 7 
Table 5.8.3: Overview of the drivers of etoposide cytotoxicity in AML cells. The drivers exhibiting stand-alone 
cytotoxicity in at least 6 AML cell lines are highlighted in light grey, drivers synergizing with etoposide in at least 6 
AML cell lines in dark grey. 
 
5.9 Etoposide-repressed essential genes contribute to cytotoxicity in AML lines 
I next analyzed co-regulated genes correlating with the etoposide IC50 concentrations, but 
transcriptionally altered by etoposide treatment. The correlated genes BRD4, MATL1, and MYC 
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were involved in the clusters of genes co-regulated only in untreated AML cell lines; the correlated 
gene SIRT1 was present in the co-expression network detected only after etoposide treatment. 
BRD4 and MYC were transcriptionally repressed, while MALT1 and SIRT1 were transcriptionally 
induced by etoposide in the less responsive AML cell lines (supplementary Fig. 3). However, all 
of them, except MYC, were predicted to be essential in only 4 AML cell lines. Therefore, I next 
analyzed and functionally verified etoposide-driven GEC at the level of individual genes. 
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Fig. 5.9.1: Etoposide-evoked changes in the expression of co-regulating genes. Cell lines F-36P, KASUMI-1, and 
MONO-MAC-6 with highest etoposide IC50 concentrations were considered as resistant, while remaining AML cell 
lines were considered as etoposide-responsive. (A) and (B) targets BRD4 and MYC respectively repressed after 
etoposide treatment in resistant cell lines, (C) and (D) targets MALT1 and SIRT1 respectively induced after etoposide 
treatment in resistant cell lines. Fold change was calculated by comparing TMM-normalized counts after and before 
etoposide treatment for respective drivers. Mann-Whitney test was performed to identify significant fold change across 
two groups. (* and ** represents q value < 0.05 and 0.01 respectively). 
The differential gene expression analysis using edgeR revealed that inductions accounted for the 
majority of etoposide treatment-driven changes in the gene expression (Fig. 5.9.2 and Table 5.9.1). 
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On average, etoposide evoked 81% of gene inductions in AML cell lines after treatment with cell 
specific IC50 concentrations for 24 hours. 
 
Fig. 5.9.2: Etoposide-evoked gene expression changes (GEC) in AML. Volcano plot representing (GEC) in F-36P 
cell line in response to etoposide treatment at IC50 concentration for 24 hours. 
Table 5.9.1: Numbers and percentages of etoposide-evoked inducing and repressing gene expression changes 
(GEC) in all investigated AML cell lines. Differentially expressed genes were identify by comparing RNA-Seq gene 
counts from untreated and etoposide-treated AML cell lines using edgeR software. 
Cell lines 
Numbers of gene 
expression changes 
Numbers of induced 
genes (%) 
Numbers of repressed 
genes (%) 
F36-P 4615 3882 (84.1) 733 (15.9) 
HL-60 1007 875 (86.9) 132 (13.1) 
KASUMI-1 3558 2874 (80.8) 684 (19.2) 
MOLM-13 1643 1284 (78.2) 359 (21.9) 
MONO-
MAC-6 
1788 1307 (73.1) 481 (26.9) 
MV-4-11 2091 1883 (90.1) 208 (10.0) 
NB-4 2383 1965 (82.5) 418 (17.5) 
NOMO-1 1679 1177 (70.1) 502 (29.9) 
OCI-AML3 1215 1028 (84.6) 187 (15.4) 
THP-1 1278 1050 (82.2) 228 (17.8) 
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Essentiality analysis suggested that, on average, about 33% of etoposide-driven changes could 
have reduced AML cell survival (Table 5.9.2). An example of GEC grouped according to 
essentiality in F-36P cell line is shown in Fig. 5.9.3. 
Table 5.9.2: Numbers and percentages of predicted essential genes using Project Achilles (PAch) among all 
etoposide-evoked gene expression changes (GEC). 
Cell lines 
Numbers of 
etoposide-
evoked GEC 
Number of 
predicted 
essential genes 
(%) 
Etoposide-
repressed predicted 
essential genes (%) 
Etoposide-induced 
predicted essential 
genes (%) 
F-36P 4615 1447 (31.3) 239 (16.5) 1208 (83.5) 
HL-60 1007 348 (34.6) 45 (12.9) 303 (87.1) 
KASUMI-
1 
3558 1234 (34.7) 227 (18.4) 1007 (81.6) 
MOLM-
13 
1643 549 (33.4) 118 (21.5) 431 (78.5) 
MONO-
MAC-6 
1788 602 (33.7) 144 (23.9) 458 (76.1) 
MV-4-11 2091 702 (33.6) 63 (9) 639 (91) 
NB-4 2383 762 (32) 128 (16.8) 634 (83.2) 
NOMO-1 1679 580 (34.5) 156 (26.9) 424 (73.1) 
OCI-
AML3 
1215 416 (34.2) 55 (13.2) 361 (86.8) 
THP-1 1278 417 (32.6) 71 (17) 346 (83) 
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Fig. 5.9.3: Scatterplot of etoposide-evoked differentially expressed genes in F-36P cell line, arranged according 
to essentiality for survival. DEMETER score < 0 signifies essentiality. The genes essential for tumor cell survival 
and differentially expressed after etoposide treatment were considered as putative essential mediators. The mediators 
shortlisted for experimental validation (BCL2A1, IGF1R, PLK1, and PRKCH) are depicted in larger font. Other gene 
names are random examples taken from the entire gene set. 
 
I selected IGF1R for experimental validation, since it was essential for 7 AML cell lines and 
repressed in 4 AML cell lines after etoposide treatment (Fig. 5.9.4). Likewise, PLK1, was essential 
as well as repressed in 4 AML cell lines (Fig. 5.9.4). I pursued PLK1 because it exhibited highest 
essentiality for the least etoposide-sensitive F-36P cell line (Fig. 5.9.3). BCL2A1 and PRKCH were 
selected because of their predicted essentiality for 6 AML cell lines each, and because they were 
induced by etoposide in 9 and 6 AML cell lines, respectively (Fig. 5.9.4). 
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I then treated all AML cell lines with the inhibitors of the protein products of these genes alone, 
as well as in combination with IC25 concentrations of etoposide. The inhibitors targeting the protein 
products of BCL2A1 and PLK1 exerted standalone cytotoxicity in all AML cell lines, while the 
IGF1R inhibitor and the PKC inhibitor exhibited cytotoxicity in 9 and 7 AML cell lines, 
respectively (Fig. 5.9.4, Fig. 5.9.5, and Table 5.8.3). Inhibition of BCL2A1 and PLK1 synergized 
with etoposide in MOLM-13 and NB-4 cell lines, respectively. Inhibition of PRKCH and IGF1R 
exhibited synergy with etoposide in 2 AML cell lines each (Table 5.8.3 and Appendix table 5). 
 
 
Fig. 5.9.4: Experimental validation of putative essential mediators shortlisted in Fig. 5.9.3. Cell viability was 
assessed by WST-8 assay after treatment with inhibitors targeting protein products of shortlisted drivers. Filled 
symbols represent predicted essentiality for survival in individual AML cell lines. Circles around the symbols 
represent experimentally confirmed cytotoxicity. 
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Fig. 5.9.5: Contribution of mediators in AML cell killing using inhibitors. Percentage cell viability in response to 
(A) sabutoclax (BCL2 inhibitor), (B) GSK-1838705A (IGF1R inhibitor), (C) volasertib (PLK1 inhibitor), and (D) 
sotrastaurin (PRKCH inhibitor) treatment respectively for 24 hours. Percentage cell viability compared to vehicle-
treated control, taken as 100%, was calculated. Two-way ANOVA with Benjamini and Hochberg FDR test was 
performed to quantify significant difference. Data are represented as mean values ± SD and derived from 3 biological 
replicates. (* p-value < 0.05). 
I additionally investigated, in HL-60 cells, the cytotoxic effects of the essential mediators BCL2A1 
and IGF1R using shRNA-mediated knockdown. Knockdown of the mediator IGF1R was cytotoxic 
to HL-60 cells. (Fig. 5.9.6). 
 
Fig. 5.9.6: Contribution of mediators in AML cell killing using shRNA-mediated knockdown. Viability of HL-
60 cells after shRNA-mediated gene knockdown of essential mediators BCL2A1 and IGF1R for 24, 48, and 72 hours. 
Percentage cell viability compared to untransduced cells, taken as 100%, was calculated. Mann-Whitney test was 
performed to identify significant change in the viability. (** represents q value < 0.01). Data are represented as mean 
values ± SD and derived from 3 biological replicates. 
5.10 Emulators are cytotoxic and synergize with etoposide 
Using the CMap resource, I identified gene modulations and drugs that cause GEC either similar 
or contrary to those evoked by etoposide. There were 32 gene knockdowns and 76 drugs whose 
application led to etoposide-like GEC. They were referred to as putative etoposide-like emulators. 
The majority of the drugs belonged to the classes mTOR inhibition, topoisomerase inhibition, and 
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HDAC inhibition. I also identified 12 drugs evoking opposite GEC, which are referred to as 
putative etoposide-contrary emulators (Table 5.10.1 and Table 5.10.2). 
Table 5.10.1: Emulators (gene knockdowns) evoking gene expression changes (GEC) either similar (etoposide-
like) or opposite (etoposide-contrary) to those evoked by etoposide. Emulators were identified by uploading top 
300 etoposide-evoked GEC overlapping in 10 AML cell lines to Connectivity Map (CMap) resource. The connectivity 
score ranging from -100 to 100 depicts the fraction of reference genes exhibiting similarity with the query. Emulators 
with connectivity score greater than |90| were considered as significant. 
Etoposide-like emulators (gene knockdowns) 
ID Target Connectivity score 
CGS001-6240 RRM1 99.66 
CGS001-4609 MYC 99.14 
CGS001-1027 CDKN1B 98.15 
CGS001-4998 ORC1 97.18 
CGS001-4067 LYN 97.04 
CGS001-1666 DECR1 96.86 
CGS001-3815 KIT 96.73 
CGS001-4199 ME1 96.33 
CGS001-11331 PHB2 95.7 
CGS001-29890 RBM15B 95.25 
CGS001-9020 MAP3K14 94.59 
CGS001-5373 PMM2 94.51 
CGS001-3226 HOXC10 94.22 
CGS001-5591 PRKDC 93.49 
CGS001-998 CDC42 93.31 
CGS001-291 SLC25A4 93.26 
CGS001-2852 GPER 92.76 
CGS001-4191 MDH2 92.52 
CGS001-2872 MKNK2 92.35 
CGS001-5245 PHB 91.58 
CGS001-5690 PSMB2 91.49 
CGS001-5770 PTPN1 91.43 
CGS001-2355 FOSL2 91.26 
CGS001-10247 HRSP12 91.08 
CGS001-2581 GALC 90.52 
CGS001-11245 GPR176 90.44 
CGS001-4792 NFKBIA 90.44 
CGS001-5184 PEPD 90.41 
CGS001-79724 ZNF768 90.4 
CGS001-64116 SLC39A8 90.21 
CGS001-63933 CCDC90A 90.15 
CGS001-4143 MAT1A 90.04 
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Etoposide-contrary emulators (gene 
knockdowns) 
CGS001-64805 P2RY12 -97.83 
CGS001-2153 F5 -95.66 
CGS001-1622 DBI -95.5 
CGS001-25805 BAMBI -94.21 
CGS001-4312 MMP1 -92.97 
CGS001-136 ADORA2B -92.66 
CGS001-57819 LSM2 -92.39 
CGS001-79796 ALG9 -92.37 
CGS001-991 CDC20 -92.27 
CGS001-7535 ZAP70 -91.91 
CGS001-25925 ZNF521 -91.68 
CGS001-6046 BRD2 -91.6 
CGS001-6478 SIAH2 -90.91 
CGS001-9128 PRPF4 -90.81 
CGS001-7132 TNFRSF1A -90.63 
CGS001-9575 CLOCK -90.34 
CGS001-83593 RASSF5 -90.31 
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Table 5.10.2: Emulators (drug treatments) evoking gene expression changes (GEC) either similar (etoposide-like) or opposite (etoposide-contrary) to 
those evoked by etoposide. Emulators were identified by uploading top 300 etoposide-evoked GEC overlapping in 10 AML cell lines to Connectivity Map (CMap) 
resource. The connectivity score ranging from -100 to 100 depicts the fraction of reference genes exhibiting similarity with the query. Emulators with connectivity 
score greater than |90| were considered as significant. 
Etoposide-like emulators (drug treatment) 
ID Drug Drug target Drug class 
Connectivity 
score 
BRD-
A62025033 temsirolimus MTOR, PTEN 
MTOR inhibitor 
96.06 
BRD-
K68174511 torin-2 MTOR 94.2 
BRD-
K69932463 AZD-8055 MTOR 91.51 
BRD-
A45498368 WYE-125132 MTOR, PIK3CA 91.3 
BRD-
K77008974 WYE-354 MTOR 90.52 
BRD-
A79768653 sirolimus MTOR, FKBP1A, CCR5, FGF2 93.94 
BRD-
K84937637 sirolimus MTOR, FKBP1A, CCR5, FGF2 93.47 
BRD-
A75409952 wortmannin 
PIK3CA, PIK3CG, PLK1, ATM, ATR, MTOR, PI4KA, 
PI4KB, PIK3CD, PIK3R1, PLK3, PRKDC 95.03 
BRD-
K06750613 GSK-1059615 PIK3CA, PIK3CG 97.99 
BRD-
K12184916 NVP-BEZ235 MTOR, PIK3CA, PIK3CG, PIK3CD, ATR, PIK3CB 90.56 
BRD-
A36630025 SN-38 TOP1 
Topoisomerase inhibitor 
97.88 
BRD-
K98490050 amsacrine TOP2A, KCNH2 97.84 
BRD-
K56334280 amonafide TOP2A, TOP2B 96.72 
BRD-
A35588707 teniposide TOP2A, CYP3A5 96.42 
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BRD-
K37798499 etoposide TOP2A, CYP2E1, CYP3A5, TOP2B 93.68 
BRD-
K08547377 irinotecan TOP1, CYP3A5, TOP1MT 91.08 
BRD-
K85985071 ellipticine TOP2A, TOP2B 90.54 
BRD-
A71390734 idarubicin TOP2A 98.49 
BRD-
A52530684 doxorubicin TOP2A 97.24 
BRD-
A18419789 etoposide TOP2A, CYP2E1, CYP3A5, TOP2B 94.59 
BRD-
K52522949 NCH-51 
HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, 
HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 
HDAC inhibitor 
96.18 
BRD-
K81418486 vorinostat 
HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, HDAC10, 
HDAC11, HDAC5, HDAC9 93.6 
BRD-
K77908580 entinostat HDAC1, HDAC2, HDAC3, HDAC9 92.85 
BRD-
K74733595 
APHA-compound-
8 HDAC8 91.88 
BRD-
K13169950 NSC-3852 HDAC1 91.72 
BRD-
K16485616 mocetinostat HDAC1, HDAC2, HDAC3, HDAC11 91.51 
BRD-
K64606589 apicidin 
HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, 
HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 90.53 
BRD-
K68336408 
tyrphostin-AG-
1478 EGFR, MAPK14 
EGFR inhibitor 
93.44 
BRD-
K85606544 neratinib EGFR, ERBB2, ERBB4, KDR 92.27 
BRD-
U25771771 WZ-4-145 CSF1R, DDR1, EGFR, PDGFRA, TIE1 91.63 
BRD-
K50168500 canertinib EGFR, ERBB2, ERBB4, AKT1 91.2 
BRD-
A25687296 emetine RPS2 
Protein synthesis inhibitor 
96.9 
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BRD-
A28970875 puromycin 
NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, 
RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, 
RSL24D1 95.88 
BRD-
K76674262 homoharringtonine RPL3 95.2 
BRD-
K80348542 cephaeline RPS2 94.76 
BRD-
K15108141 gemcitabine RRM1, CMPK1, RRM2, TYMS 
Ribonucleotide reductase inhibitor 
97.28 
BRD-
K33106058 cytarabine POLB, POLA1 96.48 
BRD-
A82371568 clofarabine RRM1, POLA1, RRM2, SLC22A8 96.35 
BRD-
K50836978 purvalanol-a 
CDK1, CDK2, CDK4, CDK5, CCND1, CCNE1, 
CSNK1G3, RPS6KA1, SRC 
CDK inhibitor 
97.58 
BRD-
K07762753 aminopurvalanol-a CDK1, CDK2, CDK5, CDK6 96.96 
BRD-
K31542390 mycophenolic-acid IMPDH1, IMPDH2 
IMPDH inhibitor 
97.57 
BRD-
K92428153 
mycophenolate-
mofetil IMPDH1, IMPDH2, HCAR2 90.42 
BRD-
A49680073 cucurbitacin-i JAK2, STAT3 
JAK-STAT inhibitor 
97.96 
BRD-
A28105619 cucurbitacin-i JAK2, STAT3 95.86 
BRD-
A15079084 
phorbol-12-
myristate-13-
acetate CD4, KCNT2, PRKCA, TRPV4 PKC activator 97.25 
BRD-
A52650764 ingenol PRKCD, PRKCE 95.15 
BRD-
A89434049 sarmentogenin ATP1A1 ATPase inhibitor 91.79 
BRD-
K51018020 VAMA-37 PRKDC 
DNA dependent protein kinase 
inhibitor 92.46 
BRD-
A48237631 mitomycin-c  DNA synthesis inhibitor 94.44 
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BRD-
K13646352 midostaurin 
FLT3, KIT, CCNB1, FLT1, KDR, PDGFRB, PRKCA, 
PRKCG, VEGFA 
FLT3 inhibitor, PDGFR/KIT 
inhibitor, PKC inhibitor, VEGFR 
inhibitor 96.9 
BRD-
A81772229 simvastatin HMGCR, CYP2C8, CYP3A4, CYP3A5, ITGB2 HMGCR inhibitor 93.91 
BRD-
K13049116 BMS-754807 IGF1R, AKT1 IGF-1 inhibitor 94.69 
BRD-
K47983010 BX-795 
PDPK1, CDK2, CHEK1, GSK3B, IKBKE, KDR, PDK1, 
TBK1 IKK inhibitor 98.8 
BRD-
A11678676 wortmannin 
PIK3CA, PIK3CG, PLK1, ATM, ATR, MTOR, PI4KA, 
PI4KB, PIK3CD, PIK3R1, PLK3, PRKDC PI3K inhibitor 97.02 
BRD-
K82823804 SA-792987 WEE1 PKC inhibitor 98.3 
BRD-
K87343924 wortmannin 
PIK3CA, PIK3CG, PLK1, ATM, ATR, MTOR, PI4KA, 
PI4KB, PIK3CD, PIK3R1, PLK3, PRKDC - 98.5 
BRD-
M86331534 
pyrvinium-
pamoate AR - 96.6 
BRD-
K30677119 PP-30 RAF1 - 96.14 
BRD-
K03067624 emetine RPS2 - 95.87 
BRD-
A24643465 homoharringtonine RPL3 - 95.63 
BRD-
A55484088 BNTX OPRD1, OPRK1, OPRM1 - 95.38 
BRD-
K91370081 anisomycin 
NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, 
RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, 
RSL24D1 - 94.36 
BRD-
K61829047 7b-cis XPO1 - 94.35 
BRD-
A19248578 latrunculin-b ACTA1, MKL1, SPIRE2 - 94.34 
BRD-
K74402642 NSC-632839 USP2, USP7, SENP2, USP1 - 94.33 
BRD-
K37392901 NSC-632839 USP2, USP7, SENP2, USP1 - 94.2 
70               Results 
 
BRD-
K36007650 puromycin 
NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, 
RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, 
RSL24D1 - 94.01 
BRD-
U86922168 QL-XII-47 BMX, BTK - 93.74 
BRD-
K67439147 SIB-1893 GRM5, GRM4 - 93.65 
BRD-
K17140735 SCH-79797 F2R - 93.26 
BRD-
A50737080 CGK-733 ATM, ATR - 92.59 
BRD-
K14821540 FCCP  - 91.53 
BRD-
K28907958 CD-437 RARG - 91.36 
BRD-
K89930444 AG-592  - 91.02 
BRD-
K73610817 BRD-K73610817  - 90.76 
BRD-
K30351863 BRD-K30351863 APEX1 - 90 
Etoposide-contrary emulators (drug treatment) 
BRD-
K23875128 
RHO-kinase-
inhibitor-
III[rockout] 
IMPDH2, ROCK1 - -98.78 
BRD-
A35108200 
dexamethasone 
ANXA1, CYP3A4, CYP3A5, NOS2, NR0B1, NR3C1, 
NR3C2 
Glucocorticoid receptor agonist -97.76 
BRD-
A69951442 
dexamethasone 
ANXA1, CYP3A4, CYP3A5, NOS2, NR0B1, NR3C1, 
NR3C2 
 -97.65 
BRD-
K89687904 
PKCbeta-inhibitor PRKCB - -96.99 
BRD-
K32107296 
temozolomide TOP2A Topoisomerase inhibitor -94.48 
BRD-
A68631409 
evodiamine TRPV1 - -94.22 
71               Results 
 
BRD-
K32536677 
AGK-2 SIRT2 - -93.98 
BRD-
A14985772 
ascorbyl-palmitate  - -93.73 
BRD-
K59184148 
SB-216763 GSK3B, CCNA2, CDK2, GSK3A Glycogen synthase kinase inhibitor -93.31 
BRD-
K59222562 
BRD-K59222562 CLK1, CLK4, DYRK1A, DYRK1B - -91.84 
BRD-
K01638814 
rilmenidine NISCH Imidazoline ligand -91.2 
BRD-
K98372770 
L-2167 PPARD - -90.8 
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I then measured cell viability in AML cell lines treated with inhibitors targeting the protein 
products of selected putative etoposide-like emulators individually, as well as in combination with 
etoposide (IC25 concentrations) for 24 hours. Targeting of the etoposide-like emulator MYC with 
TWS-119 led to cytotoxicity in all AML cell lines except MONO-MAC-6 (Fig. 5.10.1A and Table 
5.8.3). Similarly, inhibition of etoposide-like emulators mTOR with rapamycin and of HDAC with 
vorinostat evoked cell death in in 9 and 6 AML cell lines, respectively (Fig. 5.10.1B and C, and 
Table 5.8.3). Interestingly, vorinostat and rapamycin also exhibited synergy or additivity with 
etoposide in 9 and 6 AML cell lines, respectively (Table 5.8.3, Appendix table 4, and Appendix 
table 5). 
The etoposide-contrary emulator ROCK1 also synergized or exhibited additivity with etoposide in 
7 out of 11 AML cell lines, when inhibited with rockout. Inhibition of ROCK1 was cytotoxic in 
only 3 AML cell lines (Table 5.8.3 and Appendix table 4). The target specificity of rockout was 
confirmed by demonstrating cytotoxicity in HL-60 cells upon shRNA-mediated knockdown of 
ROCK1 (Fig. 5.10.3). 
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Fig. 5.10.1: AML cell viability in response to emulators. Percentage of cell viability in response to an inhibitor of 
the etoposide-like transcriptional driver (A) MYC, (B) rapamycin (mTOR inhibitor), and (C) vorinostat (HDAC 
inhibitor) respectively after 24 hours treatment. Percentage cell viability compared to vehicle-treated control, taken as 
100%, was calculated. Two-way ANOVA with Benjamini and Hochberg FDR test was performed to quantify 
significant difference. Data are represented as mean values ± SD and derived from 3 biological replicates. (* p-value 
< 0.05). 
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Fig. 5.10.2: Synergy of emulators with etoposide in AML cells. Combination index of etoposide treatment with 
protein inhibitor targeting the etoposide-like transcriptional drivers MYC, vorinostat, and rapamycin. CI < 1: 
synergism, CI = 1 (dotted line): additivity, CI > 1: antagonism. 
 
 
Fig. 5.10.3: Viability of HL-60 cells after shRNA-mediated gene knockdown of the etoposide-contrary emulator 
ROCK1. Percentage cell viability compared to untransduced cells, taken as 100%, was calculated. Mann-Whitney test 
was performed to identify significant change in the viability. (** represents q value < 0.01). Data are represented as 
mean values ± SD and derived from 3 biological replicates. 
5.11 Etoposide-driver combinations exert cytotoxicity without increasing DNA damage 
To investigate the safety of the identified combinations of etoposide with other drugs, their effect 
on DNA damage in HL-60 cell line was investigated. I measured the FITC-conjugated Anti-
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phospho H2A.X-labelled HL-60 cells by flow cytometry before and after the treatment with 
etoposide, alone or in combination with other inhibitors for 24 hours. Etoposide caused, as an 
effect of TOP2-poisoning, DNA damage in 45% of cells when treated at IC25 concentration. None 
of the investigated etoposide-combinations elevated the amount of DNA damage in comparison to 
etoposide alone (Fig. 5.11.1). Furthermore, the BIR inhibitor GDC-0152 increased the cytotoxicity 
in combination with etoposide, while reducing the amount of DNA damage in comparison to 
etoposide alone. 
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Fig. 5.11.1: DNA damage after etoposide treatment in combination with its cytotoxicity drivers. Bar plot 
representing percentage of phospho-H2A.X positive cells counted using flow cytometry and percentage cell death 
after treatment with different inhibitors alone as well as in combination with IC25 concentration of etoposide in HL-
60 cell line. Mann-Whitney test was performed using GraphPad Prism software to identify significant effect compared 
to etoposide alone. 
5.12 Drivers of etoposide cytotoxicity form unfavorable prognostic markers in AML 
patients 
To assess the clinical relevance of identified drivers, I inspected the gene expression and clinical 
data for 173 patients from TCGA and compared with gene expression in 30 normal blood samples 
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from GTEx. The analysis revealed an association between high expression of BCL2A1 and PARP9 
with poor survival in AML patients (Fig. 5.12.1A and B). Furthermore, these genes were highly 
expressed in AML patients compared to healthy individuals (Fig. 5.12.1C and D). 
 
Fig. 5.12.1: Relevance of etoposide cytotoxicity drivers in AML patients. Basal expression of (A) BCL2A1 and (B) 
PARP9 respectively in AML and normal blood cells using the RNA-Seq data from TCGA and GTEx. Kaplan–Meier 
plot representing survival analysis of the AML patients with high and low expression of (A) BCL2A1 and (B) PARP9 
respectively, obtained from TCGA. 
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Additionally, the Human Protein Atlas resource revealed high expression of BIRC5 or PLK1 to be 
association poor survival in renal, liver, and lung cancer patients (Fig. 5.12.2) and high expression 
of ROCK1 to be a marker of unfavorable prognosis in pancreatic cancer (Fig. 5.12.3). 
 
Fig. 5.12.2: Kaplan–Meier plot representing survival analysis for cancer patients with low or high expression 
of BIRC5 and PLK1, obtained from The Human Protein Atlas resource. 
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Fig. 5.12.3: Kaplan–Meier plot representing survival analysis for cancer patients with low or high expression 
of ROCK1 and PLK1, obtained from The Human Protein Atlas resource. 
6 Discussion 
 
In this work, I demonstrate that etoposide kills cancer cells depending on expression levels of 
driver genes, some of which it modulates. This effect is distinct from the etoposide concentration-
driven increase in DNA double stranded breaks (Smart, Halicka et al. 2008). Targeting these 
drivers genetically or pharmacologically mimics or augments the response to etoposide, indicating 
a potential for clinical exploration. The pipeline used to discover drivers of etoposide cytotoxicity 
is applicable to other TOP2 inhibitors and to cytotoxic drugs in general. 
Furthermore, using HTETOP cell line model, I found the TOP2A dependency of etoposide for 
cytotoxic response. Both TOP2 poisons, doxorubicin and etoposide, inhibit re-ligation of transient 
DSB, which triggers cell death. However, the dependency of etoposide for TOP2A was striking. 
Doxorubicin poisons TOP2 as well as intercalates into DNA. Doxorubicin is oxidized to 
semiquinone and then converted back to original state generating reactive oxygen species (ROS) 
in the process. ROS generates oxidative stress and contributes to DNA damage and apoptosis. This 
pathway is most likely upregulated after doxorubicin treatment in the absence of TOP2A, 
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overruling the need of TOP2A for cytotoxic response (Thorn, Oshiro et al. 2011). On the other 
hand, etoposide seems to exert its action predominantly via TOP2A poisoning. 
Altogether, this work demonstrates that: 
• Modulators synergized with etoposide 
• Mediators exhibited standalone cytotoxicity 
• Emulators exhibited standalone cytotoxicity and synergized with etoposide 
These drivers of etoposide cytotoxicity have been exploited to enhance the efficacy of etoposide. 
6.1 Gene expression changes-mediated cytotoxicity of etoposide 
Since the response of cancer cells to TOP2 poisons is variable, attempts have been made to explain 
it via pre-treatment gene expression levels (Zoppoli, Regairaz et al. 2012, Reinhold, Varma et al. 
2015, Yadav, Gopalacharyulu et al. 2015, Liu, Yang et al. 2016, Sun, Zhang et al. 2016). SLFN11 
(Zoppoli, Regairaz et al. 2012, Rees, Seashore-Ludlow et al. 2016) and SMARCA4 (Lee, Celik et 
al. 2018), re-discovered in this study, have been identified as modulators of TOP2 poisons, 
including etoposide, but failed to make clinical impact. Treatment-driven GEC have been likewise 
reported (Woo, Shimoni et al. 2015, Huang, Hsieh et al. 2018), but not explored for optimizing 
response to TOP2 poisons. I considered both pre-treatment gene expression levels and drug-
evoked changes, as a surrogate of pre- and post-treatment protein expression levels. Post-treatment 
transcriptomes turned out to be particularly important, since they were essential for the discovery 
of most of the functionally confirmed drivers (i.e. of all mediators and emulators). 
Most of the etoposide-evoked GEC were likely secondary, judging from the predominance of gene 
inductions over reductions. Indeed, only expression reductions can be expected to arise directly 
from DNA damage within regulatory or coding gene sequences. This is well reflected in a 
80        Discussion 
 
HTETOP cell model, where predominance of gene repression was observed. However, I could not 
confirm the etoposide-evoked predominance of gene repression in other cancer cell lines, including 
a panel of AML cell lines, as well as in other cells lines obtained from GEO, except in OCI-Ly3 
(B-cell lymphoma). The explanation for this observation could be variable etoposide 
concentrations and treatment times in GEO set of cell lines. The HTETOP cell line was treated 
with 20 µM of etoposide (IC50 being 7.7 µM) for 24 hours. None of the cell line from GEO set 
was treated with comparable concentration and time-points. Furthermore, HTETOP is an 
engineered cell line derived from fibrosarcoma HT-1080 cell line, with artificially high TOP2A 
expression (Carpenter and Porter 2004). Hence, the predominance of repressing GEC after 
etoposide treatment seems to be a specific attribute of HTETOP cell line. Etoposide treatment 
generates limited numbers of DSB foci (Roos and Kaina 2013), which could have been reflected 
in lower number of gene repressions in other cancer cell lines. The predominance of gene 
inductions in other cancer cell lines is most likely resulted from secondary effectors of etoposide. 
Nevertheless, these GEC could themselves contribute to cytotoxicity, especially repressions in the 
oncogenic targets and inductions in the tumor repressor targets. Considering off-target effects of 
classical anti-cancer drugs, such essential GEC could provide effective alternative for targeted 
cancer therapies. Analysis of etoposide-treated HTETOP cell line revealed majority of etoposide-
evoked gene repressions to be involved in cancer and cell proliferation processes, indicating their 
repression could be exploited as a potential therapeutic strategy. 
6.2 Mediators as standalone targets for etoposide replacement 
The mediators PFKP and PLAU reduced the viability of HTETOP cells when suppressed using 
siRNA. PFKP (phosphofructokinase) catalyzes the initial step of glycolysis by phosphorylating D-
fructose 6-phosphate to fructose 1,6-bisphosphate. Many cancer cell types depend on glycolysis 
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rather than more efficient oxidative phosphorylation for energy metabolism because of hypoxic 
environment and mutations in the mitochondrial DNA (Ganapathy-Kanniappan & Geschwind, 
2013). Hence, targeting the enzymes involved in glycolytic processes provides an effective 
strategy for managing tumor growth (Zheng, 2012). In consistent with this, PFKP is highly 
expressed in HTETOP and its high expression is associated with poor survival of liver cancer and 
head and neck cancer patients (Uhlén et al., 2015). 
PLAU (plasminogen activator, urokinase) is a serine protease responsible for tumor migration 
because of its function in degrading the extracellular matrix. I found PLAU overexpressed in 
HTETOP cell line and its overexpression reduced the survival in pancreatic, head and neck, renal, 
and lung cancer patients, most likely contributing to secondary tumors at different sites. Reduction 
in the cell viability of HTETOP cell line after PLAU knockdown suggests its utility as an alternate 
target for therapy. 
Other investigated mediators of etoposide cytotoxicity in AML cell lines also represent critical 
processes in cancer survival and were confirmed to be essential. B-cell lymphoma 2-related protein 
A1 (BCL2A1) is a member of BCL2 family proteins having anti-apoptotic function (Vogler 2012). 
BCL2A1 expression is frequently deregulated in many types of cancers, including overexpression 
in AML patients. Insulin-like growth factor receptor 1 (IGF1R), a tyrosine kinase receptor, 
augment the cell proliferation and it’s use as anti-cancer target in combination with other 
chemotherapeutic drugs is under investigation (Chen and Sharon 2013). Polo-like kinase 1 (PLK1) 
plays critical role during mitosis (Brandwein 2015). I predicted PLK1 to be essential for 4 AML 
survival. Interestingly, PLK1 inhibition was cytotoxic in all 11 AML cell lines. This suggests that 
targets derived from small sample size can even be applicable for large cohort. Protein kinase c 
eta (PRKCH) in involved many cellular processes including cell proliferation and differentiation. 
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It is required for maintaining hematopoietic stem cell function. PRKCH is highly expressed in 
leukemia and its high expression is associated with poor prognosis in AML patients (Porter and 
Magee 2017).  
These mediators exhibited synergy with etoposide only in 2 out of 11 AML cell lines each. Similar 
results were obtained using HTETOP cell line. None of the knockdowns sensitized the HTETOP 
cell line to etoposide treatment in combination experiment. This may be due to different pathways 
governing the cytotoxicity getting triggered after treatment with inhibitors compared to etoposide. 
AML cells are likely to be committed to the dominant response pathway triggered either by 
essential mediator or by etoposide. Altogether, results confirmed the contribution of etoposide-
evoked GEC to its anti-cancer activity. Such essential mediators could even replace the classical 
anti-cancer drugs because of their specificity. These specific targets could replicate the cytotoxicity 
of non-specific anti-cancer drugs with less side-effects. 
6.3 Modulators for overcoming drug resistance 
The comparison of co-expression networks before and after etoposide-treatment identified the 
etoposide-relevant biological processes such as response to DNA damage, DNA repair, and 
apoptosis regulation to be affected by the treatment. The potential negative modulators 
investigated in detail, BIRC5 and PARP9, sensitized AML cell lines to etoposide treatment. 
BIRC5, also known as survivin, is a member of inhibitor of apoptosis family. It is involved in cell 
proliferation and apoptosis inhibition, and frequently overexpressed in cancer cells (Tanaka, 
Iwamoto et al. 2000). The results demonstrated the involvement of BIRC5 in etoposide resistance 
by AML cell lines as confirmed by increased etoposide sensitivity in combination with survivin 
inhibitor. Several clinical trials are undergoing to evaluate effectiveness of survivin inhibitors in 
combination with idarubicin and cytarabine (NCT00620321 and NCT01398462). The other 
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investigated negative modulator, PARP9 (also abbreviated as ARTD9 or BAL1), plays a role in cell 
migration (Aguiar, Yakushijin et al. 2000). The high expression of catalytically inactive PARP9 
is associated with upregulated cell motility. The experiments using nicotinamide, NAD and NADP 
pre-cursor and PARP inhibitor, revealed either etoposide-synergy or additive effects in 10 out of 
11 investigated AML cell lines. As nicotinamide is not a selective inhibitor of PARP9, further 
investigation using shRNA-mediated PARP9 knockdown in HL-60 cell line revealed essentiality 
for cell survival. Furthermore, high expression of PARP9 is associated with poor survival of AML 
patients. PARP inhibitors are currently being investigate in AML patients in combination with 
TOP1 poison topotecan (NCT03289910 and NCT00588991). Altogether, the results indicated the 
essential role of PARP9 for AML cell survival and a role in DNA damage response inferred by 
etoposide-synergy in AML cell lines. I also investigated NOTCH1 as a positive modulator of 
etoposide cytotoxicity with high expression in the etoposide-responsive AML cell lines. As 
expected, treatment with Notch inhibitor did not exert cytotoxicity or etoposide synergy. 
Interestingly, Notch inhibition in F-36P cell line further reduced the etoposide cytotoxicity of this 
cell line. 
Using this approach, I re-discovered the etoposide cytotoxicity modulators SLFN11 (Zoppoli, 
Regairaz et al. 2012, Rees, Seashore-Ludlow et al. 2016) and SMARCA4 (Lee, Celik et al. 2018), 
reported previously, correlating with etoposide sensitivity. However, the predicted effector targets 
MYC, BRD4, and SIRT1 were enriched only after integrating the etoposide-evoked GEC, 
confirming their additional value for predicting the sensitivity-relevant modulators. MALT1 
(Mucosa Associated Lymphoid Tissue Lymphoma Translocation Gene 1) enhances BCL10-
mediated NF-KB activation, triggering the proliferating and anti-apoptotic program (Hadian and 
Krappmann 2011). I observed MALT1 induction after etoposide treatment in the AML cell lines 
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less responsive to etoposide treatment, especially in the most resistant F-36P cell line. SIRT1 
(Sirtuin 1) enhances the DNA damage repair by deacetylating the repair proteins TP53 and Ku70 
(Jeong, Juhn et al. 2007). I observed SIRT1 induction in the AML cell lines less responsive to 
etoposide treatment. Altogether, these results suggest the efficient repair and apoptosis regulation 
to be key processes for differential etoposide response in the investigated AML cell lines. 
Furthermore, results also suggest involvement of epigenetic regulation enhancing the DNA repair 
processes and could be the possible mechanism for the observed synergy with etoposide and a 
HDAC inhibitor vorinostat. Inhibiting such targets, those affect the downstream pathways of 
etoposide, can provide effective strategy to overcome resistance to this drug. 
6.4 Rational combination partners using etoposide-like emulators 
After confirming the respective etoposide-synergy and cytotoxicity of modulators and mediators 
of etoposide cytotoxicity, I hypothesized that the next-generation etoposide-combinations can be 
designed using etoposide-evoked GEC. The CMap resource (Subramanian, Narayan et al. 2017) 
provided other specific targets as well as drugs which evoke GEC either similar (etoposide-like 
emulators) or opposite (etoposide-contrary emulators) to those evoked by etoposide. I expected 
that etoposide-like emulators could exert etoposide-like cytotoxic response and etoposide-contrary 
emulators could synergize with etoposide, hypothesizing that such targets would induce the genes 
which are direct or indirect targets of etoposide. Interestingly, along with other TOP2 poisons, I 
identified mTOR and HDAC inhibitors as etoposide-like emulators. This analysis surprisingly 
identified, along with other topoisomerase inhibitors, class of HDAC inhibitor and mTOR 
inhibitors evoking GEC similar to those evoked by etoposide. The etoposide-synergy with HDAC 
(Thurn, Thomas et al. 2011) and mTOR inhibitors (Xu, Thompson et al. 2005) is well documented 
and undergoing clinical trials, which I confirmed in AML using vorinostat and rapamycin. Due to 
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the interaction of TOP2 with HDAC1 and 2 (Montecucco, Zanetta et al. 2015), etoposide-evoked 
DNA double-strand breaks could affect the chromatin architecture. This could be plausible 
explanation for similar GEC after treatment with etoposide and HDAC inhibitor, as well as the 
basis for synergy. 
6.5 Potential application to AML and other cancers 
Etoposide effects can be clearly optimized by targeting drivers of its toxicity, but how relevant is 
this strategy to AML management? AML accounts for 80% of leukemia cases in adult patients and 
have poor prognosis in patients (De Kouchkovsky and Abdul-Hay 2016, Pearsall, Lincz et al. 
2018). Chemotherapy is the major form of treatment for AML management (Dombret and Gardin 
2016). However, treatment strategies for relapsed AML are not yet clearly defined. MEC regimen 
(mitoxantrone in combination with etoposide and cytarabine) is one of the common regimens used 
for relapsed AML. However, it is associated with increased side-effects in AML patients (Ramos, 
Mo et al. 2015, Thol, Schlenk et al. 2015). Hence, there is a need to improve efficacy and reduce 
the toxicity of these treatment regimens. Similar needs exist for other etoposide applications, such 
as testicular, prostate and small cell lung cancer. 
Interestingly, some of the drivers investigated in this work have been or are currently undergoing 
testing. This provides an additional validation of our approach. Supplementing etoposide with the 
inhibitor of its emulator mTOR with rapamycin has already been shown to reduce the survival of 
cancer cells in a mouse model of AML (Xu, Thompson et al. 2005). A phase II trial for managing 
high-risk AML patients with rapamycin in combination with MEC regimen is ongoing 
(NCT02583893). The etoposide-synergy with HDAC is currently undergoing testing for AML 
(NCT02553460). Due to the interaction of TOP2 with HDAC1 and 2, etoposide-evoked DNA 
double strand breaks could affect the chromatin architecture (Montecucco, Zanetta et al. 2015). 
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Interestingly, we observed etoposide-evoked induction in SIRT1. It is evident that SIRT1 induction 
synergizes with HDAC inhibition (Scuto, Kirschbaum et al. 2013). This is in agreement with the 
observed etoposide-evoked induction of SIRT1 and its observed synergy with vorinostat. 
Improved clinical outcomes in AML patients have been already reported for the PLK1 inhibitor 
volasertib (Kobayashi, Yamauchi et al. 2015) and a Phase III trial is ongoing (NCT01721876). 
Strikingly, PLK1 inhibition with volasertib was cytotoxic in all 11 AML cell lines. This suggests 
that cytotoxicity drivers can be efficient beyond the cohort subset in which they were detected. 
Inhibition of IGF1R has been found to be efficacious together with etoposide and cisplatin in 
small-cell lung cancer (Ellis, Shepherd et al. 2014) and further clinical trials are undergoing with 
other drugs and cancer types. 
This work also tries to address the most common drawback of chemotherapy – side effects. The 
use of DNA damaging drugs, including etoposide, is associated with increased risk of secondary 
leukemia because of chromosomal aberrations (Ezoe, 2012; Kollmannsberger et al., 1998). Hence, 
it is crucial to formulate the combination partners which don’t raise the risk further. My primary 
investigation using DSB marker gH2A.X revealed that none of the combination partners elevated 
the DNA damage compared to etoposide alone. Moreover, the inhibitor GDC-0152 targeting BIR 
protein reduced the amount of DNA damage caused by etoposide alone. GDC-0152 targets the 
anti-apoptotic BIR family proteins and hence most likely triggers the apoptotic pathways 
effectively in combination with etoposide. 
6.6 Limitations and perspective 
Utilizing etoposide-evoked GEC, I have demonstrated a unique pipeline to identify its specific 
targets and combination partners. However, this has certain limitations and caveats, beginning with 
the assumption of gene expression reflecting protein expression. While this assumption is 
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generally true, the expression and activity levels of some proteins are regulated without changes 
in the RNA expression level. Nevertheless, all potential drivers selected for validation displayed 
standalone toxicity or modified that of etoposide. Altogether, using transcriptome data is 
sufficiently sensitive and specific to detect and confirm cytotoxicity drivers worth further 
exploration in animal models and in the clinic. 
Furthermore, it seems that some drivers serve as markers of, additional, undetected drivers. For 
example, inhibiting the etoposide modulator BCL2A1 with sabutoclax caused cytotoxicity in all 
AML cells. In contrast, a shRNA-mediated knockdown of BCL2A1 in HL-60 cells had no effect. 
Additional members of the Bcl2 family may have contributed to the effect of sabutoclax, a pan-
Bcl2 inhibitor. shRNA-mediated knockdowns did confirm the specific involvements of IGF1R 
and ROCK1. On the other hand, results using chemical inhibitors are clinically more relevant. 
Especially drivers like BCL2A1 and PARP9, which showed relevance for AML patients, exhibit 
high potential and are currently under clinical investigation. Nevertheless, if possible, putative 
drivers should undergo verification both by genetic and pharmacological means. 
Even though drug evoked GEC are found to be ideal for retrospective identification of cytotoxicity 
drivers, they are impossible to obtain in advance from cancer patients. However, it would be 
possible to model these GEC by applying machine learning to high throughput genomics data. The 
next generation CMap is an example of such efforts, which extrapolate the genome-wide GEC 
based-on expression change in 1000 genes using machine learning. Considering numerous 
ongoing big data initiatives including Cancer Cell Line Encyclopedia (CCLE), Genomics of Drug 
Sensitivity in Cancer (GDSC), Connectivity Map (CMap), project DREAM, and Cancer Target 
Discovery and Development (CTD2), the drug-evoked changes could be predicted in patient 
beforehand to optimize the treatment for maximum efficacy with least side-effects. 
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Appendix table 1: All siRNAs sequences used in this work. The Project Achilles (PAch) database was used to identify 
siRNA targeting selected mediator genes. 
Target siRNA sequence 
ANLN UGCUGGAGCGAACCCGUGCC 
CDC20 ACAGAGGAUAUAUAUUCCCC 
CDK6 AGUUCAGAUGUUGAUCAACU 
DLGAP5 GAUGUUCGAGCAAUCCGACC 
FOXM1 AUAGCCUAUCCAACAUCCAG 
IGF2B CACCACUGCCGUCUCACUCU 
KIF20A CCCCUGCCGUCAUGUCGCAA 
MCM6 GAGUUUACCCUUACCUGUGU 
MED1 UAAGCUUGUGCGUCAAGUCA 
NCAPD2 CACGUUCUGCUAGUUCUGUC 
PFKP CGUCCCCGCCGAUCACACAC 
RPA2 GCCGCCGGCUCCCCCGUAUG 
SLC7A5 UACAGCGGCCUCUUUGCCUA 
TOPBP1 UGUCUUUGAUCACCUCAAAA 
TPX2 AUUGUCACACCUUUGAAACC 
YWHAH AAGCGACCUCUGCUAAGUAG 
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Appendix table 2: List of primers used for gene expression quantification using SYBR green qPCR. 
Gene 5' - 3' 3' - 5' 
ANLN TCTGACATTCACTACTACATTTACTCTGC GCCATGACTGAAGAATGAATGTTG 
BCL2A1 CAGGAGAATGGATAAGGCAAA CCAGCCAGATTTAGGTTCAAA 
BIRC5 CCACCGCATCTCTACATTCA TATGTTCCTCTATGGGGTCG 
CDC20 GGCACCAGTGATCGACACATTCGCAT GCCATAGCCTCAGGGTCTCATCTGCT 
CDK6 TGGAGACCTTCGAGCACC CACTCCAGGCTCTGGAACTT 
CENPF TACTGAGTTTGAGCCAGAGGGACT CATGGTTGTTCTTCGCAGGATAT 
DLGAP5 GGAAGACCTGCCAAAAATGTAG TGTGCCAAAATTTCTTTTGTTG 
FOSL1 GGGCATGTTCCGACACTT CCACTCATGGTGTTGATGCT 
FOXM1 GGAGGCAGCGACAGGTTAAGG GTTGATGGCGAATTGTATCATGG 
HDAC6 TGGCTATTGCATGTTCAACC TCGAAGGTGAACTGTGTTCCT 
HMGA2 AAGTTGTTCAGAAGAAGCCTGCTCA TGGAAAGACCATGGCAATACAGAAT 
IGF1R GCCACTACTACTATGCCGGTG GTGCATCCTTGGAGCATCT 
IGF2BP1 GCGGCCAGTTCTTGGTCAA TTGGGCACCGAATGTTCAATC 
KIF20A CTACAAGCACCCAAGGACTCTT AGATGGAGAAGCGAATGTTTG 
MCM6 TGGTGGCATCAATGGTCATG TTAAGGAGGCTTTGGGAGCA 
MED1 TGCGTCAAGTCATGGAGAAG CCACTGGCACTGAGATGAGA 
NCAPD2 TGGAGGGGTGAATCAGTATGT GCGGGATACCACTTTTATCAGG 
PARP9 GCAAAGAGGTCCAAGATGCT CCTCACACATCTCTTCCACGT 
PFKP GCATGGGTATCTACGTGGGG CTCTGCGATGTTTGAGCCTC 
PLAU CACGCAAGGGGAGATGAA ACAGCATTTTGGTGGTGACTT 
ROCK1 AAAGAAAGGATGGAGGATGAAGT TGTAACAACAGCCGCTTATTTG 
RPA2 GCACCTTCTCAAGCCGAAAA CAGCTGACATATAGTACAGGGCACAA 
SLC7A5 GCTGGTGTACGTGCTGACC GCCCAGGTGATAGTTCCCG 
TOPBP1 TGTGACCCTTTTAGTGGCGTT CTTGGGACACATGGCTGG 
TPX2 CCAGACCTTGCCCTACTAAGATT AATGTGGCACAGGTTGAGC 
YWHAH CGCTATGAAGGCGGTGAC TGCTAATGACCCTCCAGGAA 
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Appendix figure 1: Mean quality scores for all RNA-Seq raw reads from AML cell lines. 
 
 
Appendix figure 2: GC content in the raw RNA-Seq reads from AML cell lines. 
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Appendix table 3: Percentage of reads mapped to the human reference genome hg38. 
Sample Name % Aligned Million Aligned 
F36P_CTR_1 87.70% 21 
F36P_CTR_2 87.30% 21.4 
F36P_CTR_3 88.50% 22.6 
F36P_ETP_2 87.70% 21 
F36P_ETP_3 88.50% 21.9 
HL60_CTR_1 87.30% 22.9 
HL60_CTR_2 87.00% 22.8 
HL60_CTR_3 87.00% 20.8 
HL60_ETP_1 87.30% 21 
HL60_ETP_2 86.90% 21.2 
HL60_ETP_3 86.70% 23 
KASUMI1_CTR_1 87.20% 23.8 
KASUMI1_CTR_2 87.00% 23.1 
KASUMI1_CTR_3 86.60% 21.9 
KASUMI1_ETP_1 86.80% 24.7 
KASUMI1_ETP_2 85.50% 23 
KASUMI1_ETP_3 86.40% 23.5 
MOLM13_CTR_1 87.20% 22.9 
MOLM13_CTR_2 86.90% 22.6 
MOLM13_CTR_3 87.10% 22.7 
MOLM13_ETP_1 85.20% 20.5 
MOLM13_ETP_2 85.60% 22.5 
MOLM13_ETP_3 85.40% 22.5 
MONOMAC6_CTR_1 89.10% 23 
MONOMAC6_CTR_2 88.90% 23.6 
MONOMAC6_CTR_3 89.00% 24 
MONOMAC6_ETP_1 88.50% 24.4 
MONOMAC6_ETP_2 88.20% 23.3 
MONOMAC6_ETP_3 88.50% 24.9 
MV411_CTR_1 88.00% 22.7 
MV411_CTR_2 87.90% 20.9 
MV411_CTR_3 88.00% 22.9 
MV411_ETP_3 87.90% 26.2 
NB4_CTR_1 88.70% 23.9 
NB4_CTR_2 88.30% 22.1 
NB4_CTR_3 87.80% 21.1 
NB4_ETP_1 87.60% 24.2 
NB4_ETP_2 87.10% 22.5 
NB4_ETP_3 86.90% 22.8 
NOMO1_CTR_1 88.20% 22.7 
NOMO1_CTR_2 88.00% 23.5 
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NOMO1_CTR_3 88.10% 21.5 
NOMO1_ETP_1 88.10% 21.8 
NOMO1_ETP_2 88.00% 22.1 
NOMO1_ETP_3 88.40% 22.2 
OCIAML2_CTR_1 87.70% 23.8 
OCIAML2_CTR_2 87.70% 22 
OCIAML2_CTR_3 87.40% 22.2 
OCIAML2_ETP_3 87.50% 21.2 
OCIAML3_CTR_1 89.00% 23.1 
OCIAML3_CTR_2 88.80% 22.8 
OCIAML3_CTR_3 88.60% 23.8 
OCIAML3_ETP_1 89.00% 24.1 
OCIAML3_ETP_2 89.00% 25.2 
OCIAML3_ETP_3 88.80% 24.8 
THP1_CTR_1 88.00% 22 
THP1_CTR_2 87.10% 22.7 
THP1_CTR_3 87.60% 21.8 
THP1_ETP_1 88.00% 23.8 
THP1_ETP_2 87.40% 22.3 
THP1_ETP_3 87.30% 24.3 
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Appendix table 4: Standalone cytotoxicity of the drugs inhibiting selected drivers in AML cell line. Cells were treated with 3 concentrations of each drug for 24 hours. Two-way 
ANOVA with Benjamini and Hochberg FDR correction test was performed to determine significant standalone cytotoxicity 
Drug 
(driver) 
Treatment 
concentratio
n (µM) 
Mean 
differenc
e 
q value 
F-36P HL-60 
KASUMI
-1 
MOLM
-13 
MONO
-MAC-6 
MV-4-
11 
NB-4 
NOMO
-1 
OCI-
AML2 
OCI-
AML3 
THP-1 
GDC-0152 
(BIRC5) 
10 10.68 0.9717 0.4994 0.5955 0.8723 0.8661 0.3159 0.2301 0.6627 0.2204 0.0408 0.1738 
0.1 1.532 0.9717 0.5612 0.5955 0.7171 0.8943 0.8857 0.2777 0.9505 0.3106 0.0408 0.9151 
0.001 -1.963 0.9717 0.83 0.8623 0.7191 0.8943 0.7337 0.8791 0.8579 0.12 0.0291 0.7585 
GSK-
1838705A 
(IGF1R) 
10 85.3 
<0.000
1 
<0.000
1 
<0.0001 0.1719 0.3331 
<0.000
1 
<0.000
1 
<0.0001 
<0.000
1 
<0.000
1 
<0.000
1 
0.1 4.08 0.9717 0.0041 0.5574 0.9473 0.8661 0.7337 0.7725 0.3015 0.2204 0.0169 0.9515 
0.001 3.502 0.9717 0.5541 0.6986 0.8 0.8661 0.7515 0.9004 0.4933 0.537 0.0549 0.719 
LY-3039478 
(NOTCH1) 
10 -2.693 0.9717 0.4994 0.7399 0.7171 0.8661 0.9605 0.0652 0.5825 0.796 0.0108 0.719 
0.1 1.129 0.9717 0.2832 0.6941 0.7171 0.8661 0.9124 0.0306 0.5421 0.8944 0.0096 0.719 
0.001 -4.146 0.9717 0.1466 0.7682 0.7519 0.8661 0.906 0.602 0.4933 0.8298 0.0035 0.719 
Nicotinamid
e (PARP9) 
10 -4.48 0.9717 0.5399 0.5955 0.7171 0.8661 0.7337 0.7725 0.9576 0.9715 0.2969 0.7856 
0.1 -6.55 0.9717 0.4416 0.5955 0.7191 0.8943 0.9605 0.8871 0.8015 0.5624 0.742 0.719 
0.001 -8.173 0.9717 0.9966 0.5574 0.6617 0.8661 0.7337 0.1449 0.7631 0.3182 0.7829 0.9151 
Rapamycin 
(mTOR) 
10 9.511 0.9717 
<0.000
1 
0.0065 0.2481 0.8661 0.6897 0.0198 0.0375 
<0.000
1 
<0.000
1 
0.0006 
0.1 3.771 0.9717 0.0003 0.0205 0.7036 0.8943 0.7337 0.2301 0.3861 0.1208 
<0.000
1 
0.719 
0.001 7.931 0.9717 0.0091 0.0602 0.7225 0.8661 0.9605 0.2056 0.3695 0.1273 
<0.000
1 
0.719 
Rockout 
(ROCK1) 
10 1.961 0.9717 0.0663 0.59 0.7876 0.8661 0.9558 0.1748 0.3015 0.0264 0.0062 0.0255 
0.1 -6.848 0.9717 0.8752 0.5955 0.7171 0.8943 0.9693 0.3002 0.9576 0.0104 0.3993 0.719 
0.001 1.646 0.9717 0.6357 0.5574 0.5752 0.8661 0.9605 0.8791 0.9576 0.0264 0.0266 0.719 
Sabutoclax 
(BCL2A1) 
10 42.76 0.0007 
<0.000
1 
<0.0001 0.0192 0.0003 
<0.000
1 
<0.000
1 
<0.0001 
<0.000
1 
<0.000
1 
<0.000
1 
0.1 -1.232 0.9717 0.6357 0.8634 0.8073 0.8943 0.8636 0.1748 0.5421 0.9976 0.1612 0.719 
0.001 -5.607 0.9717 0.5052 0.5955 0.7171 0.8661 0.7941 0.2301 0.6471 0.9887 0.0744 0.1215 
Sotrastaurin 
(PRKCH) 
10 29.98 0.0292 
<0.000
1 
<0.0001 0.0109 0.7467 0.0008 0.1748 0.3861 
<0.000
1 
<0.000
1 
0.9594 
0.1 6.969 0.9717 0.6734 0.5955 0.9699 0.8661 0.5377 0.7543 0.86 0.001 0.0549 0.719 
0.001 6.241 0.9717 0.7203 0.5574 0.7171 0.8661 0.5377 0.7725 0.8579 0.0375 0.0549 0.9151 
TWS-119 
(MYC) 
10 31.54 0.0233 
<0.000
1 
<0.0001 0.0087 0.2445 
<0.000
1 
<0.000
1 
<0.0001 
<0.000
1 
<0.000
1 
0.0152 
0.1 -1.689 0.9717 0.83 0.0277 0.8723 0.8661 0.906 0.8791 0.8579 0.2239 0.0928 0.9594 
0.001 1.202 0.9717 0.83 0.5955 0.8723 0.8661 0.8857 0.8791 0.9649 0.6895 0.1425 0.719 
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Volasertib 
(PLK1) 
10 83.03 
<0.000
1 
<0.000
1 
<0.0001 0.0008 <0.0001 
<0.000
1 
<0.000
1 
<0.0001 
<0.000
1 
<0.000
1 
<0.000
1 
0.1 21.08 0.255 
<0.000
1 
<0.0001 0.0192 0.8661 0.0001 
<0.000
1 
<0.0001 
<0.000
1 
<0.000
1 
0.1596 
0.001 14.07 0.8191 0.0149 0.9294 0.2001 0.8661 0.7337 0.8791 0.0015 0.4652 
<0.000
1 
0.719 
Vorinostat 
(HDAC) 
10 64.95 
<0.000
1 
<0.000
1 
<0.0001 0.0225 0.9508 
<0.000
1 
<0.000
1 
0.0089 
<0.000
1 
<0.000
1 
0.1596 
0.1 -9.609 0.9717 0.0177 0.7682 0.5752 0.8661 0.7674 0.997 0.9649 0.8731 0.9865 0.906 
0.001 -7.394 0.9717 0.3912 0.9294 0.4114 0.8661 0.906 0.8791 0.7631 0.9388 0.9865 0.719 
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Appendix table 5: Synergy with etoposide of the drugs inhibiting selected drivers in AML cell line. Cells were treated with 3 concentrations of each drug in combination with IC25 
concentration of etoposide for 24 hours. Combination index (CI) was calculated to determine either synergistic (CI<1), additive (CI=1), or antagonist (CI>1) effects.  
Drug 
(driver) 
Treatment 
concentration 
(µM) 
Combination index (CI) 
F-
36P 
HL-
60 
KASUMI-1 
MOLM-
13 
MONO-
MAC-6 
MV-
4-11 
NB-
4 
NOMO-1 
OCI-
AML2 
OCI-
AML3 
THP-
1 
GDC-0152 
(BIRC5) 
10 0.7 0.9 1.1 0.9 1.0 1.4 0.9 1.4 1.3 1.3 1.2 
0.1 0.7 0.9 1.1 0.8 0.8 1.2 1.0 1.0 1.1 1.3 0.8 
0.001 0.8 0.7 1.0 0.7 0.8 1.2 1.0 0.8 1.0 1.2 0.8 
GSK-
1838705A 
(IGF1R) 
10 1.4 1.0 1.2 1.4 1.3 1.6 0.5 1.3 1.3 1.5 0.8 
0.1 1.2 1.4 1.1 1.2 1.4 1.3 0.9 1.2 1.4 1.4 0.7 
0.001 1.3 1.5 1.5 1.1 1.3 1.4 1.2 1.3 1.4 1.6 1.2 
LY-3039478 
(NOTCH1) 
10 3.2 1.2 1.3 0.7 1.3 1.3 1.0 1.3 1.1 1.6 1.3 
0.1 1.3 1.2 1.2 0.8 1.1 1.2 1.8 1.3 1.1 1.5 1.3 
0.001 10.3 1.3 1.3 0.8 1.1 1.5 1.2 1.3 1.1 1.7 0.8 
Nicotinamide 
(PARP9) 
10 1.0 1.0 1.2 0.9 1.5 1.9 1.2 2.3 1.3 1.2 1.0 
0.1 0.8 1.1 1.2 0.8 1.1 0.6 0.7 1.4 0.9 1.0 0.9 
0.001 0.6 1.1 1.0 0.8 1.3 0.6 0.7 0.9 0.9 1.0 0.8 
Rapamycin 
(mTOR) 
10 1.8 1.3 1.6 0.9 1.4 0.5 1.2 1.4 1.5 1.3 1.1 
0.1 1.1 1.6 1.6 0.9 1.1 1.0 2.3 1.1 1.5 1.2 0.9 
0.001 1.9 1.4 1.4 1.1 1.0 0.8 1.0 0.9 1.1 1.3 1.1 
Rockout 
(ROCK1) 
10 1.0 0.9 1.2 0.7 0.8 0.7 1.2 0.8 1.4 1.4 1.1 
0.1 1.2 0.7 1.3 1.1 0.9 0.5 1.3 0.7 1.4 1.6 1.0 
0.001 1.1 1.0 1.3 0.6 1.0 0.7 1.5 1.1 1.3 1.5 1.3 
Sabutoclax 
(BCL2A1) 
10 - 1.1 1.8 0.8 1.2 1.4 1.5 1.4 1.1 1.6 1.7 
0.1 - 1.3 1.5 0.9 1.1 1.3 1.5 1.7 1.3 1.4 1.6 
0.001 1.2 1.5 1.6 1.3 1.5 1.4 1.3 1.4 1.6 1.6 1.3 
Sotrastaurin 
(PRKCH) 
10 1.4 1.1 1.2 0.9 1.3 1.4 1.5 1.4 1.4 1.3 0.8 
0.1 1.1 1.0 1.2 0.7 1.0 1.5 1.1 1.1 1.5 1.3 0.8 
0.001 1.3 1.5 1.5 1.2 1.2 1.3 1.2 0.8 1.2 1.6 0.6 
TWS-119 
(MYC) 
10 1.6 0.9 1.4 1.1 1.4 1.2 1.0 1.1 1.4 1.4 0.8 
0.1 4.3 1.3 1.5 1.2 1.4 1.2 1.7 1.4 1.6 1.3 1.1 
0.001 4.4 2.8 1.6 1.3 1.4 1.5 1.9 3.6 1.6 2.1 1.4 
Volasertib 
(PLK1) 
10 20.1 1.3 1.1 1.2 1.4 2.6 0.5 3.0 1.7 1.5 1.2 
0.1 2.8 2.3 2.0 2.0 2.0 15.2 2.0 5.2 1.8 3.0 1.4 
0.001 1.3 1.4 1.6 1.2 1.4 1.2 1.2 1.3 1.3 1.4 1.4 
Vorinostat 
(HDAC) 
10 1.3 1.1 1.1 0.7 1.7 0.6 0.7 1.1 0.9 0.9 0.9 
0.1 0.9 1.1 1.1 0.6 1.1 0.5 0.5 0.7 1.1 0.8 0.7 
0.001 1.1 1.4 1.5 1.1 0.6 1.2 1.1 0.7 1.2 1.2 0.8 
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R script developed in this work for comprehensive analysis of RNA-Seq data 
 
#' --- 
#' title: "AML_VP16_RNA-Seq-2017_edgeR" 
#' author: "Piyush More" 
#' date: "September 1st, 2017" 
#' output: html_document 
#' --- 
 
library(edgeR) 
library(Homo.sapiens) 
 
setwd("/media/piyush/372429ff-0d6e-45d6-b529-527e3fb69028/RNA-
seq/AML_IMB_2017/Analysis/STAR/Gene_counts/edgeR") 
 
# Read individual count files (.tab) into edgeR 
files <- dir(pattern="*\\.tab$") 
 
# Remove OCIAML2 samples 
files <- files[ !grepl("OCIAML2", files) ] 
 
# While loading counts define the groups 
RG <- readDGE(files, columns = c(1,2), sep = " ", group = rep(1:20, times = 1, length.out = 60, each = 3)) 
 
rownames(RG$samples) <- 
c("F36P_CTR_1","F36P_CTR_2","F36P_CTR_3","F36P_VP16_1","F36P_VP16_2","F36P_VP16_3","HL60_CTR
_1","HL60_CTR_2","HL60_CTR_3","HL60_VP16_1","HL60_VP16_2","HL60_VP16_3","Kasumi1_CTR_1","Ka
sumi1_CTR_2","Kasumi1_CTR_3","Kasumi1_VP16_1","Kasumi1_VP16_2","Kasumi1_VP16_3","MOLM13_CT
R_1","MOLM13_CTR_2","MOLM13_CTR_3","MOLM13_VP16_1","MOLM13_VP16_2","MOLM13_VP16_3",
"MONOMAC6_CTR_1","MONOMAC6_CTR_2","MONOMAC6_CTR_3","MONOMAC6_VP16_1","MONOMA
C6_VP16_2","MONOMAC6_VP16_3","MV411_CTR_1","MV411_CTR_2","MV411_CTR_3","MV411_VP16_1
","MV411_VP16_2","MV411_VP16_3","NB4_CTR_1","NB4_CTR_2","NB4_CTR_3","NB4_VP16_1","NB4_VP
16_2","NB4_VP16_3","NOMO1_CTR_1","NOMO1_CTR_2","NOMO1_CTR_3","NOMO1_VP16_1","NOMO1_
VP16_2","NOMO1_VP16_3","OCIAML3_CTR_1","OCIAML3_CTR_2","OCIAML3_CTR_3","OCIAML3_VP1
6_1","OCIAML3_VP16_2","OCIAML3_VP16_3","THP1_CTR_1","THP1_CTR_2","THP1_CTR_3","THP1_VP1
6_1","THP1_VP16_2","THP1_VP16_3") 
 
colnames(RG$counts) <- 
c("F36P_CTR_1","F36P_CTR_2","F36P_CTR_3","F36P_VP16_1","F36P_VP16_2","F36P_VP16_3","HL60_CTR
_1","HL60_CTR_2","HL60_CTR_3","HL60_VP16_1","HL60_VP16_2","HL60_VP16_3","Kasumi1_CTR_1","Ka
sumi1_CTR_2","Kasumi1_CTR_3","Kasumi1_VP16_1","Kasumi1_VP16_2","Kasumi1_VP16_3","MOLM13_CT
R_1","MOLM13_CTR_2","MOLM13_CTR_3","MOLM13_VP16_1","MOLM13_VP16_2","MOLM13_VP16_3",
"MONOMAC6_CTR_1","MONOMAC6_CTR_2","MONOMAC6_CTR_3","MONOMAC6_VP16_1","MONOMA
C6_VP16_2","MONOMAC6_VP16_3","MV411_CTR_1","MV411_CTR_2","MV411_CTR_3","MV411_VP16_1
","MV411_VP16_2","MV411_VP16_3","NB4_CTR_1","NB4_CTR_2","NB4_CTR_3","NB4_VP16_1","NB4_VP
16_2","NB4_VP16_3","NOMO1_CTR_1","NOMO1_CTR_2","NOMO1_CTR_3","NOMO1_VP16_1","NOMO1_
VP16_2","NOMO1_VP16_3","OCIAML3_CTR_1","OCIAML3_CTR_2","OCIAML3_CTR_3","OCIAML3_VP1
6_1","OCIAML3_VP16_2","OCIAML3_VP16_3","THP1_CTR_1","THP1_CTR_2","THP1_CTR_3","THP1_VP1
6_1","THP1_VP16_2","THP1_VP16_3") 
 
RG$samples 
View(RG$counts) 
 
# Add gene annotation to the DGEList object 
geneid <- row.names(RG) 
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geneid <- substr(geneid, 1, 15) 
head(geneid) 
genes <- select(Homo.sapiens, keys=geneid, columns=c("ENTREZID", "SYMBOL", "TXCHROM", 
"DEFINITION", "OMIM"), keytype="ENSEMBL") 
head(genes) 
genes <- genes[!duplicated(genes$ENSEMBL),] 
head(genes) 
RG$genes <- genes 
y <- RG 
 
library("DESeq2") 
library("edgeR") 
library("hexbin") 
library("latticeExtra") 
library("vsn") 
library("gplots") 
library("RColorBrewer") 
library("topGO") 
library("gplots") 
library("genefilter") 
library("rtracklayer") 
library("xtable") 
library("GO.db") 
library("goseq") 
library("GenomicFeatures") 
library("pathview") 
library("NMF") 
library("pheatmap") 
library("GOplot") 
library(knitr) 
library("pcaExplorer") 
library(DT) 
library(ideal) 
library("dplyr") 
 
# Filter low counts: 3 are the minimum numbers of samples in each group and CPM 1 corresponds to counts of 6-7 
keep <- rowSums(cpm(y)>1) >= 3 
 
# Recalculate the library size 
y <- y[keep, , keep.lib.sizes=FALSE] 
 
# Create design for glm edgeR 
group <- factor(y$samples$group) 
group 
levels(y$samples$group) 
 
design <- model.matrix(~0+group, data=y$samples) 
design 
 
# DESeq object 
 
samplesDesign <- read.csv("/media/piyush/372429ff-0d6e-45d6-b529-527e3fb69028/RNA-
seq/AML_IMB_2017/Analysis/STAR/Gene_counts/DESeq2/sampleDesign_New2.csv", sep = ",", header = T, 
stringsAsFactors = F) 
dds <- DESeqDataSetFromMatrix(y$counts ,samplesDesign, design = ~ celltype + condition) 
colnames(dds) <- samplesDesign$sampleID 
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dds <- DESeq(dds) 
 
# Variance stabilizing transformation 
dds <- estimateSizeFactors(dds) 
baseMean <- rowMeans(counts(dds, normalized=TRUE)) 
sum(baseMean > 1) 
idx <- sample(which(baseMean > 5), 1000) 
dds.sub <- dds[idx, ] 
dds.sub <- estimateDispersions(dds.sub) 
dispersionFunction(dds) <- dispersionFunction(dds.sub) 
vsd <- varianceStabilizingTransformation(dds, blind=FALSE) 
 
colnames(vsd) <- 
c("F36P_CTR_1","F36P_CTR_2","F36P_CTR_3","F36P_VP16_1","F36P_VP16_2","F36P_VP16_3","HL60_CTR
_1","HL60_CTR_2","HL60_CTR_3","HL60_VP16_1","HL60_VP16_2","HL60_VP16_3","Kasumi1_CTR_1","Ka
sumi1_CTR_2","Kasumi1_CTR_3","Kasumi1_VP16_1","Kasumi1_VP16_2","Kasumi1_VP16_3","MOLM13_CT
R_1","MOLM13_CTR_2","MOLM13_CTR_3","MOLM13_VP16_1","MOLM13_VP16_2","MOLM13_VP16_3",
"MONOMAC6_CTR_1","MONOMAC6_CTR_2","MONOMAC6_CTR_3","MONOMAC6_VP16_1","MONOMA
C6_VP16_2","MONOMAC6_VP16_3","MV411_CTR_1","MV411_CTR_2","MV411_CTR_3","MV411_VP16_1
","MV411_VP16_2","MV411_VP16_3","NB4_CTR_1","NB4_CTR_2","NB4_CTR_3","NB4_VP16_1","NB4_VP
16_2","NB4_VP16_3","NOMO1_CTR_1","NOMO1_CTR_2","NOMO1_CTR_3","NOMO1_VP16_1","NOMO1_
VP16_2","NOMO1_VP16_3","OCIAML3_CTR_1","OCIAML3_CTR_2","OCIAML3_CTR_3","OCIAML3_VP1
6_1","OCIAML3_VP16_2","OCIAML3_VP16_3","THP1_CTR_1","THP1_CTR_2","THP1_CTR_3","THP1_VP1
6_1","THP1_VP16_2","THP1_VP16_3") 
 
library(pheatmap) 
pheatmap(as.matrix(dist(t(assay(vsd))))) 
dev.print(pdf, './edgeR_Results/AML-global_pheatmap.pdf', width = 12, height = 12) 
 
library(pcaExplorer) 
pcaplot(vsd, title = "pcaplot - global", ellipse = F) 
dev.print(pdf, './edgeR_Results/AML_pca_global.pdf', width = 12, height = 12) 
pcaplot(vsd, intgroup = "celltype", title = "pcaplot celltype - global", ellipse = F) 
dev.print(pdf, './edgeR_Results/AML_pca_global_celltype.pdf', width = 12, height = 12) 
 
# Sample distances  
sampleDists <- dist( t( assay(vsd) ) ) 
library("gplots") 
library("RColorBrewer") 
sampleDistMatrix <- as.matrix( sampleDists ) 
rownames(sampleDistMatrix) <- colnames(y$counts) 
colors <- colorRampPalette( rev(brewer.pal(9, "Blues")) )(255) 
hc <- hclust(sampleDists) 
heatmap.2( sampleDistMatrix, Rowv=as.dendrogram(hc), 
           symm=TRUE, trace="none", col=colors, 
           margins=c(2,10), labCol=FALSE ) 
dev.print(pdf, './edgeR_Results/AML-global_heatmap.pdf', width = 12, height = 12) 
 
# PCA plot 
z <- plotPCA(vsd, intgroup = "condition") 
nudge <- position_nudge(y = 2) 
z + geom_label(aes(label = name), position = nudge) 
dev.print(pdf, './edgeR_Results/AML_pca.pdf', width = 12, height = 12) 
(data <- plotPCA(vsd, intgroup = "condition", returnData=TRUE)) 
percentVar <- round(100 * attr(data, "percentVar")) 
library("ggplot2") 
104        Appendix 
 
qplot(PC1, PC2, color=condition, shape=name, data=data) + 
  xlab(paste0("PC1: ",percentVar[1],"% variance")) + 
  ylab(paste0("PC2: ",percentVar[2],"% variance")) 
 
# Calculate library normalization factor 
y <- calcNormFactors(y) 
 
# MDS plot to identify outliers 
plotMDS(y, col = rainbow(22)) 
dev.print(pdf, './edgeR_Results/AML-global_MDS_plot.pdf', width = 12, height = 12) 
y <- estimateDisp(y, design) 
plotMeanVar(y, show.tagwise.vars = TRUE, NBline = TRUE) 
dev.print(pdf, './edgeR_Results/AML-global_mean_var.pdf') 
plotBCV(y) 
dev.print(pdf, './edgeR_Results/AML-global_BCV.pdf', width = 12, height = 12) 
fit <- glmFit(y, design) 
 
# Make all contrasts together 
my.contrasts <- makeContrasts(f36p=group2-group1, hl60=group4-group3, kasumi1=group6-group5, 
molm13=group8-group7, monomac6=group10-group9, mv411=group12-group11, nb4=group14-group13, 
nomo1=group16-group15, ociaml3=group18-group17, thp1=group20-group19, levels = design) 
my.contrasts 
my.contrasts2 <- makeContrasts(resistant=group2-group8, resistant.ctr=group1-group7, levels = design) 
my.contrasts2 
 
# Differential expression 
f36p.vp16.VS.ctr <- glmLRT(fit, contrast = my.contrasts[,"f36p"]) 
hl60.vp16.VS.ctr <- glmLRT(fit, contrast = my.contrasts[,"hl60"]) 
kasumi1.vp16.VS.ctr <- glmLRT(fit, contrast = my.contrasts[,"kasumi1"]) 
molm13.vp16.VS.ctr <- glmLRT(fit, contrast = my.contrasts[,"molm13"]) 
monomac6.vp16.VS.ctr <- glmLRT(fit, contrast = my.contrasts[,"monomac6"]) 
mv411.vp16.VS.ctr <- glmLRT(fit, contrast = my.contrasts[,"mv411"]) 
nb4.vp16.VS.ctr <- glmLRT(fit, contrast = my.contrasts[,"nb4"]) 
nomo1.vp16.VS.ctr <- glmLRT(fit, contrast = my.contrasts[,"nomo1"]) 
ociaml3.vp16.VS.ctr <- glmLRT(fit, contrast = my.contrasts[,"ociaml3"]) 
thp1.vp16.VS.ctr <- glmLRT(fit, contrast = my.contrasts[,"thp1"]) 
f36p.vp16.VS.molm13.vp16 <- glmLRT(fit, contrast = my.contrasts2[,"resistant"]) 
f36p.VS.molm13.ctr <- glmLRT(fit, contrast = my.contrasts2[,"resistant.ctr"]) 
 
# Filter top DEG according to FDR 
res_f36p.vp16.VS.ctr <- topTags(f36p.vp16.VS.ctr, n = nrow(f36p.vp16.VS.ctr), sort.by = "PValue", p.value = 0.05) 
res_hl60.vp16.VS.ctr <- topTags(hl60.vp16.VS.ctr, n = nrow(hl60.vp16.VS.ctr), sort.by = "PValue", p.value = 0.05) 
res_kasumi1.vp16.VS.ctr <- topTags(kasumi1.vp16.VS.ctr, n = nrow(kasumi1.vp16.VS.ctr), sort.by = "PValue", 
p.value = 0.05) 
res_molm13.vp16.VS.ctr <- topTags(molm13.vp16.VS.ctr, n = nrow(molm13.vp16.VS.ctr), sort.by = "PValue", 
p.value = 0.05) 
res_monomac6.vp16.VS.ctr <- topTags(monomac6.vp16.VS.ctr, n = nrow(monomac6.vp16.VS.ctr), sort.by = 
"PValue", p.value = 0.05) 
res_mv411.vp16.VS.ctr <- topTags(mv411.vp16.VS.ctr, n = nrow(mv411.vp16.VS.ctr), sort.by = "PValue", p.value 
= 0.05) 
res_nb4.vp16.VS.ctr <- topTags(nb4.vp16.VS.ctr, n = nrow(nb4.vp16.VS.ctr), sort.by = "PValue", p.value = 0.05) 
res_nomo1.vp16.VS.ctr <- topTags(nomo1.vp16.VS.ctr, n = nrow(nomo1.vp16.VS.ctr), sort.by = "PValue", p.value 
= 0.05) 
res_ociaml3.vp16.VS.ctr <- topTags(ociaml3.vp16.VS.ctr, n = nrow(ociaml3.vp16.VS.ctr), sort.by = "PValue", 
p.value = 0.05) 
res_thp1.vp16.VS.ctr <- topTags(thp1.vp16.VS.ctr, n = nrow(thp1.vp16.VS.ctr), sort.by = "PValue", p.value = 0.05) 
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res_f36p.vp16.VS.molm13.vp16 <- topTags(f36p.vp16.VS.molm13.vp16, n = nrow(f36p.vp16.VS.molm13.vp16), 
sort.by = "PValue", p.value = 0.05) 
res_f36p.VS.molm13.ctr <- topTags(f36p.VS.molm13.ctr, n = nrow(f36p.VS.molm13.ctr), sort.by = "PValue", 
p.value = 0.05) 
 
# Filter DEG with logFC >= |1| 
keep_f36p <- abs(res_f36p.vp16.VS.ctr$table$logFC) >= 1 
res_f36p.vp16.VS.ctr <- res_f36p.vp16.VS.ctr[keep_f36p, ] 
keep_hl60 <- abs(res_hl60.vp16.VS.ctr$table$logFC) >= 1 
res_hl60.vp16.VS.ctr <- res_hl60.vp16.VS.ctr[keep_hl60, ] 
keep_kasumi1 <- abs(res_kasumi1.vp16.VS.ctr$table$logFC) >= 1 
res_kasumi1.vp16.VS.ctr <- res_kasumi1.vp16.VS.ctr[keep_kasumi1, ] 
keep_molm13 <- abs(res_molm13.vp16.VS.ctr$table$logFC) >= 1 
res_molm13.vp16.VS.ctr <- res_molm13.vp16.VS.ctr[keep_molm13, ] 
keep_monomac6 <- abs(res_monomac6.vp16.VS.ctr$table$logFC) >= 1 
res_monomac6.vp16.VS.ctr <- res_monomac6.vp16.VS.ctr[keep_monomac6, ] 
keep_mv411 <- abs(res_mv411.vp16.VS.ctr$table$logFC) >= 1 
res_mv411.vp16.VS.ctr <- res_mv411.vp16.VS.ctr[keep_mv411, ] 
keep_nb4 <- abs(res_nb4.vp16.VS.ctr$table$logFC) >= 1 
res_nb4.vp16.VS.ctr <- res_nb4.vp16.VS.ctr[keep_nb4, ] 
keep_nomo1 <- abs(res_nomo1.vp16.VS.ctr$table$logFC) >= 1 
res_nomo1.vp16.VS.ctr <- res_nomo1.vp16.VS.ctr[keep_nomo1, ] 
keep_ociaml3 <- abs(res_ociaml3.vp16.VS.ctr$table$logFC) >= 1 
res_ociaml3.vp16.VS.ctr <- res_ociaml3.vp16.VS.ctr[keep_ociaml3, ] 
keep_thp1 <- abs(res_thp1.vp16.VS.ctr$table$logFC) >= 1 
res_thp1.vp16.VS.ctr <- res_thp1.vp16.VS.ctr[keep_thp1, ] 
keep_resistant <- abs(res_f36p.vp16.VS.molm13.vp16$table$logFC) >= 1 
res_f36p.vp16.VS.molm13.vp16 <- res_f36p.vp16.VS.molm13.vp16[keep_resistant, ] 
keep_resistant.ctr <- abs(res_f36p.VS.molm13.ctr$table$logFC) >= 1 
res_f36p.VS.molm13.ctr <- res_f36p.VS.molm13.ctr[keep_resistant.ctr, ] 
 
plotMD(f36p.vp16.VS.ctr) 
abline(h=c(-1, 1), col="blue") 
dev.print(pdf, 'f36p_MD_plot.pdf') 
plotMD(hl60.vp16.VS.ctr) 
abline(h=c(-1, 1), col="blue") 
dev.print(pdf, 'hl60_MD_plot.pdf') 
plotMD(kasumi1.vp16.VS.ctr) 
abline(h=c(-1, 1), col="blue") 
dev.print(pdf, 'kasumi1_MD_plot.pdf') 
plotMD(molm13.vp16.VS.ctr) 
abline(h=c(-1, 1), col="blue") 
dev.print(pdf, 'molm13_MD_plot.pdf') 
plotMD(monomac6.vp16.VS.ctr) 
abline(h=c(-1, 1), col="blue") 
dev.print(pdf, 'monomac6_MD_plot.pdf') 
plotMD(mv411.vp16.VS.ctr) 
abline(h=c(-1, 1), col="blue") 
dev.print(pdf, 'mv411_MD_plot.pdf') 
plotMD(nb4.vp16.VS.ctr) 
abline(h=c(-1, 1), col="blue") 
dev.print(pdf, 'nb4_MD_plot.pdf') 
plotMD(nomo1.vp16.VS.ctr) 
abline(h=c(-1, 1), col="blue") 
dev.print(pdf, 'nomo1_MD_plot.pdf') 
plotMD(ociaml3.vp16.VS.ctr) 
106        Appendix 
 
abline(h=c(-1, 1), col="blue") 
dev.print(pdf, 'ociaml3_MD_plot.pdf') 
plotMD(thp1.vp16.VS.ctr) 
abline(h=c(-1, 1), col="blue") 
dev.print(pdf, 'thp1_MD_plot.pdf') 
plotMD(f36p.vp16.VS.molm13.vp16) 
abline(h=c(-1, 1), col="blue") 
dev.print(pdf, 'f36p_vs_molm13_vp16_MD_plot.pdf') 
plotMD(f36p.VS.molm13.ctr) 
abline(h=c(-1, 1), col="blue") 
dev.print(pdf, 'f36p_vs_molm13_ctr_MD_plot.pdf') 
 
# Inspect depth-adjusted reads per million for some top DEGs 
nc <- cpm(y, normalized.lib.sizes = TRUE) 
rn_f36p <- rownames(topTags(f36p.vp16.VS.ctr)$table) 
rn_hl60 <- rownames(topTags(hl60.vp16.VS.ctr)$table) 
rn_kasumi1 <- rownames(topTags(kasumi1.vp16.VS.ctr)$table) 
rn_molm13 <- rownames(topTags(molm13.vp16.VS.ctr)$table) 
rn_monomac6 <- rownames(topTags(monomac6.vp16.VS.ctr)$table) 
rn_mv411 <- rownames(topTags(mv411.vp16.VS.ctr)$table) 
rn_nb4 <- rownames(topTags(nb4.vp16.VS.ctr)$table) 
rn_nomo1 <- rownames(topTags(nomo1.vp16.VS.ctr)$table) 
rn_ociaml3 <- rownames(topTags(ociaml3.vp16.VS.ctr)$table) 
rn_thp1 <- rownames(topTags(thp1.vp16.VS.ctr)$table) 
rn_resistant <- rownames(topTags(f36p.vp16.VS.molm13.vp16)$table) 
rn_resistant.ctr <- rownames(topTags(f36p.VS.molm13.ctr)$table) 
 
# MA plot 
# F36P 
deg_f36p <- rn_f36p[topTags(f36p.vp16.VS.ctr)$table$FDR < .05] 
plotSmear(y, de.tags = deg_f36p, main = "F36P - VP16 VS Control") 
dev.print(pdf, './edgeR_Results/f36p_smear_plot.pdf') 
tt_f36p <- topTags(f36p.vp16.VS.ctr, n=nrow(y)) 
plot(-log10(PValue) ~ logFC, tt_f36p, pch=20) 
title(main = "F36P - VP16 VS Control") 
with(subset(tt_f36p$table, FDR < .05), points(logFC, -log10(PValue), col = "red")) 
with(subset(tt_f36p$table, abs(logFC) > 1), points(logFC, -log10(PValue),col = "orange")) 
with(subset(tt_f36p$table, FDR < 0.05 & abs(logFC) > 1), points(logFC, -log10(PValue), col = "green")) 
legend("topright", legend = c("FDR < 0.05", "logFC > 1", "Both"), pch = 16, col = c("red", "orange", "green")) 
dev.print(pdf, './edgeR_Results/f36p_volcano_plot.pdf') 
 
# HL60 
deg_hl60 <- rn_hl60[topTags(hl60.vp16.VS.ctr)$table$FDR < .05] 
plotSmear(y, de.tags = deg_hl60, main = "HL60 - VP16 VS Control") 
dev.print(pdf, './edgeR_Results/hl60_smear_plot.pdf') 
tt_hl60 <- topTags(hl60.vp16.VS.ctr, n=nrow(y)) 
plot(-log10(PValue) ~ logFC, tt_hl60, pch=20) 
title(main = "HL60 - VP16 VS Control") 
with(subset(tt_hl60$table, FDR < .05), points(logFC, -log10(PValue), col = "red")) 
with(subset(tt_hl60$table, abs(logFC) > 1), points(logFC, -log10(PValue),col = "orange")) 
with(subset(tt_hl60$table, FDR < 0.05 & abs(logFC) > 1), points(logFC, -log10(PValue), col = "green")) 
legend("topright", legend = c("FDR < 0.05", "logFC > 1", "Both"), pch = 16, col = c("red", "orange", "green")) 
dev.print(pdf, './edgeR_Results/hl60_volcano_plot.pdf') 
 
# KASUMI1 
deg_kasumi1 <- rn_kasumi1[topTags(kasumi1.vp16.VS.ctr)$table$FDR < .05] 
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plotSmear(y, de.tags = deg_kasumi1, main = "KASUMI1 - VP16 VS Control") 
dev.print(pdf, './edgeR_Results/kasumi1_smear_plot.pdf') 
tt_kasumi1 <- topTags(kasumi1.vp16.VS.ctr, n=nrow(y)) 
plot(-log10(PValue) ~ logFC, tt_kasumi1, pch=20) 
title(main = "KASUMI1 - VP16 VS Control") 
with(subset(tt_kasumi1$table, FDR < .05), points(logFC, -log10(PValue), col = "red")) 
with(subset(tt_kasumi1$table, abs(logFC) > 1), points(logFC, -log10(PValue),col = "orange")) 
with(subset(tt_kasumi1$table, FDR < 0.05 & abs(logFC) > 1), points(logFC, -log10(PValue), col = "green")) 
legend("topright", legend = c("FDR < 0.05", "logFC > 1", "Both"), pch = 16, col = c("red", "orange", "green")) 
dev.print(pdf, './edgeR_Results/kasumi1_volcano_plot.pdf') 
 
# MOLM13 
deg_molm13 <- rn_molm13[topTags(molm13.vp16.VS.ctr)$table$FDR < .05] 
plotSmear(y, de.tags = deg_molm13, main = "MOLM13 - VP16 VS Control") 
dev.print(pdf, './edgeR_Results/molm13_smear_plot.pdf') 
tt_molm13 <- topTags(molm13.vp16.VS.ctr, n=nrow(y)) 
plot(-log10(PValue) ~ logFC, tt_molm13, pch=20) 
title(main = "MOLM13 - VP16 VS Control") 
with(subset(tt_molm13$table, FDR < .05), points(logFC, -log10(PValue), col = "red")) 
with(subset(tt_molm13$table, abs(logFC) > 1), points(logFC, -log10(PValue),col = "orange")) 
with(subset(tt_molm13$table, FDR < 0.05 & abs(logFC) > 1), points(logFC, -log10(PValue), col = "green")) 
legend("topright", legend = c("FDR < 0.05", "logFC > 1", "Both"), pch = 16, col = c("red", "orange", "green")) 
dev.print(pdf, './edgeR_Results/molm13_volcano_plot.pdf') 
 
# MONOMAC6 
deg_monomac6 <- rn_monomac6[topTags(monomac6.vp16.VS.ctr)$table$FDR < .05] 
plotSmear(y, de.tags = deg_monomac6, main = "MONOMAC6 - VP16 VS Control") 
dev.print(pdf, './edgeR_Results/monomac6_smear_plot.pdf') 
tt_monomac6 <- topTags(monomac6.vp16.VS.ctr, n=nrow(y)) 
plot(-log10(PValue) ~ logFC, tt_monomac6, pch=20) 
title(main = "MONOMAC6 - VP16 VS Control") 
with(subset(tt_monomac6$table, FDR < .05), points(logFC, -log10(PValue), col = "red")) 
with(subset(tt_monomac6$table, abs(logFC) > 1), points(logFC, -log10(PValue),col = "orange")) 
with(subset(tt_monomac6$table, FDR < 0.05 & abs(logFC) > 1), points(logFC, -log10(PValue), col = "green")) 
legend("topright", legend = c("FDR < 0.05", "logFC > 1", "Both"), pch = 16, col = c("red", "orange", "green")) 
dev.print(pdf, './edgeR_Results/monomac6_volcano_plot.pdf') 
 
# MV411 
deg_mv411 <- rn_mv411[topTags(mv411.vp16.VS.ctr)$table$FDR < .05] 
plotSmear(y, de.tags = deg_mv411, main = "MV411 - VP16 VS Control") 
dev.print(pdf, './edgeR_Results/mv411_smear_plot.pdf') 
tt_mv411 <- topTags(mv411.vp16.VS.ctr, n=nrow(y)) 
plot(-log10(PValue) ~ logFC, tt_mv411, pch=20) 
title(main = "MV411 - VP16 VS Control") 
with(subset(tt_mv411$table, FDR < .05), points(logFC, -log10(PValue), col = "red")) 
with(subset(tt_mv411$table, abs(logFC) > 1), points(logFC, -log10(PValue),col = "orange")) 
with(subset(tt_mv411$table, FDR < 0.05 & abs(logFC) > 1), points(logFC, -log10(PValue), col = "green")) 
legend("topright", legend = c("FDR < 0.05", "logFC > 1", "Both"), pch = 16, col = c("red", "orange", "green")) 
dev.print(pdf, './edgeR_Results/mv411_volcano_plot.pdf') 
 
# NB4 
deg_nb4 <- rn_nb4[topTags(nb4.vp16.VS.ctr)$table$FDR < .05] 
plotSmear(y, de.tags = deg_nb4, main = "NB4 - VP16 VS Control") 
dev.print(pdf, './edgeR_Results/nb4_smear_plot.pdf') 
tt_nb4 <- topTags(nb4.vp16.VS.ctr, n=nrow(y)) 
plot(-log10(PValue) ~ logFC, tt_nb4, pch=20) 
108        Appendix 
 
title(main = "NB4 - VP16 VS Control") 
with(subset(tt_nb4$table, FDR < .05), points(logFC, -log10(PValue), col = "red")) 
with(subset(tt_nb4$table, abs(logFC) > 1), points(logFC, -log10(PValue),col = "orange")) 
with(subset(tt_nb4$table, FDR < 0.05 & abs(logFC) > 1), points(logFC, -log10(PValue), col = "green")) 
legend("topright", legend = c("FDR < 0.05", "logFC > 1", "Both"), pch = 16, col = c("red", "orange", "green")) 
dev.print(pdf, './edgeR_Results/nb4_volcano_plot.pdf') 
 
# NOMO1 
deg_nomo1 <- rn_nomo1[topTags(nomo1.vp16.VS.ctr)$table$FDR < .05] 
plotSmear(y, de.tags = deg_nomo1, main = "NOMO1 - VP16 VS Control") 
dev.print(pdf, './edgeR_Results/nomo1_smear_plot.pdf') 
tt_nomo1 <- topTags(nomo1.vp16.VS.ctr, n=nrow(y)) 
plot(-log10(PValue) ~ logFC, tt_nomo1, pch=20) 
title(main = "NOMO1 - VP16 VS Control") 
with(subset(tt_nomo1$table, FDR < .05), points(logFC, -log10(PValue), col = "red")) 
with(subset(tt_nomo1$table, abs(logFC) > 1), points(logFC, -log10(PValue),col = "orange")) 
with(subset(tt_nomo1$table, FDR < 0.05 & abs(logFC) > 1), points(logFC, -log10(PValue), col = "green")) 
legend("topright", legend = c("FDR < 0.05", "logFC > 1", "Both"), pch = 16, col = c("red", "orange", "green")) 
dev.print(pdf, './edgeR_Results/nomo1_volcano_plot.pdf') 
 
# OCIAML3 
deg_ociaml3 <- rn_ociaml3[topTags(ociaml3.vp16.VS.ctr)$table$FDR < .05] 
plotSmear(y, de.tags = deg_ociaml3, main = "OCIAML3 - VP16 VS Control") 
dev.print(pdf, './edgeR_Results/ociaml3_smear_plot.pdf') 
tt_ociaml3 <- topTags(ociaml3.vp16.VS.ctr, n=nrow(y)) 
plot(-log10(PValue) ~ logFC, tt_ociaml3, pch=20) 
title(main = "OCIAML3 - VP16 VS Control") 
with(subset(tt_ociaml3$table, FDR < .05), points(logFC, -log10(PValue), col = "red")) 
with(subset(tt_ociaml3$table, abs(logFC) > 1), points(logFC, -log10(PValue),col = "orange")) 
with(subset(tt_ociaml3$table, FDR < 0.05 & abs(logFC) > 1), points(logFC, -log10(PValue), col = "green")) 
legend("topright", legend = c("FDR < 0.05", "logFC > 1", "Both"), pch = 16, col = c("red", "orange", "green")) 
dev.print(pdf, './edgeR_Results/ociaml3_volcano_plot.pdf') 
 
# THP1 
deg_thp1 <- rn_thp1[topTags(thp1.vp16.VS.ctr)$table$FDR < .05] 
plotSmear(y, de.tags = deg_thp1, main = "THP1 - VP16 VS Control") 
dev.print(pdf, './edgeR_Results/thp1_smear_plot.pdf') 
tt_thp1 <- topTags(thp1.vp16.VS.ctr, n=nrow(y)) 
plot(-log10(PValue) ~ logFC, tt_thp1, pch=20) 
title(main = "THP1 - VP16 VS Control") 
with(subset(tt_thp1$table, FDR < .05), points(logFC, -log10(PValue), col = "red")) 
with(subset(tt_thp1$table, abs(logFC) > 1), points(logFC, -log10(PValue),col = "orange")) 
with(subset(tt_thp1$table, FDR < 0.05 & abs(logFC) > 1), points(logFC, -log10(PValue), col = "green")) 
legend("topright", legend = c("FDR < 0.05", "logFC > 1", "Both"), pch = 16, col = c("red", "orange", "green")) 
dev.print(pdf, './edgeR_Results/thp1_volcano_plot.pdf') 
 
# F36P VS MOLM13 VP16 
deg_resistant <- rn_resistant[topTags(f36p.vp16.VS.molm13.vp16)$table$FDR < .05] 
plotSmear(y, de.tags = deg_resistant, main = "F36P VP16 VS MOLM13 VP16") 
dev.print(pdf, './edgeR_Results/f36p-vp16_VS_mol13-vp16_smear_plot.pdf') 
tt_resistant <- topTags(f36p.vp16.VS.molm13.vp16, n=nrow(y)) 
plot(-log10(PValue) ~ logFC, tt_resistant, pch=20) 
title(main = "F36P VP16 VS MOLM13 VP16") 
with(subset(tt_resistant$table, FDR < .05), points(logFC, -log10(PValue), col = "red")) 
with(subset(tt_resistant$table, abs(logFC) > 1), points(logFC, -log10(PValue),col = "orange")) 
with(subset(tt_resistant$table, FDR < 0.05 & abs(logFC) > 1), points(logFC, -log10(PValue), col = "green")) 
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legend("topright", legend = c("FDR < 0.05", "logFC > 1", "Both"), pch = 16, col = c("red", "orange", "green")) 
dev.print(pdf, './edgeR_Results/f36p-vp16_VS_molm13-vp16_volcano_plot.pdf') 
 
# F36P VS MOLM13 CTR 
deg_resistant.ctr <- rn_resistant[topTags(f36p.VS.molm13.ctr)$table$FDR < .05] 
plotSmear(y, de.tags = deg_resistant.ctr, main = "F36P VP16 VS MOLM13 CTR") 
dev.print(pdf, './edgeR_Results/f36p-vp16_VS_mol13-ctr_smear_plot.pdf') 
tt_resistant.ctr <- topTags(f36p.VS.molm13.ctr, n=nrow(y)) 
plot(-log10(PValue) ~ logFC, tt_resistant.ctr, pch=20) 
title(main = "F36P VP16 VS MOLM13 CTR") 
with(subset(tt_resistant.ctr$table, FDR < .05), points(logFC, -log10(PValue), col = "red")) 
with(subset(tt_resistant.ctr$table, abs(logFC) > 1), points(logFC, -log10(PValue),col = "orange")) 
with(subset(tt_resistant.ctr$table, FDR < 0.05 & abs(logFC) > 1), points(logFC, -log10(PValue), col = "green")) 
legend("topright", legend = c("FDR < 0.05", "logFC > 1", "Both"), pch = 16, col = c("red", "orange", "green")) 
dev.print(pdf, './edgeR_Results/f36p_VS_molm13-ctr_volcano_plot.pdf') 
 
# Create result table 
# Define functions to create links 
 
createLinkGO <- function(val) { 
  sprintf('<a href="http://amigo.geneontology.org/amigo/term/%s" target="_blank" class="btn btn-
primary">%s</a>',val,val) 
} 
 
createLinkENS  <- function(val, species="Homo_sapiens") { 
  paste0('<a href="http://www.ensembl.org/',species,'/Gene/Summary?g=',val,'" target="_blank" class="btn btn-
primary">',val,'</a>') 
} 
 
createLinkGeneSymbol <- function(val) { 
  paste0('<a href="http://www.genecards.org/cgi-bin/carddisp.pl?gene=',val,'" target="_blank" class="btn btn-
primary">',val,'</a>') 
} 
 
# Create tables 
# F36P 
tbl_res_f36p.vp16.VS.ctr <- res_f36p.vp16.VS.ctr$table 
etbl_res_f36p.vp16.VS.ctr <- tbl_res_f36p.vp16.VS.ctr 
etbl_res_f36p.vp16.VS.ctr$ENSEMBL <- createLinkENS(etbl_res_f36p.vp16.VS.ctr$ENSEMBL, species = 
"Homo_sapiens") 
etbl_res_f36p.vp16.VS.ctr$SYMBOL <- createLinkGeneSymbol(etbl_res_f36p.vp16.VS.ctr$SYMBOL) 
datatable(etbl_res_f36p.vp16.VS.ctr, caption = "F36P - VP16 vs Control, DE genes", escape=F) 
write.table(tbl_res_f36p.vp16.VS.ctr, "./edgeR_Results/DEG_Table_f36p.txt", sep = "\t", row.names = F) 
 
# HL60 
tbl_res_hl60.vp16.VS.ctr <- res_hl60.vp16.VS.ctr$table 
etbl_res_hl60.vp16.VS.ctr <- tbl_res_hl60.vp16.VS.ctr 
etbl_res_hl60.vp16.VS.ctr$ENSEMBL <- createLinkENS(etbl_res_hl60.vp16.VS.ctr$ENSEMBL, species = 
"Homo_sapiens") 
etbl_res_hl60.vp16.VS.ctr$SYMBOL <- createLinkGeneSymbol(etbl_res_hl60.vp16.VS.ctr$SYMBOL) 
datatable(etbl_res_hl60.vp16.VS.ctr, caption = "HL60 - VP16 vs Control, DE genes", escape=F) 
write.table(tbl_res_hl60.vp16.VS.ctr, "./edgeR_Results/DEG_Table_hl60.txt", sep = "\t", row.names = F) 
 
# KASUMI1 
tbl_res_kasumi1.vp16.VS.ctr <- res_kasumi1.vp16.VS.ctr$table 
etbl_res_kasumi1.vp16.VS.ctr <- tbl_res_kasumi1.vp16.VS.ctr 
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etbl_res_kasumi1.vp16.VS.ctr$ENSEMBL <- createLinkENS(etbl_res_kasumi1.vp16.VS.ctr$ENSEMBL, species = 
"Homo_sapiens") 
etbl_res_kasumi1.vp16.VS.ctr$SYMBOL <- createLinkGeneSymbol(etbl_res_kasumi1.vp16.VS.ctr$SYMBOL) 
datatable(etbl_res_kasumi1.vp16.VS.ctr, caption = "KASUMI1 - VP16 vs Control, DE genes", escape=F) 
write.table(tbl_res_kasumi1.vp16.VS.ctr, "./edgeR_Results/DEG_Table_kasumi1.txt", sep = "\t", row.names = F) 
 
# MOLM13 
tbl_res_molm13.vp16.VS.ctr <- res_molm13.vp16.VS.ctr$table 
etbl_res_molm13.vp16.VS.ctr <- tbl_res_molm13.vp16.VS.ctr 
etbl_res_molm13.vp16.VS.ctr$ENSEMBL <- createLinkENS(etbl_res_molm13.vp16.VS.ctr$ENSEMBL, species = 
"Homo_sapiens") 
etbl_res_molm13.vp16.VS.ctr$SYMBOL <- createLinkGeneSymbol(etbl_res_molm13.vp16.VS.ctr$SYMBOL) 
datatable(etbl_res_molm13.vp16.VS.ctr, caption = "MOLM13 - VP16 vs Control, DE genes", escape=F) 
write.table(tbl_res_molm13.vp16.VS.ctr, "./edgeR_Results/DEG_Table_molm13.txt", sep = "\t", row.names = F) 
 
# MONOMAC6 
tbl_res_monomac6.vp16.VS.ctr <- res_monomac6.vp16.VS.ctr$table 
etbl_res_monomac6.vp16.VS.ctr <- tbl_res_monomac6.vp16.VS.ctr 
etbl_res_monomac6.vp16.VS.ctr$ENSEMBL <- createLinkENS(etbl_res_monomac6.vp16.VS.ctr$ENSEMBL, 
species = "Homo_sapiens") 
etbl_res_monomac6.vp16.VS.ctr$SYMBOL <- 
createLinkGeneSymbol(etbl_res_monomac6.vp16.VS.ctr$SYMBOL) 
datatable(etbl_res_monomac6.vp16.VS.ctr, caption = "MONOMAC6 - VP16 vs Control, DE genes", escape=F) 
write.table(tbl_res_monomac6.vp16.VS.ctr, "./edgeR_Results/DEG_Table_monomac6.txt", sep = "\t", row.names = 
F) 
 
# MV411 
tbl_res_mv411.vp16.VS.ctr <- res_mv411.vp16.VS.ctr$table 
etbl_res_mv411.vp16.VS.ctr <- tbl_res_mv411.vp16.VS.ctr 
etbl_res_mv411.vp16.VS.ctr$ENSEMBL <- createLinkENS(etbl_res_mv411.vp16.VS.ctr$ENSEMBL, species = 
"Homo_sapiens") 
etbl_res_mv411.vp16.VS.ctr$SYMBOL <- createLinkGeneSymbol(etbl_res_mv411.vp16.VS.ctr$SYMBOL) 
datatable(etbl_res_mv411.vp16.VS.ctr, caption = "MV411 - VP16 vs Control, DE genes", escape=F) 
write.table(tbl_res_mv411.vp16.VS.ctr, "./edgeR_Results/DEG_Table_mv411.txt", sep = "\t", row.names = F) 
 
# NB4 
tbl_res_nb4.vp16.VS.ctr <- res_nb4.vp16.VS.ctr$table 
etbl_res_nb4.vp16.VS.ctr <- tbl_res_nb4.vp16.VS.ctr 
etbl_res_nb4.vp16.VS.ctr$ENSEMBL <- createLinkENS(etbl_res_nb4.vp16.VS.ctr$ENSEMBL, species = 
"Homo_sapiens") 
etbl_res_nb4.vp16.VS.ctr$SYMBOL <- createLinkGeneSymbol(etbl_res_nb4.vp16.VS.ctr$SYMBOL) 
datatable(etbl_res_nb4.vp16.VS.ctr, caption = "NB4 - VP16 vs Control, DE genes", escape=F) 
write.table(tbl_res_nb4.vp16.VS.ctr, "./edgeR_Results/DEG_Table_nb4.txt", sep = "\t", row.names = F) 
 
# NOMO1 
tbl_res_nomo1.vp16.VS.ctr <- res_nomo1.vp16.VS.ctr$table 
etbl_res_nomo1.vp16.VS.ctr <- tbl_res_nomo1.vp16.VS.ctr 
etbl_res_nomo1.vp16.VS.ctr$ENSEMBL <- createLinkENS(etbl_res_nomo1.vp16.VS.ctr$ENSEMBL, species = 
"Homo_sapiens") 
etbl_res_nomo1.vp16.VS.ctr$SYMBOL <- createLinkGeneSymbol(etbl_res_nomo1.vp16.VS.ctr$SYMBOL) 
datatable(etbl_res_nomo1.vp16.VS.ctr, caption = "NOMO1 - VP16 vs Control, DE genes", escape=F) 
write.table(tbl_res_nomo1.vp16.VS.ctr, "./edgeR_Results/DEG_Table_nomo1.txt", sep = "\t", row.names = F) 
 
# OCIAML3 
tbl_res_ociaml3.vp16.VS.ctr <- res_ociaml3.vp16.VS.ctr$table 
etbl_res_ociaml3.vp16.VS.ctr <- tbl_res_ociaml3.vp16.VS.ctr 
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etbl_res_ociaml3.vp16.VS.ctr$ENSEMBL <- createLinkENS(etbl_res_ociaml3.vp16.VS.ctr$ENSEMBL, species = 
"Homo_sapiens") 
etbl_res_ociaml3.vp16.VS.ctr$SYMBOL <- createLinkGeneSymbol(etbl_res_ociaml3.vp16.VS.ctr$SYMBOL) 
datatable(etbl_res_ociaml3.vp16.VS.ctr, caption = "OCIAML3 - VP16 vs Control, DE genes", escape=F) 
write.table(tbl_res_ociaml3.vp16.VS.ctr, "./edgeR_Results/DEG_Table_ociaml3.txt", sep = "\t", row.names = F) 
 
# THP1 
tbl_res_thp1.vp16.VS.ctr <- res_thp1.vp16.VS.ctr$table 
etbl_res_thp1.vp16.VS.ctr <- tbl_res_thp1.vp16.VS.ctr 
etbl_res_thp1.vp16.VS.ctr$ENSEMBL <- createLinkENS(etbl_res_thp1.vp16.VS.ctr$ENSEMBL, species = 
"Homo_sapiens") 
etbl_res_thp1.vp16.VS.ctr$SYMBOL <- createLinkGeneSymbol(etbl_res_thp1.vp16.VS.ctr$SYMBOL) 
datatable(etbl_res_thp1.vp16.VS.ctr, caption = "THP1 - VP16 vs Control, DE genes", escape=F) 
write.table(tbl_res_thp1.vp16.VS.ctr, "./edgeR_Results/DEG_Table_thp1.txt", sep = "\t", row.names = F) 
 
# F36P VS MOLM13 VP16 
tbl_res_f36p.vp16.VS.molm13.vp16 <- res_f36p.vp16.VS.molm13.vp16$table 
etbl_res_f36p.vp16.VS.molm13.vp16 <- tbl_res_f36p.vp16.VS.molm13.vp16 
etbl_res_f36p.vp16.VS.molm13.vp16$ENSEMBL <- 
createLinkENS(etbl_res_f36p.vp16.VS.molm13.vp16$ENSEMBL, species = "Homo_sapiens") 
etbl_res_f36p.vp16.VS.molm13.vp16$SYMBOL <- 
createLinkGeneSymbol(etbl_res_f36p.vp16.VS.molm13.vp16$SYMBOL) 
datatable(etbl_res_f36p.vp16.VS.molm13.vp16, caption = "F36P VS MOLM13 VP16, DE genes", escape=F) 
write.table(tbl_res_f36p.vp16.VS.molm13.vp16, "./edgeR_Results/DEG_Table_f36p-vp16_VS-molm13-vp16.txt", 
sep = "\t", row.names = F) 
 
# F36P VS MOLM13 CTR 
tbl_res_f36p.VS.molm13.ctr <- res_f36p.VS.molm13.ctr$table 
etbl_res_f36p.VS.molm13.ctr <- tbl_res_f36p.VS.molm13.ctr 
etbl_res_f36p.VS.molm13.ctr$ENSEMBL <- createLinkENS(etbl_res_f36p.VS.molm13.ctr$ENSEMBL, species = 
"Homo_sapiens") 
etbl_res_f36p.VS.molm13.ctr$SYMBOL <- createLinkGeneSymbol(etbl_res_f36p.VS.molm13.ctr$SYMBOL) 
datatable(etbl_res_f36p.VS.molm13.ctr, caption = "F36P VS MOLM13 Control, DE genes", escape=F) 
write.table(tbl_res_f36p.VS.molm13.ctr, "./edgeR_Results/DEG_Table_f36p_VS-molm13-ctr.txt", sep = "\t", 
row.names = F) 
 
# Functional interpretation 
# Create annotation file 
 
annoHuman <- import("/media/piyush/372429ff-0d6e-45d6-b529-527e3fb69028/RNA-
seq/AML_IMB_2017/Analysis/STAR/NOISeq/Gencode_v25_GRCh38.p7/gencode.v25.annotation.gtf") 
cm2=data.frame(ensid=mcols(annoHuman)$gene_id,fromgtf=mcols(annoHuman)$gene_name,stringsAsFactors = 
FALSE) 
cm2 <- cm2[!duplicated(cm2),] 
rownames(cm2) <- cm2$ensid 
anno_df <- data.frame(gene_id = rownames(dds), stringsAsFactors = F) 
anno_df$gene_name <- cm2$fromgtf[match(anno_df$gene_id,rownames(cm2))] 
rownames(anno_df) <- anno_df$gene_id 
head(anno_df) 
 
# Create list of universally expressed genes 
expressedInAssay <- (rowSums(assay(dds))>0) 
geneUniverseExprENS <- rownames(dds)[expressedInAssay] 
geneUniverseExpr <- anno_df$gene_name[match(geneUniverseExprENS,anno_df$gene_id)] 
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# Use topGOtable to annotate DEGs for biological processesGObps_f36p.vp16.VS.ctr <- topGOtable(DEgenes = 
res_f36p.vp16.VS.ctr$table$SYMBOL, BGgenes = geneUniverseExpr, ontology = "BP", geneID = "symbol", 
addGeneToTerms = TRUE, mapping = "org.Hs.eg.db") 
# F36P 
GObps_f36p.vp16.VS.ctr <- topGOtable(DEgenes = res_f36p.vp16.VS.ctr$table$SYMBOL, BGgenes = 
geneUniverseExpr, ontology = "BP", geneID = "symbol", addGeneToTerms = TRUE, mapping = "org.Hs.eg.db") 
eGObps_f36p.vp16.VS.ctr <- GObps_f36p.vp16.VS.ctr 
eGObps_f36p.vp16.VS.ctr$GO.ID <- createLinkGO(eGObps_f36p.vp16.VS.ctr$GO.ID) 
eGObps_f36p.vp16.VS.ctr %>% datatable(caption = "topGO - Biological processes enriched in DE genes - F36P- 
VP16 vs Control", options = list(pageLength = 20),escape = FALSE) 
write.table(GObps_f36p.vp16.VS.ctr, "./edgeR_Results/topGO_BP_f36p_vp16_VS_ctr.txt", sep = "\t", row.names 
= F) 
 
# HL60 
GObps_hl60.vp16.VS.ctr <- topGOtable(DEgenes = res_hl60.vp16.VS.ctr$table$SYMBOL, BGgenes = 
geneUniverseExpr, ontology = "BP", geneID = "symbol", addGeneToTerms = TRUE, mapping = "org.Hs.eg.db") 
eGObps_hl60.vp16.VS.ctr <- GObps_hl60.vp16.VS.ctr 
eGObps_hl60.vp16.VS.ctr$GO.ID <- createLinkGO(eGObps_hl60.vp16.VS.ctr$GO.ID) 
eGObps_hl60.vp16.VS.ctr %>% datatable(caption = "topGO - Biological processes enriched in DE genes - HL60- 
VP16 vs Control", options = list(pageLength = 20),escape = FALSE) 
write.table(GObps_hl60.vp16.VS.ctr, "./edgeR_Results/topGO_BP_hl60_vp16_VS_ctr.txt", sep = "\t", row.names = 
F) 
 
# KASUMI1 
GObps_kasumi1.vp16.VS.ctr <- topGOtable(DEgenes = res_kasumi1.vp16.VS.ctr$table$SYMBOL, BGgenes = 
geneUniverseExpr, ontology = "BP", geneID = "symbol", addGeneToTerms = TRUE, mapping = "org.Hs.eg.db") 
eGObps_kasumi1.vp16.VS.ctr <- GObps_kasumi1.vp16.VS.ctr 
eGObps_kasumi1.vp16.VS.ctr$GO.ID <- createLinkGO(eGObps_kasumi1.vp16.VS.ctr$GO.ID) 
eGObps_kasumi1.vp16.VS.ctr %>% datatable(caption = "topGO - Biological processes enriched in DE genes - 
KASUMI1- VP16 vs Control", options = list(pageLength = 20),escape = FALSE) 
write.table(GObps_kasumi1.vp16.VS.ctr, "./edgeR_Results/topGO_BP_kasumi1_vp16_VS_ctr.txt", sep = "\t", 
row.names = F) 
 
# MOLM13 
GObps_molm13.vp16.VS.ctr <- topGOtable(DEgenes = res_molm13.vp16.VS.ctr$table$SYMBOL, BGgenes = 
geneUniverseExpr, ontology = "BP", geneID = "symbol", addGeneToTerms = TRUE, mapping = "org.Hs.eg.db") 
eGObps_molm13.vp16.VS.ctr <- GObps_molm13.vp16.VS.ctr 
eGObps_molm13.vp16.VS.ctr$GO.ID <- createLinkGO(eGObps_molm13.vp16.VS.ctr$GO.ID) 
eGObps_molm13.vp16.VS.ctr %>% datatable(caption = "topGO - Biological processes enriched in DE genes - 
MOLM13- VP16 vs Control", options = list(pageLength = 20),escape = FALSE) 
write.table(GObps_molm13.vp16.VS.ctr, "./edgeR_Results/topGO_BP_molm13_vp16_VS_ctr.txt", sep = "\t", 
row.names = F) 
 
# MONOMAC6 
GObps_monomac6.vp16.VS.ctr <- topGOtable(DEgenes = res_monomac6.vp16.VS.ctr$table$SYMBOL, BGgenes 
= geneUniverseExpr, ontology = "BP", geneID = "symbol", addGeneToTerms = TRUE, mapping = "org.Hs.eg.db") 
eGObps_monomac6.vp16.VS.ctr <- GObps_monomac6.vp16.VS.ctr 
eGObps_monomac6.vp16.VS.ctr$GO.ID <- createLinkGO(eGObps_monomac6.vp16.VS.ctr$GO.ID) 
eGObps_monomac6.vp16.VS.ctr %>% datatable(caption = "topGO - Biological processes enriched in DE genes - 
MONOMAC6- VP16 vs Control", options = list(pageLength = 20),escape = FALSE) 
write.table(GObps_monomac6.vp16.VS.ctr, "./edgeR_Results/topGO_BP_monomac6_vp16_VS_ctr.txt", sep = "\t", 
row.names = F) 
 
# MV411 
GObps_mv411.vp16.VS.ctr <- topGOtable(DEgenes = res_mv411.vp16.VS.ctr$table$SYMBOL, BGgenes = 
geneUniverseExpr, ontology = "BP", geneID = "symbol", addGeneToTerms = TRUE, mapping = "org.Hs.eg.db") 
113        Appendix 
 
eGObps_mv411.vp16.VS.ctr <- GObps_mv411.vp16.VS.ctr 
eGObps_mv411.vp16.VS.ctr$GO.ID <- createLinkGO(eGObps_mv411.vp16.VS.ctr$GO.ID) 
eGObps_mv411.vp16.VS.ctr %>% datatable(caption = "topGO - Biological processes enriched in DE genes - 
MV411- VP16 vs Control", options = list(pageLength = 20),escape = FALSE) 
write.table(GObps_mv411.vp16.VS.ctr, "./edgeR_Results/topGO_BP_mv411_vp16_VS_ctr.txt", sep = "\t", 
row.names = F) 
 
# NB4 
GObps_nb4.vp16.VS.ctr <- topGOtable(DEgenes = res_nb4.vp16.VS.ctr$table$SYMBOL, BGgenes = 
geneUniverseExpr, ontology = "BP", geneID = "symbol", addGeneToTerms = TRUE, mapping = "org.Hs.eg.db") 
eGObps_nb4.vp16.VS.ctr <- GObps_nb4.vp16.VS.ctr 
eGObps_nb4.vp16.VS.ctr$GO.ID <- createLinkGO(eGObps_nb4.vp16.VS.ctr$GO.ID) 
eGObps_nb4.vp16.VS.ctr %>% datatable(caption = "topGO - Biological processes enriched in DE genes - NB4- 
VP16 vs Control", options = list(pageLength = 20),escape = FALSE) 
write.table(GObps_nb4.vp16.VS.ctr, "./edgeR_Results/topGO_BP_nb4_vp16_VS_ctr.txt", sep = "\t", row.names = 
F) 
 
# NOMO1 
GObps_nomo1.vp16.VS.ctr <- topGOtable(DEgenes = res_nomo1.vp16.VS.ctr$table$SYMBOL, BGgenes = 
geneUniverseExpr, ontology = "BP", geneID = "symbol", addGeneToTerms = TRUE, mapping = "org.Hs.eg.db") 
eGObps_nomo1.vp16.VS.ctr <- GObps_nomo1.vp16.VS.ctr 
eGObps_nomo1.vp16.VS.ctr$GO.ID <- createLinkGO(eGObps_nomo1.vp16.VS.ctr$GO.ID) 
eGObps_nomo1.vp16.VS.ctr %>% datatable(caption = "topGO - Biological processes enriched in DE genes - 
NOMO1- VP16 vs Control", options = list(pageLength = 20),escape = FALSE) 
write.table(GObps_nomo1.vp16.VS.ctr, "./edgeR_Results/topGO_BP_nomo1_vp16_VS_ctr.txt", sep = "\t", 
row.names = F) 
 
# OCIAML3 
GObps_ociaml3.vp16.VS.ctr <- topGOtable(DEgenes = res_ociaml3.vp16.VS.ctr$table$SYMBOL, BGgenes = 
geneUniverseExpr, ontology = "BP", geneID = "symbol", addGeneToTerms = TRUE, mapping = "org.Hs.eg.db") 
eGObps_ociaml3.vp16.VS.ctr <- GObps_ociaml3.vp16.VS.ctr 
eGObps_ociaml3.vp16.VS.ctr$GO.ID <- createLinkGO(eGObps_ociaml3.vp16.VS.ctr$GO.ID) 
eGObps_ociaml3.vp16.VS.ctr %>% datatable(caption = "topGO - Biological processes enriched in DE genes - 
OCIAML3- VP16 vs Control", options = list(pageLength = 20),escape = FALSE) 
write.table(GObps_ociaml3.vp16.VS.ctr, "./edgeR_Results/topGO_BP_ociaml3_vp16_VS_ctr.txt", sep = "\t", 
row.names = F) 
 
# THP1 
GObps_thp1.vp16.VS.ctr <- topGOtable(DEgenes = res_thp1.vp16.VS.ctr$table$SYMBOL, BGgenes = 
geneUniverseExpr, ontology = "BP", geneID = "symbol", addGeneToTerms = TRUE, mapping = "org.Hs.eg.db") 
eGObps_thp1.vp16.VS.ctr <- GObps_thp1.vp16.VS.ctr 
eGObps_thp1.vp16.VS.ctr$GO.ID <- createLinkGO(eGObps_thp1.vp16.VS.ctr$GO.ID) 
eGObps_thp1.vp16.VS.ctr %>% datatable(caption = "topGO - Biological processes enriched in DE genes - THP1- 
VP16 vs Control", options = list(pageLength = 20),escape = FALSE) 
write.table(GObps_thp1.vp16.VS.ctr, "./edgeR_Results/topGO_BP_thp1_vp16_VS_ctr.txt", sep = "\t", row.names = 
F) 
 
# F36P VS MOLM13 VP16 
GObps_f36p.vp16.VS.molm13.vp16 <- topGOtable(DEgenes = res_f36p.vp16.VS.molm13.vp16$table$SYMBOL, 
BGgenes = geneUniverseExpr, ontology = "BP", geneID = "symbol", addGeneToTerms = TRUE, mapping = 
"org.Hs.eg.db") 
eGObps_f36p.vp16.VS.molm13.vp16 <- GObps_f36p.vp16.VS.molm13.vp16 
eGObps_f36p.vp16.VS.molm13.vp16$GO.ID <- createLinkGO(eGObps_f36p.vp16.VS.molm13.vp16$GO.ID) 
eGObps_f36p.vp16.VS.molm13.vp16 %>% datatable(caption = "topGO - Biological processes enriched in DE 
genes - F36P-VP16 VS MOLM13-VP16", options = list(pageLength = 20),escape = FALSE) 
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write.table(GObps_f36p.vp16.VS.molm13.vp16, "./edgeR_Results/topGO_BP_f36p-vp16_VS_molm13-vp16.txt", 
sep = "\t", row.names = F) 
 
# F36P VS MOLM13 CTR 
GObps_f36p.VS.molm13.ctr <- topGOtable(DEgenes = res_f36p.VS.molm13.ctr$table$SYMBOL, BGgenes = 
geneUniverseExpr, ontology = "BP", geneID = "symbol", addGeneToTerms = TRUE, mapping = "org.Hs.eg.db") 
eGObps_f36p.VS.molm13.ctr <- GObps_f36p.VS.molm13.ctr 
eGObps_f36p.VS.molm13.ctr$GO.ID <- createLinkGO(eGObps_f36p.VS.molm13.ctr$GO.ID) 
eGObps_f36p.VS.molm13.ctr %>% datatable(caption = "topGO - Biological processes enriched in DE genes - F36P 
VS MOLM13 Control", options = list(pageLength = 20),escape = FALSE) 
write.table(GObps_f36p.VS.molm13.ctr, "./edgeR_Results/topGO_BP_f36p_VS_molm13-control.txt", sep = "\t", 
row.names = F) 
 
# remove NA values in ENTREZ and SYMBOL field 
deg_table_f36p <- data.frame(tbl_res_f36p.vp16.VS.ctr[complete.cases(tbl_res_f36p.vp16.VS.ctr[,2:3]),]) 
deg_table_hl60 <- data.frame(tbl_res_hl60.vp16.VS.ctr[complete.cases(tbl_res_hl60.vp16.VS.ctr[,2:3]),]) 
deg_table_kasumi1 <- 
data.frame(tbl_res_kasumi1.vp16.VS.ctr[complete.cases(tbl_res_kasumi1.vp16.VS.ctr[,2:3]),]) 
deg_table_molm13 <- 
data.frame(tbl_res_molm13.vp16.VS.ctr[complete.cases(tbl_res_molm13.vp16.VS.ctr[,2:3]),]) 
deg_table_monomac6 <- 
data.frame(tbl_res_monomac6.vp16.VS.ctr[complete.cases(tbl_res_monomac6.vp16.VS.ctr[,2:3]),]) 
deg_table_mv411 <- data.frame(tbl_res_mv411.vp16.VS.ctr[complete.cases(tbl_res_mv411.vp16.VS.ctr[,2:3]),]) 
deg_table_nb4 <- data.frame(tbl_res_nb4.vp16.VS.ctr[complete.cases(tbl_res_nb4.vp16.VS.ctr[,2:3]),]) 
deg_table_nomo1 <- data.frame(tbl_res_nomo1.vp16.VS.ctr[complete.cases(tbl_res_nomo1.vp16.VS.ctr[,2:3]),]) 
deg_table_ociaml3 <- data.frame(tbl_res_ociaml3.vp16.VS.ctr[complete.cases(tbl_res_ociaml3.vp16.VS.ctr[,2:3]),]) 
deg_table_thp1 <- data.frame(tbl_res_thp1.vp16.VS.ctr[complete.cases(tbl_res_thp1.vp16.VS.ctr[,2:3]),]) 
 
# DEG statistics  
deg_stat <- data.frame("Total_DEG" = c(length(deg_table_f36p$SYMBOL), length(deg_table_hl60$SYMBOL), 
length(deg_table_kasumi1$SYMBOL), length(deg_table_molm13$SYMBOL), 
length(deg_table_monomac6$SYMBOL), length(deg_table_mv411$SYMBOL), length(deg_table_nb4$SYMBOL), 
length(deg_table_nomo1$SYMBOL), length(deg_table_ociaml3$SYMBOL), length(deg_table_thp1$SYMBOL)), 
"UP" = c(length(which(deg_table_f36p$logFC >= 1)), length(which(deg_table_hl60$logFC >= 1)), 
length(which(deg_table_kasumi1$logFC >= 1)), length(which(deg_table_molm13$logFC >= 1)), 
length(which(deg_table_monomac6$logFC >= 1)), length(which(deg_table_mv411$logFC >= 1)), 
length(which(deg_table_nb4$logFC >= 1)), length(which(deg_table_nomo1$logFC >= 1)), 
length(which(deg_table_ociaml3$logFC >= 1)), length(which(deg_table_thp1$logFC >= 1))), "DOWN" = 
c(length(which(deg_table_f36p$logFC <= 1)), length(which(deg_table_hl60$logFC <= 1)), 
length(which(deg_table_kasumi1$logFC <= 1)), length(which(deg_table_molm13$logFC <= 1)), 
length(which(deg_table_monomac6$logFC <= 1)), length(which(deg_table_mv411$logFC <= 1)), 
length(which(deg_table_nb4$logFC <= 1)), length(which(deg_table_nomo1$logFC <= 1)), 
length(which(deg_table_ociaml3$logFC <= 1)), length(which(deg_table_thp1$logFC <= 1)))) 
deg_stat$"%_Up" <- round(((deg_stat$UP / deg_stat$Total_DEG) * 100), digits = 2) 
deg_stat$"%_Down" <- round(((deg_stat$DOWN / deg_stat$Total_DEG) * 100), digits = 2) 
rownames(deg_stat) <- c("F36-P", "HL-60", "KASUMI-1", "MOLM-13", "MONO-MAC-6", "MV-4-11", "NB-4", 
"NOMO-1", "OCI-AML3", "THP-1") 
deg_stat$"VP16-IC50 (µM)" <- c(98.81, 0.74, 6.80, 0.39, 4.39, 1.33, 0.50, 1.65, 1.00, 1.01) 
deg_stat %>% datatable(caption = "DEG statistics (VP16 VS Control)", escape = F) 
 
 
deg_table_UP_f36p <- data.frame(deg_table_f36p[which(deg_table_f36p$logFC >= 1),]) 
deg_table_DOWN_f36p <- data.frame(deg_table_f36p[which(deg_table_f36p$logFC <= 1),]) 
deg_table_UP_hl60 <- data.frame(deg_table_hl60[which(deg_table_hl60$logFC >= 1),]) 
deg_table_DOWN_hl60 <- data.frame(deg_table_hl60[which(deg_table_hl60$logFC <= 1),]) 
deg_table_UP_kasumi1 <- data.frame(deg_table_kasumi1[which(deg_table_kasumi1$logFC >= 1),]) 
115        Appendix 
 
deg_table_DOWN_kasumi1 <- data.frame(deg_table_kasumi1[which(deg_table_kasumi1$logFC <= 1),]) 
deg_table_UP_molm13 <- data.frame(deg_table_molm13[which(deg_table_molm13$logFC >= 1),]) 
deg_table_DOWN_molm13 <- data.frame(deg_table_molm13[which(deg_table_molm13$logFC <= 1),]) 
deg_table_UP_monomac6 <- data.frame(deg_table_monomac6[which(deg_table_monomac6$logFC >= 1),]) 
deg_table_DOWN_monomac6 <- data.frame(deg_table_monomac6[which(deg_table_monomac6$logFC <= 1),]) 
deg_table_UP_mv411 <- data.frame(deg_table_mv411[which(deg_table_mv411$logFC >= 1),]) 
deg_table_DOWN_mv411 <- data.frame(deg_table_mv411[which(deg_table_mv411$logFC <= 1),]) 
deg_table_UP_nb4 <- data.frame(deg_table_nb4[which(deg_table_nb4$logFC >= 1),]) 
deg_table_DOWN_nb4 <- data.frame(deg_table_nb4[which(deg_table_nb4$logFC <= 1),]) 
deg_table_UP_nomo1 <- data.frame(deg_table_nomo1[which(deg_table_nomo1$logFC >= 1),]) 
deg_table_DOWN_nomo1 <- data.frame(deg_table_nomo1[which(deg_table_nomo1$logFC <= 1),]) 
deg_table_UP_ociaml3 <- data.frame(deg_table_ociaml3[which(deg_table_ociaml3$logFC >= 1),]) 
deg_table_DOWN_ociaml3 <- data.frame(deg_table_ociaml3[which(deg_table_ociaml3$logFC <= 1),]) 
deg_table_UP_thp1 <- data.frame(deg_table_thp1[which(deg_table_thp1$logFC >= 1),]) 
deg_table_DOWN_thp1 <- data.frame(deg_table_thp1[which(deg_table_thp1$logFC <= 1),]) 
 
 
max.len.up = max(length(deg_table_UP_f36p$SYMBOL), length(deg_table_UP_hl60$SYMBOL), 
length(deg_table_UP_kasumi1$SYMBOL), length(deg_table_UP_molm13$SYMBOL), 
length(deg_table_UP_monomac6$SYMBOL), length(deg_table_UP_mv411$SYMBOL), 
length(deg_table_UP_nb4$SYMBOL), length(deg_table_UP_nomo1$SYMBOL), 
length(deg_table_UP_ociaml3$SYMBOL), length(deg_table_UP_thp1$SYMBOL)) 
f36p_UP_genes <- c(deg_table_UP_f36p$SYMBOL, rep(NA, max.len.up - 
length(deg_table_UP_f36p$SYMBOL))) 
hl60_UP_genes <- c(deg_table_UP_hl60$SYMBOL, rep(NA, max.len.up - 
length(deg_table_UP_hl60$SYMBOL))) 
kasumi1_UP_genes <- c(deg_table_UP_kasumi1$SYMBOL, rep(NA, max.len.up - 
length(deg_table_UP_kasumi1$SYMBOL))) 
molm13_UP_genes <- c(deg_table_UP_molm13$SYMBOL, rep(NA, max.len.up - 
length(deg_table_UP_molm13$SYMBOL))) 
monomac6_UP_genes <- c(deg_table_UP_monomac6$SYMBOL, rep(NA, max.len.up - 
length(deg_table_UP_monomac6$SYMBOL))) 
mv411_UP_genes <- c(deg_table_UP_mv411$SYMBOL, rep(NA, max.len.up - 
length(deg_table_UP_mv411$SYMBOL))) 
nb4_UP_genes <- c(deg_table_UP_nb4$SYMBOL, rep(NA, max.len.up - length(deg_table_UP_nb4$SYMBOL))) 
nomo1_UP_genes <- c(deg_table_UP_nomo1$SYMBOL, rep(NA, max.len.up - 
length(deg_table_UP_nomo1$SYMBOL))) 
ociaml3_UP_genes <- c(deg_table_UP_ociaml3$SYMBOL, rep(NA, max.len.up - 
length(deg_table_UP_ociaml3$SYMBOL))) 
thp1_UP_genes <- c(deg_table_UP_thp1$SYMBOL, rep(NA, max.len.up - 
length(deg_table_UP_thp1$SYMBOL))) 
 
max.len.down = max(length(deg_table_DOWN_f36p$SYMBOL), length(deg_table_DOWN_hl60$SYMBOL), 
length(deg_table_DOWN_kasumi1$SYMBOL), length(deg_table_DOWN_molm13$SYMBOL), 
length(deg_table_DOWN_monomac6$SYMBOL), length(deg_table_DOWN_mv411$SYMBOL), 
length(deg_table_DOWN_nb4$SYMBOL), length(deg_table_DOWN_nomo1$SYMBOL), 
length(deg_table_DOWN_ociaml3$SYMBOL), length(deg_table_DOWN_thp1$SYMBOL)) 
f36p_DOWN_genes <- c(deg_table_DOWN_f36p$SYMBOL, rep(NA, max.len.down - 
length(deg_table_DOWN_f36p$SYMBOL))) 
hl60_DOWN_genes <- c(deg_table_DOWN_hl60$SYMBOL, rep(NA, max.len.down - 
length(deg_table_DOWN_hl60$SYMBOL))) 
kasumi1_DOWN_genes <- c(deg_table_DOWN_kasumi1$SYMBOL, rep(NA, max.len.down - 
length(deg_table_DOWN_kasumi1$SYMBOL))) 
molm13_DOWN_genes <- c(deg_table_DOWN_molm13$SYMBOL, rep(NA, max.len.down - 
length(deg_table_DOWN_molm13$SYMBOL))) 
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monomac6_DOWN_genes <- c(deg_table_DOWN_monomac6$SYMBOL, rep(NA, max.len.down - 
length(deg_table_DOWN_monomac6$SYMBOL))) 
mv411_DOWN_genes <- c(deg_table_DOWN_mv411$SYMBOL, rep(NA, max.len.down - 
length(deg_table_DOWN_mv411$SYMBOL))) 
nb4_DOWN_genes <- c(deg_table_DOWN_nb4$SYMBOL, rep(NA, max.len.down - 
length(deg_table_DOWN_nb4$SYMBOL))) 
nomo1_DOWN_genes <- c(deg_table_DOWN_nomo1$SYMBOL, rep(NA, max.len.down - 
length(deg_table_DOWN_nomo1$SYMBOL))) 
ociaml3_DOWN_genes <- c(deg_table_DOWN_ociaml3$SYMBOL, rep(NA, max.len.down - 
length(deg_table_DOWN_ociaml3$SYMBOL))) 
thp1_DOWN_genes <- c(deg_table_DOWN_thp1$SYMBOL, rep(NA, max.len.down - 
length(deg_table_DOWN_thp1$SYMBOL))) 
 
deg_table_UP_ALL <- data.frame(F36P = f36p_UP_genes, HL60 = hl60_UP_genes, KASUMI1 = 
kasumi1_UP_genes, MOLM13 = molm13_UP_genes, MONOMAC6 = monomac6_UP_genes, MV411 = 
mv411_UP_genes, NB4 = nb4_UP_genes, NOMO1 = nomo1_UP_genes, OCIAML3 = ociaml3_UP_genes, THP1 = 
thp1_UP_genes) 
deg_table_DOWN_ALL <- data.frame(F36P = f36p_DOWN_genes, HL60 = hl60_DOWN_genes, KASUMI1 = 
kasumi1_DOWN_genes, MOLM13 = molm13_DOWN_genes, MONOMAC6 = monomac6_DOWN_genes, 
MV411 = mv411_DOWN_genes, NB4 = nb4_DOWN_genes, NOMO1 = nomo1_DOWN_genes, OCIAML3 = 
ociaml3_DOWN_genes, THP1 = thp1_DOWN_genes) 
 
tab_UP <- table(unlist(deg_table_UP_ALL)) 
tab_DOWN <- table(unlist(deg_table_DOWN_ALL)) 
 
write.table(as.data.frame(tab_UP), "./edgeR_Results/AML_UP_DEG_ALL.txt", sep = "\t", row.names = F) 
write.table(as.data.frame(tab_DOWN), "./edgeR_Results/AML_DOWN_DEG_ALL.txt", sep = "\t", row.names = F) 
 
View(as.data.frame(tab[tab > 1])) 
 
sessionInfo() 
 
# Save R session 
save.image("./edgeR_Results/AML_RNA-Seq_2017_edgeR.RData") 
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